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cost-effectiveness of minimal incision approaches to
total hip replacement (THR) for arthritis of the hip. 
Data sources: Major electronic databases were
searched from 1966 to 2007. Relevant websites were
also examined and experts in the field were consulted. 
Review methods: Studies of minimal (one or two)
incision THR compared with standard THR were
assessed for inclusion in the review of clinical
effectiveness. A systematic review of economic
evaluations comparing a minimal incision approach to
standard THR was also performed and the estimates
from the systematic review of clinical effectiveness
were incorporated into an economic model. Utilities
data were sourced to estimate quality-adjusted life-
years (QALYs). Due to lack of data, no economic
analysis was conducted for the two mini-incision
surgical method. 
Results: Nine randomised controlled trials (RCTs), 17
non-randomised comparative studies, six case series
and one registry were found to be useful for the
comparison of single mini-incision THR with standard
THR. One RCT compared two mini-incision THR with
standard THR, and two RCTs, five non-randomised
comparative studies and two case series compared two
mini-incision with single mini-incision THR. The RCTs
were of moderate quality. Most had fewer than 200
patients and had a follow-up period of less than 1 year.
The single mini-incision THR may have some
perioperative advantages, e.g. blood loss [weighted
mean difference (WMD) –57.71 ml, p < 0.01] and
shorter operative time, of uncertain practical
significance. It may also offer a shorter recovery period
and greater patient satisfaction. Evidence on long-term
outcomes (especially revision) is too limited to be
useful. Lack of data prevented subgroup analysis. With
respect to the two-incision approach, data were
suggestive of shorter recovery compared with single-
incision THR, but conclusions must be treated with
caution. The costs to the health service, per patient, of
single mini-incision THR depend upon assumptions
made, but are similar at one year (£7060 vs £7350 for
standard THR). For a 40-year time horizon the costs
were £11,618 for mini-incision and £11,899 for
standard THR. Two existing economic evaluations were
identified, but they added little, if any, value to the
current evidence base owing to their limited quality. In
the economic model, mini-incision THR was less costly
and provided slightly more QALYs in both the 1- and
40-year analyses. The mean QALYs at 1 year were
0.677 for standard THR and 0.695 for mini-incision
THR. At 40 years, the mean QALYs were 8.463 for
standard THR and 8.480 for mini-incision. At 1 year the
probabilistic sensitivity analyses indicate that mini-
incision THR has a 95% probability of being cost-
effective if society’s willingness to pay for a QALY were
up to £50,000. This is reduced to approximately 55%
for the 40-year analysis. The results were driven by the
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* Corresponding authorassumption of a 1-month earlier return to usual
activities and a decreased hospital length of stay and
operation duration following mini-incision THR. If mini-
incision THR actually required more intensive use of
resources it would become approximately £200 more
expensive and would only be cost-effective (cost per
QALY > £30,000) if recovery was 1.5 weeks faster. 
A threshold analysis around risk of revision showed,
using the same cost per QALY threshold, 
mini-incision THR would have to have no more 
than a 7.5% increase in revisions compared with
standard THR for it to be no longer considered cost
effective (one more revision for every 200 procedures
performed). Further sensitivity analysis involved
relaxing assumptions of equal long-term outcomes
where possible. and broadly similar results to the base-
case analysis were found in this and further sensitivity
analyses. 
Conclusions: Compared with standard THR, minimal
incision THR has small perioperative advantages in
terms of blood loss and operation time. It may offer a
shorter hospital stay and quicker recovery. It appears
to have a similar procedure cost to standard THR, but
evidence on its longer term performance is very
limited. Further long-term follow-up data on costs and
outcomes including analysis of subgroups of interest to
the NHS would strengthen the current economic
evaluation.
Abstract
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Description of proposed service
Minimal incision total hip replacement (THR) is
performed with significant variations between
surgeons but approaches fall into two main groups.
Of these, the ‘double-incision’ or ‘two-incision’
approach is novel and specific to minimally
invasive hip surgery, whereas the single mini-
incision approach is a development of traditional
anterolateral and posterior approaches. Minimal
incision techniques can be used for all the main
categories of hip prostheses. Although shorter
incisions may result in less muscle dissection, they
may also reduce visualisation at operation, leading
to potential risks that the placement of the
prosthesis will be sub-optimal and may, therefore,
lead to a higher rate of revisions than might be
expected with standard THR. 
Epidemiology and background
Osteoarthritis was the primary diagnosis in 94% of
THR operations in England and Wales in 2005. Its
incidence increases with age, and consequently
THR is most common in older people (the
average age of patients is 68 years). With
improvements in implant design and longevity,
younger patients are also now considered for
THR. Over 55,000 primary THRs are recorded
annually in the National Joint Registry, of which
6–14% are reported to be mini-incision THR.
Minimally invasive surgery (MIS) is thought to be
less suitable for patients who are obese, very
muscular or with severe osteoporosis. 
Objective
This review aimed to assess the clinical
effectiveness and cost-effectiveness of minimal
incision approaches to THR for arthritis of the hip. 
Methods
The search strategy included electronic databases
(covering 1966–2007) and relevant websites, contact
with experts in the field and scrutiny of retrieved
papers to identify reports of published and ongoing
studies. Systematic reviews and selected conference
proceedings were also searched. 
Studies of minimal (one or two) incision THR
compared with standard THR were assessed for
inclusion for the review of clinical effectiveness.
Studies of two-incision THR compared with one
mini-incision THR were also eligible. Randomised
controlled trials (RCTs), quasi-RCTs, prospective
non-randomised studies with concurrent
comparisons and matched-pair studies, and
retrospective comparative studies with prospective
design or total population recruitment were
included. Additional long-term data were sought
from national registries, and also single-surgeon
case series with a minimum follow-up of 3 years
and multiple-surgeon case series with a minimum
follow-up of 1 year. Pre-specified subgroups were
based on age, gender, deformity, muscularity and
body mass index (BMI), and also operative
approach (i.e. posterior, anterior).
Two reviewers independently extracted data and
assessed methodological quality. Meta-analyses
were performed with the RCT data; dichotomous
data were combined using the Peto odds ratios
and continuous data were combined using the
inverse variance weighted mean differences. 
A systematic review of economic evaluations
comparing a minimal incision approach to
standard THR was performed and the estimates
from the systematic review of clinical effectiveness
were incorporated into an economic model. This
model estimated the cost–utility of single mini-
incision THR for time horizons of 1 and 40 years
(although few long-term data relevant to the 40-
year time horizon were available). Many of the
outcomes produced by the meta-analysis were
implausible and it was not possible to incorporate
them into the model. Data were suggestive of equal
outcomes following standard and mini-incision
THR, hence the risks of revision, postoperative
dislocation and infection, deep vein thrombosis
(DVT) and pulmonary embolism (PE) were
assumed to be equal but with wide confidence
intervals (CIs) [relative risk (RR) 1, 95% CI 0.1 to
1.89]. The key costs included in the model were
operative costs in terms of hospital costs,
equipment and staffing for the two procedures and
hospital stay. Differences in hospital stay [weighted
mean difference (WMD) –0.5 days, p  0.01] and
operation duration (WMD –3.70 minutes, p  0.01)
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both favoured single mini-incision THR and were
taken directly from the meta-analysis conducted as
part of the review of effectiveness. The
management costs of postoperative complications
were also included, such as the cost of a revision
surgery (£7858) after a subsequent failure, the cost
of reoperations, due to both dislocations (£1925)
and infections (£3365) and the cost associated with
managing DVT (which varied depending on
severity) and non-fatal pulmonary embolisms
(£1326). Long-term costs of care included the
follow-up of patients in consultant-led outpatient
visits (£103 per visit) and the management costs of
those patients whose surgeries have failed and who,
therefore, are treated non-operatively for the
remainder of their lives (annual cost £743).
Utilities data were sourced to estimate quality-
adjusted life-years (QALYs) and therefore utilities
were also assigned to the main quality of life
outcomes included in the model, such as success
(0.75), failure (0.33) and the utility associated with
various complications. Due to lack of data, no
economic analysis was conducted for the two mini-
incision surgical method. 
Results
Number and quality of studies, and
direction of evidence
Fifty-five reports describing 42 studies were
identified. Of these, 32 studies (nine RCTs, 17
non-randomised comparative studies and six case
series and one registry) were useful for the
comparison of single mini-incision THR with
standard THR. One RCT compared two mini-
incision THR with standard THR and nine studies
(two RCTs, five non-randomised comparative
studies and two case series) compared two mini-
incision with single mini-incision THR. The RCTs
were of moderate quality. The majority had fewer
than 200 patients (range 20–219). The majority 
of comparative studies comparing single 
mini-incision with standard THR (four RCTs, 
12 non-randomised) and those comparing the 
two mini-incision THR with single mini- or
standard THR (one RCT, three non-randomised)
had a follow-up period of less than 1 year. 
Summary of benefits
The single mini-incision THR may have some
perioperative advantages, namely less blood loss
(WMD –57.71 ml, p  0.01) and shorter operative
time, of uncertain practical significance. The mini-
incision approach may also offer a shorter recovery
period and greater patient satisfaction with the
operation and scar appearance. Evidence on long-
term outcomes (especially revision) is too limited
to be useful. Subgroup analysis was not possible
due to lack of suitable data.
With respect to the two-incision approach, data
were suggestive of shorter recovery compared with
single-incision THR, although the data were not
in a form amenable to meta-analysis. As data were
sparse, conclusions must be treated with caution. 
Costs
The costs to the health service, per patient, of
single mini-incision THR depends on the
assumptions made, but are similar (£7060) to
standard THR, which costs the NHS, on average,
£7350 per patient. In the base-case analysis, the
cost difference between standard and single mini-
incision THR for a 1-year time horizon was
approximately £300 less per patient than standard
THR (for the 40-year time horizon the costs were
£11,618 for mini-incision and £11,899 for
standard THR).
Cost-effectiveness
Two existing economic evaluations were identified,
but they added little, if any, value to the current
evidence base owing to their limited quality. In the
economic model, mini-incision THR was less costly
and provided slightly more QALYs and therefore
dominated standard THR, in both the 1- and 40-
year analyses. The mean QALYs at 1 year were
0.677 for standard THR and 0.695 for mini-incision
THR. At 40 years, the mean QALYs were 8.463 for
standard THR and 8.480 for mini-incision. The
probabilistic sensitivity analyses conducted indicate
that mini-incision THR has a 95% probability of
being cost-effective at threshold values of up to
£50,000 for society’s willingness to pay for a QALY.
This probability is reduced to approximately 55%
for the 40-year analyses. The cost-effectiveness
results were driven by the assumption of a 1-month
earlier return to usual activities and a decreased
hospital length of stay and operation duration
following mini-incision THR. 
Sensitivity analyses
Although it appeared that mini-incision THR was
associated with a shorter recovery, the precise
reduction could not be estimated, so a threshold
analysis was performed around time to return to
usual activities following mini-incision THR. This
analysis was conducted for the base-case model
and a model assuming more intensive use of
resources for mini-incision patients. In terms of
the base-case model, as mini-incision THR is less
Executive summarycostly than standard THR, mini-incision continued
to dominate standard THR. When increased
resource use was assumed for mini-incision
compared with standard THR (mini-incision THR
is approximately £200 more expensive than
standard THR in this analysis), then provided that
recovery was 1.5 weeks faster, the incremental 
cost-effectiveness per QALY would be £30,000 
or less. 
One major area of uncertainty is in risk of
revision. Initially it was assumed that revision rates
in the long-term would be equal (with wide CIs). 
A threshold analysis around risk of revision
showed that if society would be willing to pay
£30,000 for a QALY, mini-incision THR would
have to be associated with a 7.5% increase in
revisions compared with standard THR for it to be
no longer considered cost-effective (one more
revision for every 200 procedures performed). 
Further sensitivity analysis involved relaxing
assumptions of equal long-term outcomes where
possible. Data produced by the meta-analysis in
relation to postoperative dislocation [odds ratio
(OR) 1.72, 95% CI 0.43 to 6.92] favouring
standard THR, and DVT (OR 0.39, 95% CI 0.12
to 1.30), favouring mini-incision THR, were
utilised in this sensitivity analysis. Broadly similar
results to the base-case analysis were found in this
and further sensitivity analyses. 
Limitations of the calculations
(assumptions made)
Much of the information available was reported in
a form unsuitable for meta-analysis. Few data were
available for many outcomes, including revision
rates. Lack of standardisation in outcome
measures was also evident and some outcomes
were assessed in only one or two reports. The
extent of the imprecision surrounding estimates
was such that many of the meta-analysis results
were not included in the base-case model (risk of
revision, postoperative dislocation, DVT and PE).
Consequently, these outcomes in relation to mini-
incision are assumed to have, on average, equal
relative effect sizes compared with standard THR
(but with wide CIs). This represents an analyst
assumption and is a limitation of the data inputs
used by the model. Further limitations related to
the estimates of costs and the impact that minimal
incision THR had on QALYs in both the short and
long term. In terms of utility, very few comparative
and short-term data were available. Cost data
would be greatly enhanced if they were collected
within a full economic evaluation, alongside a
clinical trial, for example.
Other important issues regarding
implications
If the use of MIS were increased from its current
level of 6% of all THRs to 25% of all THRs, then
NHS costs may reduce by £4.1 million per year.
These savings depend on judgements made about
the relevance in reality of reductions in operation
time, length of stay, the need for little extra
specialised equipment and whether differences
exist in longer term outcomes. 
The increased adoption of mini-incision
techniques may allow an earlier return to usual
activities, which, in turn, reduces loss of income or
need for informal care by family and friends.
However, few patients currently have access to
minimal incision THR and more surgeons would
need training in this approach, which would be
costly and take time to achieve. Furthermore, not
all patients are clinically suitable. 
Notes on the generalisability of the
findings
Only two of the nine trials were conducted in the
UK. No data were available to conduct any
worthwhile subgroup analysis. No UK economic
studies were identified. 
Conclusions
Compared with standard THR, minimal incision
THR has small perioperative advantages in terms
of blood loss and operation time. It may offer a
shorter hospital stay and quicker recovery. It
appears to have a similar procedure cost to
standard THR, but evidence on its longer term
performance is very limited.
Further data are needed to assess long-term
outcomes of single mini-incision or two mini-
incision THR before robust decisions can be
made. Further long-term follow-up data are also
required on costs and outcomes.
Recommendations for further research
No useful data on long-term outcomes of single
mini-incision or two mini-incision THR were
available. Such data are required before robust
decisions can be made. The sparse effectiveness
data limit subsequent economic analysis. Further
long-term follow-up data on costs and outcomes
including analysis of subgroups of interest to the
NHS (e.g. obese or muscular patients, patients
with significant bone deformity or severe
osteoporosis and patients who present as
emergency cases) would strengthen the current
Health Technology Assessment 2008; Vol. 12: No. 26
xi
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.economic evaluation. The economic evaluation
would also be strengthened by the collection of
costs on long-term events and management, such
as failure. In relation to utilities, short-term
differences in recovery are required, in addition to
long-term differences in outcomes which depend
on both subsequent failures and differences in
quality of life, caused by long-term implications of
different degrees of dissection. If a large RCT
addressing long-term effectiveness is conducted in
the future, it is strongly recommended that a full
economic evaluation be incorporated as an
integral part of the study from design to
dissemination. Further careful work would be
required to explore the value of such a large RCT
more formally.
Executive summary
xiiDescription of underlying health
problem
Introduction
Hip replacement has been described as “the
operation of the (20th) century”1 and it has
become outstandingly successful in relieving pain
and disability. It is estimated that over 80,000
primary hip replacements are now performed
annually in the UK.2,3
The usual indication for the procedure is arthritis
of the hip, most commonly osteoarthritis, but
inflammatory arthropathies such as rheumatoid
arthritis may provide indications. Occasionally it
may also be undertaken for other pathologies 
such as fracture or tumour, or deformity 
secondary to childhood hip disease. Osteoarthritis
affects all the tissues in a joint, with the most
marked effects on the articular cartilage (which
may be damaged and destroyed) and the
underlying bone (which may become thickened
and sclerotic). The joint surface becomes irregular
and the joint space is reduced. Osteophytes (spurs
of bone) form around the joint in an attempt at
repair. The result is pain, stiffness, deformity and
loss of function, such as a reduced walking
distance and a limp. Total hip replacement (THR)
involves exposing and dislocating the hip joint,
preparing the cup-shaped acetabulum in the
pelvis by excising any osteophytes, reaming the
surface to remove remaining articular cartilage
down to subchondral bone and inserting an
artificial cup with or without cement. The
proximal femur is usually prepared by excising
and discarding the head of the femur and
inserting a metal stem with a ball top into the
medullary canal of the proximal femur, again with
or without cement. 
Many variations of the operation exist, with
differences in the design of the implants and their
composition (metal, plastic, ceramic), and whether
they are inserted with bone cement or not
(cementless THR). There are also different
combinations of the implants, producing different
bearing surfaces (metal or ceramic-on-plastic;
metal-on-metal; ceramic-on-ceramic). Whatever
implant is chosen, the surgeon should follow the
guidance from the National Institute for Health
and Clinical Excellence (NICE)4,5 and the
Orthopaedic Device Evaluation Panel (ODEP).6
Resurfacing arthroplasty has returned as a possible
option. The head of the femur is prepared and a
large-diameter metal cap is fitted, which
articulates with a thin-walled metal cup implanted
in the acetabulum. These methods were
considered by NICE in 2001, but few data were
available.7 More recently, it has been reported that
with improved metallurgy and implant finishing,
these prostheses seem to be functioning well.8
However, long-term results are awaited. It is
reserved for more active younger patients with
good bone stock and has the attraction that
subsequent revision, if required, may be simpler. 
Epidemiology
Osteoarthritis is the single biggest cause of
locomotor problems, and the commonest joint
disease, in the UK and was the diagnosis in 94%
of THR operations in England and Wales in
2005.3 Its incidence increases with age, and THR
is more commonly performed on this older
population (average age 68 years), approximately
60% of whom are women.3 However, with
improvements in anaesthesia, older patients with
medical co-morbidities may have surgery. With
improvements in implant design and longevity,
increasing numbers of younger patients are also
now considered for hip replacement (in 2005 12%
were aged less than 55 years).3 The principal
indication for surgery remains pain. 
Current service provision
The National Joint Registry (NJR) for England
and Wales holds information on hip and knee
replacement procedures performed in the NHS
and the independent sector in England and Wales
since 2003.3,9,10 In 2005, the NJR recorded an
estimated 77% (124,036) of all hip and knee joint
replacement procedures carried out in England
and Wales, compared with 60% (93,885) in 2004
and 51% (46,798) in 2003. 
A total of 61,881 hip replacement procedures were
recorded on NJR in 2005. This represents a 1-year
increase of 26% from 48,987 in 2004 and a 2-year
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Backgroundincrease of 148% from 24,997 in 2003, which is
likely to reflect improved reporting to the registry
rather than a true increase in the number of
surgical procedures. 
About 90% (55,812) of hip replacement
procedures recorded in 2005 were performed as
primary procedures and the majority of these
procedures used cement (Table 1). The other 10%
were revisions (5769) and re-operations (300).
Currently, only a very small subset of revisions and
re-operations can be linked to the primary
operation data captured by NJR. Since at least
90% of hip implants are expected to last 10 years
or more, fewer revision procedures are likely to
occur before that time. 
Use of minimally invasive surgery (MIS) was
reported in 6% of primary THRs in 2005, an
increase of 2% over 2003 (Table 2). It is worth
noting, however, that 14% of the procedures were
also recorded as having a short incision length of
10 cm or less in the same year. Although not
shown in the table, in 2005, 9% of those not
classified as minimally invasive had a short
incision length (10 cm), and 24% of those
classified as minimally invasive had a long incision
length (>10 cm). This reflects inconsistency in the
definition of MIS. 
In Scotland, the number of THRs recorded in the
Scottish Arthroplasty Project2 has been increasing
steadily over the last decade and especially since
2002. In 2004–5, around 86% (4823) of Scottish
THRs were primary procedures, whereas 14%
(753) were revision procedures. No data are
available on the number of MIS for THRs
performed in Scotland. 
Outside the UK, the Norwegian Arthroplasty
Register11 reported a lower rate of MIS (2% of
6566 primary hip replacements) performed in
2005, compared with that recorded in England
and Wales. On the other hand, the Canadian Joint
Replacement Registry12,13 recorded a higher rate
of MIS for hip replacements: 9% of 12,474 hip
replacements (including revisions) in 2003–4 and
12% of 14,307 hip replacements (including
revisions) in 2004–5. Almost all minimally invasive
procedures (99%) were primary procedures, rather
than revisions. The proportions of MIS were
significantly higher among males than females
[odds ratio (OR) 1.12, 95% confidence interval
(CI) 1.02 to 1.24], but significantly lower among
patients who were overweight and obese than
those who were underweight or normal weight
(22% versus 34%). The use of a minimally invasive
procedure was not associated with patients’ age.
After adjusting for other factors, females and
overweight or obese patients were still significantly
less likely to receive MIS.
Description of new intervention
Outline of the procedure
Minimal incision hip arthroplasty continues a
general trend towards less invasive approaches,
both in orthopaedics14 and other surgical
specialties.15 Historically, the concept arose in
North America, where the typical incision length
had perhaps been rather longer than in Europe.16
Minimal incision THR is not a uniform procedure,
but is performed with significant variations
Background
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TABLE 2 MIS in primary hip replacement procedures in England and Wales, 2003–20053,9,10
2003 2004 2005
Primary hip replacement 22,672 44,262 55,812
Minimally invasive
Yes 883 (4%) 2733 (6%) 3124 (6%)
No 21,779 (96%) 39,528 (94%) 47,437 (94%)
Incision length
10 cm NR 4390 (17%) 6448 (14%)
>10 cm NR 21,678 (83%) 40,605 (86%)
NR, not reported.
TABLE 1 Primary hip procedures in England and Wales, 20053
Procedure type N %
Cemented THR 28,602 51
Cementless THR 13,955 25
Hybrid or reverse hybrid THR 8232 15
Primary resurfacing 2746 5
Other 2277 4
Total 55,812 100between surgeons. Approaches, however, fall into
three main groups. Of these, the so-called ‘double
incision’ or two-incision approach can be regarded
as novel and specific to MIS, whereas the
anterolateral and posterior approaches are
essentially developments of traditional approaches
performed through smaller incisions. Further
variation within these groups will depend on the
precise surgical interval used, the extent of the
deep dissection (which may or may not be less
than with conventional surgery) and the use or
otherwise of instruments specially designed for
minimally invasive procedures. Minimal incision
techniques can be used for the implantation of
cemented, cementless or hybrid (cemented stem
and cementless cup) prostheses.
The two-incision technique17 is performed with
the patient supine and, unlike other minimal
incision approaches, X-ray fluoroscopy is required
throughout the procedure. A short incision is
made anterior to the femoral neck and the hip
approached by means of medial retraction of the
sartorius and rectus femoris muscles and lateral
retraction of tensor fascia lata. The lateral
circumflex vessels are coagulated and the femoral
head and neck resected after a capsulotomy.
Lighted angled retractors are used to obtain
acetabular exposure, allowing for preparation and
cup implantation. A second incision is then made
laterally above the greater trochanter and
deepened to form a track through which the
femoral instrumentation can be inserted. After
femoral preparation and trial reduction, the
definitive femoral component is implanted.
The posterior (or posterolateral) approach is a
minimal incision adaptation of the approach
originally described by Moore.18 The patient is
positioned laterally and an incision made along
the posterior edge of the greater trochanter and
deepened through the gluteal fascia. Obturator
internus and the gemelli muscles are divided close
to their insertions, with or without piriformis
superiorly and part of quadratus femoris inferiorly.
Care is taken to avoid injury to the nearby sciatic
nerve and a capsulotomy is performed, allowing
dislocation and resection of the femoral head.
With appropriate retraction and positioning of the
leg, acetabular and subsequently femoral
preparation and implantation can be performed.
Minimal incision anterolateral (or anterior)
approaches are usually derivates of the 
Hardinge approach,19 or sometimes the Watson-
Jones approach.20 The patient may be positioned
supine or more commonly laterally. A skin incision
is made over the anterior part of the greater
trochanter and again deepened through fascia
lata. With the Hardinge-type approach the
anterior parts of gluteus medius/minimus and
vastus lateralis are reflected subperiosteally. The
Watson-Jones variation is performed more
anteriorly between tensor fascia lata and gluteus
medius. Capsulotomy and dislocation/resection of
the femoral head allow acetabular and femoral
exposure for the procedure to be performed. The
anterior Smith Peterson approach has also been
used in hip surgery, although perhaps it is
relatively rarely used in hip replacement.
Criteria for treatment
The indications for minimal incision THR are the
same as that for standard THR, namely severe
pain due to primary or secondary degenerative
conditions of the hip joint which does not respond
to conservative treatment.21 Degenerative
conditions necessitating hip replacement may
include primary and secondary osteoarthritis,
inflammatory arthritis and the consequences of
osteonecrosis and metabolic bone conditions. Hip
fracture and tumour are additional indications for
THR, but these conditions fall outside the scope
of this review.
It has been claimed that the majority of patients
suitable for THR are theoretically suitable for
minimal incision procedures,17 depending on the
particular expertise of the operating surgeon and
the facilities available. Contraindications suggested
for the use of minimal incision techniques,22
however, include:
● obese or excessively muscular patients
● patients with abnormal anatomy requiring
complex reconstruction (due, for example, to
severe developmental hip dysplasia, acetabular
erosion or previous fracture)
● previous hip surgery
● bone weakness, such as osteoporosis.
Personnel involved
For a single minimal incision THR, substantially
the same staff are required for the operation. The
precise configuration of staff is described in more
detail in Chapter 5. However, it has been
suggested that an additional nurse may be
required during the procedure. Additionally, a
further outpatient appointment may be required
during patient follow-up, although the need for
this may decline, as experience and confidence
with the technique improve. Again, the impact of
the addition of an extra outpatient visit is
discussed further in Chapter 5.
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available to determine the staff required.
Nevertheless, it is likely that for the operation the
surgical team will be similar to that for standard
THR. However, additional personnel will be
required to provide the additional imaging
needed for the two-incision approach.
Setting and equipment required
Both the minimal incision and the standard
techniques can be performed in the same setting
using the same prostheses. The single minimal
incision THR can be performed with the same
equipment as a standard THR, although
specialised equipment such as angled retractors
with a light source and other customised
instruments are available to expose the hip, to
prepare the socket and to insert prostheses. The
likely purchase cost for such equipment is
approximately £3000 but, as the equipment is
reusable, this equates to an additional cost of
approximately £13 per patient (note: many
manufacturers will supply the instrumentation free
of charge if their implant is being used). 
The two-incision approach typically requires
specialised equipment and prostheses which are
marketed by specific manufacturers as a package.
As noted above, additional X-ray fluoroscopy
guidance is recommended to aid positioning of
instruments and prostheses during the procedure.
Further, computer-assisted navigation tools may
also be used for both minimal incision (single or
double) and standard THR. 
Degree of diffusion
Concern has been raised that commercial
pressures and direct to consumer marketing rather
than clinical evidence were largely responsible for
its initial spread in popularity.23,24 The current
guidance by NICE on the safety and efficacy of
single mini-incision surgery for THR states that it
“should only be used in appropriately selected
patients by clinicians with adequate training in this
technique”.5 The NICE guidance on the safety
and efficacy of two-incision surgery for THR states
that, owing to lack of evidence of this procedure, it
should not be used “without special arrangements
for consent and for audit or research”.4 In this
regard, the NICE guidance recommends clinicians
undertaking two-incision surgery to “inform the
clinical governance leads in their Trusts” and to
“ensure that patients understand the uncertainty
about the procedure’s safety and efficacy and
provide them with clear written information” and
also to “have adequate training before performing
this procedure”. 
Anticipated costs
The current use of mini-incision THR is low but
there is the potential for its use to increase
dramatically. The anticipated costs of mini-incision
THR surgery based on different degrees of
diffusion are illustrated in Table 3. The total direct
costs to the NHS for a follow-up period of
3 months after surgery are based on mean costs of
£7345 and £7064 for standard and single mini-
incision THR, respectively (the methods used to
estimate these costs are described in Chapter 5).
The number of hip replacements per year is based
on the data for 2005 reported in Table 2.
These projections suggest that if the use of
minimally invasive THR increased to a relatively
modest 10% from the 6% figure quoted in Table 2,
then the total cost to the NHS in England and
Wales would decrease by approximately £826,300
per year. However, these estimates are subject to
considerable uncertainty. First, the costs of both
standard and mini-incision THR are not known
precisely. Second, the calculations have assumed a
fixed operation cost and therefore have not
considered whether the unit cost of aspects such as
specialist instrumentation used for mini-incision
THR would change as diffusion increases. Finally,
these figures do not reflect the cost of training the
increased numbers of surgeons required to
perform the additional operations.
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TABLE 3 Cost of surgery for primary THR
Proportion of total THRs performed  NHS cost  Reduction in cost below the cost 
minimally invasively (%) (£ million) of current provision (£000)
5.0 431.1 826.3
10.0 430.3 1,652.6
15.0 429.5 2,478.9
20.0 428.7 3,305.2
25.0 427.8 4,131.5T
he aim of this study was to assess the relative
effectiveness and cost-effectiveness of 
(1) single mini-incision THR compared with
standard THR and (2) two mini-incision THR
compared with standard THR or single mini-
incision THR (as the quantity of data available was
expected to be limited). It was hypothesised that
the mini-incision approaches may involve less soft
tissue dissection that would facilitate shorter
recovery. The smaller incision may lead to poorer
visualisation of the hip, however, and this may
lead to higher revision rates.
As described in Chapter 1, patients receiving either
minimal incision or standard THR follow a similar
pathway of care. However, there is uncertainty
surrounding minimal incision compared with
standard incision performance in terms of:
● short- and long-term clinical performance
● short- and long-term safety
● resource use and costs
● patient-centred measures such as quality of life
● cost-effectiveness.
For single mini-incision THR, this study sought to
address the following questions:
1. Short- and long-term clinical performance:
(a) Does single minimal incision THR
compared with standard THR provide
better outcomes
(i) in terms of clinical effectiveness
measures of surrogates for long-term
outcomes (implant position, implant
migration, heterotopic ossification and
cement quality)?
(ii) in terms of long-term measures of
treatment success (revision rates, time
to revision, dislocation rates and limb
length inequalities)? 
2. Short- and long-term safety
(b) How does single minimal incision THR
compare with standard THR with respect to
blood loss, intraoperative fractures,
periprosthetic fractures and various
complications, such as wound infections,
nerve injuries, vascular injuries and the risk
of thrombosis [deep vein thrombosis (DVT)
and pulmonary embolism (PE)]?
3. Resource use and costs
(c) Is single minimal incision THR compared
with standard THR:
(i) associated with a shorter operation
time and length of stay? 
(ii) less costly when differences in
operation time, length of stay, 
staffing and equipment are taken into
account?
(iii) less costly when differences in the 
costs of treating revisions and other
long-term events are taken into
account?
4. Patient-centred measures such as quality of life
(d) Does single minimal incision THR
compared with standard THR improve:
(i) the short-term quality of life 
(measured in terms of postoperative
pain, use of pain relief, return to usual
activities and formal measures of
quality of life)?
(ii) long-term quality of life (measured in
terms of long-term pain, functional
results, mortality and formal measures
of quality of life)?
(iii) patient satisfaction?
(iv) quality of life as measured by QALYs
when differences in speed of recovery
and longer term outcomes including
complications are accounted for?
5. Cost-effectiveness
(e) Is single minimal incision THR compared
with standard THR cost-effective as judged
against standard decision rules on how
much an extra unit of outcome (i.e. a
QALY) is worth to society?25
In addition to these questions, the performance of
single minimal incision THR may vary according
to the experience of the surgeon and by the
characteristics of the patients selected for surgery.
Therefore, if possible, the differences in the
outcomes were reconsidered in the light of
evidence on:
● experience of the surgeon
● characteristics of the patient (obese; muscular;
have significant bone deformity or severe
osteoporosis; and who present as emergency
cases).
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The decision problemThese subgroups were chosen because, as
described in the section ‘Criteria for treatment’
(p. 3), it has been argued that surgeon expertise
might influence outcomes and it has been
suggested that minimally invasive THR may be
contraindicated in these patients.
For the comparison of two mini-incisions THR
with standard or single mini-incision THR, an
attempt was made to address the same questions
as set out above. 
Chapter 3 reports the methods used and results
obtained for the questions on short- and long-
term clinical performance, short and long-term
safety, and question (c)(i) for ‘resource use and
costs’ and questions (d)(i) and (d)(ii) for ‘patient-
centred measures’. Chapters 4 and 5 address the
remaining questions under ‘resource use and costs’
and ‘patient-centred measures’ and address the
cost-effectiveness question. The questions relating
to the subgroups and the two incision approach
will be addressed where data will be available in
the relevant subsections of Chapters 3, 4 and 5. 
The decision problem
6Methods for reviewing
effectiveness
Search strategy
The search strategy involved searching 
electronic databases and relevant websites, 
contact with experts in the field and scrutiny of
bibliographies of retrieved papers. Extensive
electronic searches were conducted to identify
reports of published and ongoing studies on 
the effectiveness of minimal incision THR.
Searches were carried out for both full papers 
and conference abstracts and there were no
language restrictions in this search of titles and
abstracts. The databases searched were 
MEDLINE (1966–February Week 3 2007),
MEDLINE In-Process (1 March 2007), EMBASE
(1980–2007 Week 8), BIOSIS (1985–1 March
2007), Science Citation Index (1985–2 March
2007), Cochrane Controlled Trials Register (The
Cochrane Library, Issue 1, 2007) and current
research registers (National Research Register,
Issue 4, 2006), Current Controlled Trials
(December 2006) and Clinical Trials (December
2006)). Additional databases searched for
systematic reviews and other background
information included the Cochrane Database of
Systematic Reviews (The Cochrane Library, Issue
1, 2007), Database of Abstracts of Reviews of
Effectiveness (December 2006), HTA Database
(December 2006) and Health Management
Information Consortium (1979–January 2007).
Full-text searching of key surgical journals
(American and British editions of the Journal of
Bone and Joint Surgery, Journal of Arthroplasty and
Clinical Orthopaedics and Related Research, all from
2000 to February 2007) was also undertaken.
Recent relevant conference proceedings and
reference lists of all included studies were 
scanned to identify additional potentially relevant
studies. Websites of national orthopaedic 
registries were searched, and also both key
professional organisations (including the 
American Association of Orthopaedic Surgeons,
British Orthopaedic Association and British Hip
Society) and manufacturers (DePuy International,
Smith and Nephew, Stryker Howmedica and
Zimmer). Full details of the search strategies 
used and websites consulted are documented in
Appendix 1.
All titles and abstracts identified in these ways
were assessed to identify potentially eligible
studies. Two reviewers independently assessed
them for inclusion, using a study eligibility form
developed for this purpose (Appendix 2). Any
disagreements were resolved by discussion.
Inclusion and exclusion criteria
Types of studies
All randomised controlled trials (RCTs) and quasi-
RCTs were included. Prospective non-randomised
studies with concurrent comparisons and matched-
pair studies, irrespective of duration of follow-up,
were also included. Retrospective comparative
studies were eligible only if there was clear
evidence of prospective design, consecutive series
or total population recruitment. Additionally, case
series or single cohort studies with two or more
surgeons with a minimum follow-up of 1 year, and
single-surgeon case series with a minimum follow-
up of 3 years, and where a report was available in
full text were included. We also included data from
national registries where these registries provided
long-term outcomes such as revision rates. Studies
or reports reported in a language other than
English, Chinese or Japanese were excluded after
full-text copies of all potentially relevant reports
were obtained. 
Types of participants
All adults eligible for standard THR for arthritis
were included. Studies that focused solely or
primarily on patients undergoing total hip
arthroplasty for other reasons, such as
osteoporosis, fracture or tumour, were excluded. 
Types of interventions
We included studies of single mini-incision
primary THR compared with standard primary
THR. Additionally, we also considered two-incision
primary THR compared with either standard
primary THR or single mini-incision primary
THR. Revision surgery, hip resurfacing or
computer modelling surgery were excluded.
Types of outcomes
The following measures of outcomes were sought. 
Clinical performance:
1. revision rates
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Effectiveness2. time to revision 
3. dislocation
4. surrogates for long-term outcomes
(a) implant position (radiographic analysis)
(b) implant migration (radiostereometric
analysis)
(c) heterotopic ossification
(d) cement quality
5. limb length inequality.
Safety:
1. blood loss
2. intraoperative fracture 
3. periprosthetic fracture 
4. wound infection
5. nerve injury
6. vascular injury
7. DVT and PE.
Resource utilisation:
1. duration of surgery 
2. length of hospital stay.
Patient-centred measures:
1. 30-day mortality 
2. long-term mortality
3. pain relief 
4. postoperative pain
5. long-term pain
6. time to return to usual activities
7. functional result, e.g. Harris Hip, Mayo,
Oxford Hip and Charnley Scores
8. health-related quality of life
9. patient satisfaction.
Other:
1. operating theatre throughput
2. opposite method initiated (preoperatively)
3. conversions to alternative procedure
(intraoperatively) and reasons for conversion.
Opposite method initiated was defined as a
minimal incision THR initiated when a standard
THR was randomly allocated, or vice versa.
Duration of operation was defined as time from
first incision to last suture or, where this was not
available, time in theatre or duration of
anaesthesia. Length of hospital stay was defined as
time from admission to discharge. Conversion was
defined as a procedure initiated as minimal
incision but converted to a standard THR
intraoperatively.
Data extraction strategy
Full-text copies of all potentially relevant reports
were obtained. Two reviewers independently
selected studies for inclusion and extracted data
using a standard data extraction form
(Appendix 3). Discrepancies were solved by
discussion, with involvement of a third reviewer
when necessary. The reviewers were not blinded to
authors, institutions or publication details. Where
there was insufficient information in the published
report, attempt was made to contact the authors
for clarification (one case).
Quality assessment strategy
Methodological quality of RCTs, quasi-RCTs and
comparative studies of other designs was assessed
using the Delphi criteria list (Appendix 4).26 Each
study was assessed independently by two reviewers.
Any disagreements were resolved through
discussion.
Data synthesis
Quantitative data syntheses were performed with
the trial data only. For trials with multiple
publications, only the most up-to-date or complete
data for each outcome were included. The data
from the comparative studies were not formally
combined in data synthesis to avoid the risk of
accentuating possible systematic bias inherent in
any non-randomised studies. To estimate a
summary measure of effect on relevant outcomes
in the trial data, dichotomous outcome data were
combined using the Peto OR method, since there
were relatively few events reported for many of 
the dichotomous outcomes. Continuous outcomes
were combined using the inverse variance
weighted mean difference (WMD) method; 
95% CIs and p-values were calculated for the
estimates of OR and WMD. The results were
reported using a fixed-effects model. To explore
statistical heterogeneity across studies 2 tests 
and I2 statistics were used. Where there was
evidence of heterogeneity, a random effects 
model was applied for continuous outcomes 
and also possible reasons for heterogeneity 
were explored. Quantitative syntheses were
performed using the standard Cochrane software
RevMan 4.2. 
Owing to a lack of uniformity of the data present
in many studies, a qualitative review looking for
consistency between studies was performed. For
continuous variables, this was supplemented by
two additional analyses. First, where standard
deviations (SDs) were not reported by the authors,
they were estimated on the basis of available
information on p-values (calculated SDs). This
approach made the assumption that SDs are the
same in both arms of the trial. Where studies only
reported p-values less than a certain value (e.g.
p < 0.05), we calculated SDs on the basis of a 
Effectiveness
8p-value equal to that value (i.e. p = 0.05). Second,
where information on p-values was also
unavailable, SDs were estimated as the weighted
means of SDs reported in the other studies which
did report data on the same outcome (dummy
SDs) or where they could be inputed from 
p-values. A judgement was made for each 
outcome as to which of the three analyses, 
namely (1) reported means and SDs, (2) reported
means and SDs with calculated SDs, (3) reported
means and SDs with calculated and dummy SDs,
should be used as the base case. This judgement
was based on consideration of the nature and
pattern of missing data. The other analyses are
reported in appendices. Where a quantitative
synthesis was considered to be inappropriate or
not feasible, a narrative synthesis of results was
provided. 
Results
Quantity and quality of research
available
Number of studies identified
The results of the searches are summarised in
Tables 4 and 5. The numbers retrieved from the
searches in Science Citation Index, BIOSIS,
CENTRAL and full-text journal searches include
only the additional reports found after excluding
those identified from the MEDLINE/EMBASE
multi-file search. A total of 887 reports were
identified, of which 186 were selected for full
assessment. 
Number and type of studies included
Fifty-four papers (43 full text papers17,27–68 and 11
abstracts69–79) met the inclusion criteria for the
review. In addition, relevant data were
supplemented by a published registry report
(Norwegian Arthroplasty Register)11 and extra
information from the registry holders
(Espehaug B, Norwegian Arthroplasty Register:
personal communication; 5 January 2007). In
total, 55 reports describing 42 studies [12 trials,
22 non-randomised comparative studies and eight
case series (including registry data)] were
identified as relevant to the review. Of these,
32 studies were useful for the comparison of single
mini-incision with standard incision, including
nine trials,31,32,40,43,46,58,69,75,77 17 comparative
studies,28–30,33–36,42,44,45,48,52,54–56,74,78 and six case
series or registry;11,39,41,49–51 one was used for the
comparison of two mini-incision THR with
standard THR (one trial)57 and nine were relevant
to the comparison of two mini-incision with single
mini-incision THR, including two trials,72,73 five
comparative studies38,47,53,71,79 and two case
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TABLE 4 Search results
Database No. retrieved No. selected for assessment
MEDLINE/EMBASE/MEDLINE In-Process multi-file search 552 104
(after de-duplication in Ovid)
SCI 61 11
BIOSIS 28 3
CENTRAL 4 0
Full-text journals 19 4
NRR 22 8
CCT 24 3
Clinical Trials 4 4
DARE 35 7
HTA database 35 11
HMIC 0 0
Conference abstracts 96 24
Registry Reports 7 7
Total retrieved 887 186
CCT, Current Controlled Trials; DARE, Database of Abstracts of Reviews of Effects; HMIC, Health Management Information
Consortium; NRR, National Research Register; SCI, Science Citation Index.
TABLE 5 Paper selected for full assessment 
Assessment No. of papers
Included in review 55
Retained for background information 42
Excluded 81
Unobtainable 8
Total 186series.27,37 The list of included studies and
associated references is given in Appendix 5. In
addition, 14 ongoing trialists were identified and
contacted for information. The list of ongoing
trials identified is given in Appendix 6. 
Number and type of studies excluded, with
reasons for specific exclusions
A total of 81 reports were also obtained but did
not meet the inclusion criteria and were
subsequently excluded. Of these, four studies did
not use concurrent comparisons (i.e. had historical
controls), 10 were retrospective studies and 18
were descriptive studies. Five studies only included
participants who received THR for reasons other
than arthritis (e.g. fracture) and five studies
primarily focused on revision surgery. Seventeen
did not report relevant outcomes or did not have a
sufficient length of follow-up (1 year for multiple-
surgeon case series and 3 years for single-surgeon
case series were required). The remaining 22
studies were excluded because they were reported
in languages other than English, Japanese or
Chinese.
Study quality, characteristics and evidence rating
for RCTs and comparative studies
Table 6 provides a summary of the methodological
quality of the 12 trials and 22 comparative studies
by type of intervention and study design. Details
of the quality assessment are given in Appendix 7. 
Single mini-incision procedure
With respect to the studies examining the single
mini-incision procedure, randomisation was
performed in nine studies. In only three of these
Effectiveness
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TABLE 6 Summary of the methodological quality of the included trials and comparative studies
Criteria One incision Two incisions
Trials Comparative Trials Comparative
1a. Was a method of randomisation performed?  Y 9 0 3 0
N0 1 7 0 5
U0 0 0 0
1b. Was a method of sequence generation adequate? Y 3 0 2 0
N3 1 7 0 5
U3 0 1 0
2. Was the treatment allocation concealed? Y 1 0 0 0
N5 1 7 0 5
U3 0 3 0
3. Were the groups similar at baseline regarding the  Y 6 6 3 3
most important prognostic indicators? N 1 7 0 1
U2 4 0 1
4. Were the eligibility criteria specified? Y 6 12 1 3
N3 5 2 2
U0 0 0 0
5. Was the outcome assessor blinded? Y 8 6 0 1
N0 5 0 1
U1 6 3 3
6. Was the care provider blinded? Y 5 1 0 0
N2 7 0 2
U2 9 3 3
7. Was the patient blinded? Y 4 2 0 0
N1 1 0 0 3
U4 5 3 2
8. Were point estimates and measures of  Y 4 10 1 1
variability presented for the primary outcome  N 4 7 2 4
measures? U 1 0 0 0
9. Did the analysis include an intention-to-treat  Y 4 9 0 1
analysis? N 1 0 0 0
U4 8 3 4
N, no; U, unclear; Y, yes.studies was this considered to be adequate (e.g. 
a computer-generated sequence, random number
tables or a card drawn by the anaesthetist at the
time of surgery).31,46,58 Methods used for
allocation concealment were considered
inadequate (e.g. alternation, sealed envelopes) in
five studies31,32,40,43,46 and unclear in a further
three (which were abstracts or poster).69,75,77
Six of the nine randomised trials reported that the
intervention and comparison groups were similar
at baseline,31,43,46,58,69,75 although the two groups
were not balanced in one,77 and it was unclear for
the other two.32,40 The criteria by which patients
were assessed as eligible for inclusion was not
described in three trials.43,69,77 All but one trial75
reported that the outcome assessors were blinded.
It is questionable whether blinding of care
providers and patients is possible, given the nature
of the intervention. Nevertheless, four
trials43,46,69,77 reported that both care providers
and patients were blinded, and one further trial
also suggested that care providers were unaware of
the incision length.58 One of these studies
reported that blinding was achieved by means of a
standard-length wound dressing.46 Point estimates
and measures of variability were presented for the
primary outcome measures in just under half of
the studies.31,32,46,58 Four trials included an
intention-to-treat analysis31,32,46,58 but it was
unclear if this was the case in four.43,46,75,77
Of the 17 (non-randomised) comparative studies
examining the single mini-incision procedure,
only six reported that the intervention and
comparison groups were similar at
baseline.33–36,44,74 The groups were dissimilar in
seven studies,28,42,45,48,52,55,56 and it was unclear in
a further four.29,30,54,78 The eligibility criteria 
were not described in five studies.29,36,48,74,78 In
two-thirds of the studies, either the outcome
assessors were not blinded30,33,34,42,48 or it was
unclear if they were blinded.29,36,45,56,74,78 Only
one study reported that both care providers 
and patients were blinded: this was done by means
of a standard-length wound dressing.28 One
further study also suggested that patients were
unaware of the incision length.52 Point estimates
and measures of variability were presented 
for the primary outcome measures in
10 studies.30,34,36,42,44,45,52,54–56 An intention-to-treat
analysis was included in nine.28,34–36,44,45,48,52,55
Two-incision procedure
In respect of the eight studies examining the two-
incision procedure, an adequate method of
random sequence generation (computerised
randomisation) was performed in only two
studies.72,73 One further study reported that
patients were randomised but did not provide
information on the method of randomisation
used.57 No information was available as to whether
treatment allocation was concealed in these
studies. In all three randomised studies57,72,73 and
the majority of non-randomised studies,38,47,71 the
intervention and comparison groups were similar
at baseline, although this was not the case for
one53 and unclear in another.79 Only half of the
studies described the patient eligibility
criteria.38,47,53,57 One study reported that the
outcome assessor was blinded53 but none of the
studies reported blinding of the care provider or
patient. Point estimates and measures of variability
for the primary outcome measures were presented
in two,53,57 and only one study included an
intention-to-treat analysis.47
Characteristics of included studies
Table 7 provides a summary of the baseline
characteristics of the participants in the included
trials, comparative studies and case series and
registry. This is described in more detail in
Appendix 8. 
Within the nine trials and 17 comparative studies
comparing single mini-incision and standard
incision, there were 27 comparisons, as one non-
randomised comparative study divided the
participants into three groups postoperatively
according to the incision length, namely mini-
incision (<10 cm), midi-incision (10–14 cm) and
standard incision (>14 cm).52 The results of this
study are presented as two comparisons, mini-
incision versus midi-incision and mini-incision
versus standard incision. Hip replacements were
performed through several approaches, including
anterolateral, lateral, posterolateral, anterior and
posterior. It is worth noting that in three
trials58,75,77 and one comparative study,48 the mini-
incision procedure and the standard incision
procedure were performed through different
approaches (e.g. mini-incision anterior approach
versus standard incision lateral approach). A
further three comparative studies did not provide
information on the operative approaches
used.54,74,78 This is a possible confounder,
comparing the potential effects of different
surgical approaches and also length of incision. 
The sample sizes ranged from 2048,78 to 219,46
with only one trial46 and one comparative study29
having 200 or more participants. The total
number of participants was 979 in the trials
(recruited between November 1999 and June
Health Technology Assessment 2008; Vol. 12: No. 26
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TABLE 7 Summary of the baseline characteristics
Study Comparator (operative  No. of  Age Sex (M/F) BMI Comments
approach, average  partici- (years)a
incision length) pants
One incision
RCT and quasi-RCT
Charles, 200669b MI lateral 20 66.6 NR 25.8
SI lateral 20 70.8 NR 25.2
Chimento, 200531 MI posterolateral, 8 cm 28 67.2 16/12 25.2
SI posterolateral, 15 cm 32 65.6 13/19 24.8
Chung, 200432 MI posterolateral, 9.2 cm 60 61.0 24/36 NR
SI posterior, 20.0 cm 60 64.0 28/32 NR
Hart, 200540 MI posterolateral, 9–10 cm 60 72.4 40/80 27.6
SI posterolateral, 20 cm 60
Kim, 200643 MI posterolateral, 8 cm 70 55.6 53/17 25.6 Bilateral THRs (MI on 
SI posterolateral, 15–20 cm 70 one hip, SI on the other)
Ogonda, 200546 MI posterior, 9.5 cm 109 67.4 49/60 28.2
SI posterior, 15.8 cm 110 65.9 58/52 28.9
Rachbauer, 200675b MI anterior 60 NR NR NR
SI lateral 60 NR NR NR
Sharma, 200677b MI posterior 20 67.0 NR 26.5
SI posterolateral, 12 cm 20 68.6 NR 24.4
Zhang, 200658 MI anterior, 7.9 cm 60 61.0 25/35 NR
SI posterolateral, 16.3 cm 60 62.5 28/32 NR
Comparative studies
Asayama, 200628 MI lateral, 8–10 cm 52 64.3 24/28 26.1
SI lateral, 15–20 cm 50 65.1 25/25 28.7
Berger, 200429 MI anterolateral, 8.3 cm 100 57.0 NR NR
SI anterolateral, 15–20 cm 100 59.0 NR NR
Chen, 200630 MI posterior, 10 cmc 51 68.1 28/23 NR
SI posterior, 15–20 cm 95 69.8 54/41 NR
Ciminiello, 200633 MI anterolateral, <12.7 cm 60 69.8 15/45 23.8 Matched-pair study
SI anterolateral, 12.7 cm 60 70.2 15/45 24.1
de Beer, 200434 MI lateral, 7.7 cm 30 71.0 10/20 32.4 Matched-pair study
SI lateral, 13.9 cm 30 69.0 10/20 31.7
DiGioia, 200335 MI posterior, 11.7 cm 33 65.0 19/14 27.0 With image navigation; 
SI posterior, 20.2 cm 33 65.0 19/14 28.0 matched pairs
Dorr, 200736 MI posterior, 9.6 cm 109 63.5 52/57 26.7
SI posterior, 17.9 cm 56 65.6 26/30 26.4
Howell, 200442 MI anterolateral 46 59.8 34/16 26.2
SI anterolateral 56 62.3 27/30 28.8
Li, 200544 MI posterolateral, 9.3 cm 18 NR 13/5 24.6
SI posterolateral, 16.8 cm 18 NR 14/4 26.1
O’Brien, 200545 MI lateral, 10cm 32 67.0 19/13 27.0
SI lateral, >10 cm 51 67.0 25/26 30.0
Panisello, 200674b Mini-incision 40 NR NR NR
Classic approach 40 NR NR NR
Pilot, 200648 MI anterior, 8.6 cm 10 67.9 4/6 29.1
SI posterolateral, 17.4 cm 10 67.5 2/8 26.4
Szendrói, 200652 MI lateral, 8.8 cm 38 64.0 NR 26.0
(MI/MD) MD lateral, 12.6 cm 43 62.0 NR 28.0
Szendrói 200652 MI lateral, 8.8 cm 38 64.0 NR 26.0
(MI/SI) SI lateral, 16.1 cm 21 57.0 NR 29.5
continuedHealth Technology Assessment 2008; Vol. 12: No. 26
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TABLE 7 Summary of the baseline characteristics (cont’d)
Study Comparator (operative  No. of  Age Sex (M/F) BMI Comments
approach, average  partici- (years)a
incision length) pants
Takahira, 200678b MI 7.5 cm 10 NR 3/7 NR
SI 13.8 cm 10 NR 1/9 NR
Teet, 200654 MI 10 cm 73 NR NR NR
SI 17–22 cm 54 NR NR NR
Woolson, 200455 MI posterior, 10 cmd 50 60.0 29/21 25.1
SI posterior, 15–25 cmd 85 63.0 31/54 28.2
Wright, 200456 MI posterolateral, 8.8 cm 42 64.2 NR 24.4
SI posterolateral, 23 cm 42 65.0 NR 28.3
Case series and registries
Flören, 200639 MI posterior 79 73.0 31/48 NR Participants with min. 
10-year FU only
Hartzband, 200641 MI posterolateral 100 M61, F65 41/57 NR
Pipino, 200449 MI lateral, 8–10 or 12–15 cm 368 60.0 220/148 NR Single surgeon in two 
locations
Siguier, 200450 MI anterior, <10 cm 926 67.8 336/590 NR
Swanson, 200551 MI posterior, 8.8 cm 759 62.3 415/585 26.5
Norwegian Mini-incision 200 NR NR NR
Arthroplasty 
Register 200611
Two-incision
RCT and quasi-RCT
Pagnano 2007a72b Two-incision 10 NR NR NR
MI posterior 10 NR NR NR
Pagnano 2007b73b Two-incision 36 66 20/16 NR
MI posterior 36 20/16 NR
Yan, 200557 Two-incision 15 63.0 6/9 NR
SI posterolateral, 12 cm 15 61.0 7/8 NR
Comparative studies
Duwelius, 200738 Two-incision 43 57.4 24/19 NR Matched-pair study
MI posterior 43 59.1 24/19 NR
Greidanus, 200671b Two-incision 66 NR NR NR
Mini-incision 99 NR NR NR
Pagnano, 200647 Two-incision 26 69.0 10/16 NR Staged bilateral THRs 
MI posterior, 6–9 cm 26 (2MI on one hip, MI on
the other)
Tanavalee, 200653 Two-incision 35 53.0 8/27 25.0
Mini-posterior, 9 cm 35 54.9 20/15 24.2
Yoon, 200579b Two-incision 100 NR NR NR
Mini-incision, 7.5 cm 118 NR NR NR
Case series
Archibeck, 200427 Two-incision 831 61 435/396 26 159 trainee surgeons
Duwelius, 200337 Two-incision 375 30-76 188/112 NR 4 centres (4 surgeons)
FU, Follow-up; MD, midi-incision; MI, mini-incision; 2MI, two-incision; NR, not reported; SI, standard incision.
a Age is mean or as reported by individual studies.
b Abstract only.
c Includes two-incision surgeries in 29% of the mini-incision group.
d Incision length measured before the operation began.2004) and 1686 in the comparative studies
(recruited between October 1998 and January
2005). The range of average age of participants
was comparable between the trials and
comparative studies, between 55.643 and
72.4 years40 in the trials, and between 57.052 and
71.0 years34 in the comparative studies. There
were more female than male participants across
both trials (334 males versus 375 females) and
comparative studies (510 males versus 567
females), excluding those studies which did not
provide information about gender
distributions.29,30,52,54,69,74,75,77 Within the trials,
participants’ body mass index (BMI) was similar
between the mini-incision group and the standard
incision group, except in one trial where it was
higher for the mini-incision group.77 However, in
nine comparative studies, the BMI in the mini-
incision group was lower28,33,35,42,45,52,55,56 and all
but two reported this to be statistically
significant.33,35
The nine trials were conducted in eight countries:
two in the UK46,77 and one each in Canada,69 the
USA,31 Australia,32 Czech Republic,40 Korea,43
Austria75 and China.58 Eight comparative studies
took place in the USA,28,29,33,35,36,54–56 three in
Canada34,42,45 two in China30,44 and one each in
Hungary,52 Japan,78 The Netherlands48 and
Spain.74 Five trials31,32,40,43,58 and five comparative
studies28,35,44,54,56 had a follow-up period of
1 year. In four trials31,32,43,46 and eight
comparative studies28,33,35,42,45,52,54,56 it was
reported that all operations had been performed
by or directly supervised by a single surgeon, and
in two trials69,75 and four comparative
studies34,36,48,55 it was reported that two or more
surgeons performed operations in a single
institution, and a further trial involved two
surgeons from two institutions.40
For case series and registries regarding the single
mini-incision procedure, a total of 1175
participants (551 males and 624 females) were
identified between 1988 and July 2004 with the
sample size in each study ranging from under
10039 to over 1000.50,51 Participants’ average age
was between 6049 and 73 years.39 Information on
participants’ BMI was available from only one
study,51 which gave a mean BMI of 26.5,
comparable to the value reported in the trials and
comparative studies examining the same mini-
incision procedure. The case series and registry
data came from five countries: Germany,39 Italy,49
France,50 the USA41,51 and Norway.11 All case
series were based on single surgeon experience,
except for the French study, which involved two
surgeons,50 and the registry data.11 Duration of
follow-up ranged from 1 year,11 through 3 years,50,51
6 years41 and 7 years49 to 10 years.39
With respect to eight studies comparing the two-
incision procedure with either the single mini-
incision38,47,53,71–73,79 or standard incision57
procedure, there were a total of 713 participants
(122 in the trials and 591 in the comparative
studies) recruited between 2002 and 2004. The
sample sizes ranged from 2072 to 218.79 Where
reported, there were more females than males
(139 versus 204 females) with the average age
between 53 and 66 years. Information on
participants’ BMI was largely unavailable. Four
studies took place in the USA38,47,72,73 and one
each in China,57 Canada,71 Thailand53 and
Korea.79 Four studies had an average follow-up of
1 year.38,53,72,73 Three studies38,47,53 reported that
a single surgeon performed all operations.
Two case series also examined the two-incision
procedure.27,37 Both studies were multi-centred
and conducted in the USA. The first study
involved 159 surgeons who attended corporate-
sponsored training on the two-incision THR and
who were asked to report to the company on their
first 10 cases.27 A total of 851 cases from 831
patients were reported between October 2002 and
April 2004. The second study involved four
surgeons in four different institutions performing
a total of 375 procedures followed for a period of
1 year.37 In both studies, the number of male
participants was higher than that of female
participants (435 versus 396 and 188 versus 112,
respectively). 
Description of surgery received
In one comparative study,29 one patient assigned
to the mini-incision group received a standard
incision THR due to retained hardware (dynamic
hip screw). In no other included trials and
comparative studies was the opposite method
initiated to the one to which the patient was
assigned or randomised. No information was
available on operating theatre throughput.
Two comparative studies reported conversions
from single mini-incision surgery to single
standard incision surgery.52,56 The first of these
studies reported that two of the 42 participants
were converted to longer incisions in order to
relieve skin tension and increase acetabular
exposure.56 In the second study, all participants
were started with a short incision (<10 cm) and
incisions were extended as necessary during
surgery.52 Participants were then divided into three
Effectiveness
14groups according to incision length, namely, mini-
incision (<10 cm, N = 38), midi-incision 
(10–14 cm, N = 43) and standard incision 
(>14 cm, N = 21). 
In terms of surgeon experience in the single mini-
incision procedure, four studies (three trials and
one comparative study) indicated that the
surgeons involved were experienced in this
procedure.31,40,46,56 Two further non-randomised
comparative studies did not report specifically on
the level of experience of the surgeon performing
the mini-incision procedure but reported that all
procedures took place in a high-volume
arthroplasty centre. In contrast, five studies (one
trial and four comparative studies) suggested that
the mini-incision procedure represented surgeons’
early experience in this technique.32,42,48,52,55
In terms of surgeon experience in the two-incision
procedure, one study reported that the study did
not represent the surgeon’s “initial learning
curve”,38 whereas another study reported that the
surgeon performing all operations was
experienced in the standard single incision
procedure but the two-incision procedure
represented the surgeon’s learning curve.53
THRs may be combined with the accelerated
rehabilitation programme and the refined
analgesic package. Although these may vary across
studies, none of the included studies indicated
that the programmes differed significantly
between the groups.
Assessment of effectiveness
A full description of the selected outcomes
reported in the included studies is given in
Appendix 9. Detailed results of meta-analyses
performed are given in Appendix 10.
One mini-incision versus one standard incision
Clinical performance
Revision rate
Table 8 and Figure 1 show the number of patients
requiring revision operations in the single mini-
Health Technology Assessment 2008; Vol. 12: No. 26
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TABLE 8 Revision rate (number having revision surgery)a
Study Mini-incision Standard incision Reported p-values
n/N % n/N %
RCT and quasi-RCT
Chimento, 200531 1/27 0/29
Hart, 200540 0/60 0/60
Ogonda, 200546 0/110 0/109
Subtotal 1/197 0.5 0/198 0
Peto OR (95% CI) 7.96 (0.16 to 402.02), p = 0.30
Comparative studies
Asayama, 200628 2/50 0/52
Ciminiello, 200633 1/60 0/60
Li, 200544 0/18 1/18
Szendrói 2006,52 MI/MD 0/38 0/43
Szendrói 2006,52 MI/SI 0/38 0/21
Wright, 200456 0/37 0/39
Subtotal 3/241 1.2 1/233 0.4
Case series
Flören, 200639 8/90
Pipino, 200449 2/331
Siguier, 200450 0/926
Swanson, 200551 21/1000
Norwegian Arthroplasty  2/143
Register, 200611b
Norwegian Arthroplasty  0/57
Register (unpublished)c
Subtotal 33/2547 1.3
a Time to revision was not reported. 
b Based on the 2005 data collection period.
c Based on the 2006 data collection period up to 19 December 2006 (Espehaug B, Norwegian Arthroplasty Register:
personal communication, 5 January 2007).incision group and the standard incision group by
study type. Of the three trials (RCTs and quasi-
RCTs) and six comparative studies reporting this
outcome, the length of follow-up ranged from
3 months33,46,52 through <1 year44 and
2 years28,31 to >3 years.40,56 In both trials and
comparative studies, a total of only five
participants had a revision surgery. Given the
limited data available, the CIs are very wide and
include differences that are not clinically plausible
(Appendix 10, Comparison 01:01, Peto OR 7.96,
95% CI 0.16 to 402.02, p = 0.30). Overall, revisions
occurred in between 0.5 and 1.2% of minimal
incision cases depending on the source of data,
with case series and registries showing a higher
percentage, which probably reflects their relatively
longer follow-up (between 1 and 10 years).
Postoperative dislocation rates
Dislocation was also uncommon, occurring in
between 0.2 and 1.8% (the latter estimate being
based on case series data) of minimal incision
cases depending on the source of data (Table 9 and
Figure 2; Appendix 10, Comparison 01:02). The
corresponding rates for standard THR were 0.9
and 1.1% based on data from trials and
comparative studies, respectively. There were no
clear differences between groups and the CIs were
wide, including differences that are not clinically
plausible. There was a tendency in favour of the
mini-incision groups in the comparative studies,
but this was not apparent in the randomised 
trials.
Surrogates for long-term outcomes
Implant position (cup and stem) Three trials and six
comparative studies provided information
describing poor placement of the acetabular
component (cup) using various definitions
(Table 10 and Figure 3; Appendix 10, Comparison
01:03). Compared with standard incision 
THR, the proportion of cups poorly placed in
Effectiveness
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Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  01 Revision rate (number having revision surgery)
01 RCT
 Chimento  2005  (RCT)  1/27  0/29
  Hart 2005 (Q-RCT)  0/60  0/60
  Ogonda 2005 (RCT)    0/110    0/109
Subtotal (95% CI)       197       198
Total events: 1 (Mini-incision), 0 (Standard incision)
Test for heterogeneity: not applicable
Test for overall effect: z = 1.04 (p = 0.30)
02 Comparative studies
 Asayama  2006  2/50  0/52
 Ciminiello  2006  1/60  0/60
 Li  2005  0/18  1/18
  Szendrói 2006 MI/MD  0/38  0/43
  Szendrói 2006 MI/SI  0/38  0/21
 Wright  2004  0/37  0/39
Total events: 3 (Mini-incision), 1 (Standard incision)
7.96 (0.16 to 402.02)
        Not estimable
        Not estimable
7.96 (0.16 to 402.02)
7.85 (0.48 to 127.30)
7.39 (0.15 to 372.38)
0.14 (0.00 to 6.82)
        Not estimable
        Not estimable
        Not estimable
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
100.00
100.00
49.74
25.13
25.13
0.001 0.01 0.1 1 10
Mini-incision Standard incision
100 1000
FIGURE 1 Meta-analysis of revision ratesHealth Technology Assessment 2008; Vol. 12: No. 26
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8mini-incision THR was similar based on the trial
data [22/235 (9.4%) versus 24/239 (10%), Peto OR
0.93, 95% CI 0.50 to 1.74, p = 0.83] but slightly
higher based on data from comparative studies
[23/280 (8.2%) versus 18/301 (6%)]. There were
marked differences between studies in their overall
rates, which may be explained by the differences
in definitions used.
Table 11 and Figure 4 (Appendix 10, Comparison
01:04) show the results of studies reporting the
number of (variously defined) femoral component
(stems) that were poorly placed in mini- and
standard incision THR. No trend was discernible
favouring either treatment group and again there
were wide differences between studies in their
overall rates.
Implant migration One trial40 and one comparative
study33 provided information on implant
migration (Appendix 10, Comparison 01:05).
There was no case of implant migration 
observed in the trial [mini-incision (MI) 0/60
versus standard incision (SI) 0/60] and the
comparative study reported one case in the 
mini-incision group (MI 1/60 versus SI 0/60).
Effectiveness
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Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  02 Postoperative dislocation rates
 
01 RCT
  Chimento 2005 (RCT)  2/28  0/32
  Chung 2004 (Q-RCT)  0/60  0/60
  Hart 2005 (Q-RCT)  1/60  1/60
  Kim 2006 (Q-RCT)  1/70  1/70
  Ogonda 2005 (RCT)    1/109    1/110
  Sharma 2006 (Q-RCT)  0/20  0/20
Subtotal (95% CI)      347      352
Total events: 5 (Mini-incision), 3 (Standard incision)
Test for heterogeneity: 2 = 1.75, df = 3 (p = 0.63), I2 = 0%
Test for overall effect: z = 0.76 (p = 0.45)
02 Comparative studies
 Asayama  2006  0/52  1/50
  Berger 20  0/99    0/100
 Chen  2006  0/51  0/95
 Ciminiello  2006  0/60  0/60
   DiGioia 2003  0/33  0/33
 O’Brien  2005  0/34  0/53
  Szendrói 2006 MI/MD  0/38  0/43
  Szendrói 2006 MI/SI  0/38  0/21
 Teet  2006  1/73  4/54
 Woolson  2004  0/50  1/85
 Wright  2004  0/42  1/42
Total events: 1 (Mini-incision), 7 (Standard incision)
8.84 (0.54 to 145.71)
     Not estimable
1.00 (0.06 to 16.18)
1.00 (0.06 to 16.15)
1.01 (0.06 to 16.24)
        Not estimable
1.72 (0.43 to 6.92)
0.13 (0.00 to 6.56)
     Not estimable
     Not estimable
     Not estimable
     Not estimable
     Not estimable
     Not estimable
     Not estimable
0.21 (0.03 to 1.24)
0.20 (0.00 to 11.83)
0.14 (0.00 to 6.82)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
24.72
25.05
25.08
25.15
100.00
13.04
61.74
12.17
13.05
0.01 0.1 1 10
Mini-incision Standard incision
100
FIGURE 2 Meta-analysis of postoperative dislocation ratesHealth Technology Assessment 2008; Vol. 12: No. 26
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TABLE 10 Implant position (cup, number poorly placed)
Study Mini-incision Standard incision Reported p-values
n/N % n/N %
RCT and quasi-RCT
Chung, 200432 0/60 0/60 0
Kim, 200643 6/70 5/70
Ogonda, 200546 16/105 19/109 NS
Subtotal 22/235 9.4 24/239 10.0
Peto OR (95% CI) 0.93 (0.50 to 1.74), p = 0.83
Comparative studies
Asayama ,200628 0/52 0/50
Ciminiello, 200633 0/60 0/60
Szendrói, 200652 MI/MD 4/38 2/43 0.348
Szendrói, 200652 MI/SI 4/38 3/21 0.686
Woolson, 200455 15/50 13/85 0.04
Wright, 200456 0/42 0/42
Subtotal 23/280 8.2 18/301 6.0
Case series
Pipino, 200449 29/353
Swanson, 200551 30/1000
Subtotal 59/1353 4.4
NS, not significant.
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  03 Implant position (cup, number poorly placed)
 
01 RCT
  Chung 2004 (Q-RCT)    0/60    0/60
  Kim 2006 (Q-RCT)    6/70    5/70
  Ogonda 2005 (RCT)    16/105    19/109
Subtotal (95% CI)         235         239
Total events: 22 (Mini-incision), 24 (Standard incision)
Test for heterogeneity: 2 = 0.24, df = 1 (p = 0.62), I2 = 0%
Test for overall effect: z = 0.21 (p = 0.83)
02 Comparative studies
  Asayama 2006    0/52    0/50
  Ciminiello 2006    0/60    0/60
  Szendrói 2006 MI/MD    4/38    2/43
  Szendrói 2006 MI/SI    4/38    3/21
 Woolson  2004  15/50  13/85
  Wright 2004    0/42    0/42
Total events: 23 (Mini-incision), 18 (Standard incision)
     Not estimable
1.22 (0.36 to 4.15)
0.85 (0.41 to 1.76)
0.93 (0.50 to 1.74)
     Not estimable
     Not estimable
2.33 (0.44 to 12.21)
0.70 (0.14 to 3.60)
2.43 (1.03 to 5.73)
     Not estimable 
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
25.77
74.23
100.00
17.39
17.86
64.74
Mini-incision Standard incision
0.1 0.2 0.5 1 2 5 10
FIGURE 3 Meta-analysis of implant position (cup, number poorly placed)Effectiveness
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8Three further case series with 70, 100 and 331
participants, respectively, reported no case of
implant migration.39,41,49
Heterotopic ossification Two comparative studies
(N = 86) reported a total of four cases of
heterotopic ossification, all occurring in the
standard incision group (Appendix 10,
Comparison 01:06).35,78 Two further case series
also provided information on heterotopic
ossification. One of these studies with
926 participants50 reported no incidents, 
whereas the other study49 reported that it 
occurred in 44% (155/353) of the participants. 
The latter study is based on the Brooker’s
classification grades (grade I = 106, 
II = 28, III = 21, IV = 0, where grade IV is 
the worst).
Cement quality Table 12 (Appendix 10, Comparison
01:07) shows the results of studies reporting the
number of implants with poor cement quality
(variously defined). The trial data show no
statistically significant differences in the average
number of implants with poor cement quality [MI
31/192 (16.1%) versus SI 27/197 (13.7%), Peto OR
1.26, 95% CI 0.70 to 2.27, p = 0.45]. None of the
comparative studies reporting this outcome
observed any implants with poor cement quality.
One case series with 70 participants39 reported
that ten arthroplasties showed radiolucent lines in
one or more zone. 
Limb length inequality
One comparative study reported that there were
no patients who had inequality in length across
their limbs post-operation (MI 0/52 versus SI
Health Technology Assessment 2008; Vol. 12: No. 26
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Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  04 Implant position (stem, number poorly placed)
 
01 RCT
 Chimento  2005  (RCT)  1/28  1/32
  Chung 2004 (Q-RCT)  0/60  0/60
  Hart 2005 (Q-RCT)  6/60  7/60
  Kim 2006 (Q-RCT)  4/70  4/70
  Ogonda 2005 (RCT)    3/105    8/109
Subtotal (95% CI)       323       331
Total events: 14 (Mini-incision), 20 (Standard incision)
Test for heterogeneity: 2 = 1.28, df = 3 (p = 0.73), I2 = 0%
Test for overall effect: z = 0.76 (p = 0.45)
02 Comparative studies
 Asayama  2006  0/52  0/50
 Ciminiello  2006  0/60  0/60
   de Beer 2004  0/30  0/30
 O’Brien  2005  1/34  3/53
  Szendrói 2006 MI/MD  2/38  2/43
  Szendrói 2006 MI/SI  2/38  1/21
 Teet  2006  4/73  4/54
 Woolson  2004  6/50  3/85
 Wright  2004  0/42  0/42
Total events: 15 (Mini-incision), 13 (Standard incision)
1.15 (0.07 to 18.88)
     Not estimable
0.84 (0.27 to 2.65)
1.00 (0.24 to 4.15)
0.40 (0.12 to 1.34)
0.70 (0.35 to 1.40)
     Not estimable
     Not estimable
     Not estimable
0.54 (0.07 to 4.19)
1.14 (0.15 to 8.42)
1.11 (0.10 to 12.27)
0.72 (0.17 to 3.06)
3.86 (0.96 to 15.59)
     Not estimable
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
6.17
36.85
23.95
33.04
100.00
14.45
15.07
10.44
29.03
31.02
Mini-incision Standard incision
0.1 0.2 0.5 1 2 5 10
FIGURE 4 Meta-analysis of implant position (stem, number poorly placed)Effectiveness
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TABLE 13 Blood loss (intraoperative, ml)
Study Mini-incision Standard incision Reported p-values
n/N Valuea n/N Valuea
RCT and quasi-RCT
Charles, 200669 20 460.0 20 462.5 0.966
Chimento, 200531 28 127 (48) 32 170 (65) 0.003
Chung, 200432 60 136.0 (41.1) 60 200.5 (65.2) <0.01
Hart ,200540 60 318.8 [200–460] 60 544.4 [390–880]
Kim, 200643 70 445.8 70 567.5 0.1687
Ogonda, 200546 109 314.0 [90–1310] 110 365.8 [100–1100] 0.03
Rachbauer 200675 60 Less 60 More <0.01
Subtotal 407 412
WMD (95% CI)b –56.59 (–71.63 to –41.55), 
p < 0.00001
Comparative studies
Asayama, 200628 52 217.0 [50–600] 50 247.0 [100–550]
Berger, 200429 99 154 100 278 >0.05
Chen, 200630 51 175.49 (51.9) 95 293.68 (84.5)
Ciminiello, 200633 60 201.67 [40–170] 60 191.73 [100–400] 0.812
de Beer, 200434 30 180.0 (69) 30 246.7 (99) 0.04
Howell, 200442 50 387 (155) 57 469 (147) 0.007
Pilot, 200648 10 699 10 540 0.28
Szendrói, 200652 MI/MD 38 244 (100) 43 265(114) 0.399
Szendrói, 200652 MI/SI 38 244 (100) 43 304 (136) 0.098
Woolson, 200455 50 603 85 507 0.12
Wright, 200456 42 151.8 (53.9) 42 173.2 (57.5) 0.08
Subtotal 520 615
Case series
Pipino 200449 368 150
Swanson 200551 1000 317.3 (230.6)
Subtotal 1368
a Values are reported as average (SD) [range].
b Based on the analysis using estimated SDs from p-values where relevant data were not reported.
TABLE 12 Cement quality (number with poor quality)
Study Mini-incision Standard incision Reported p-values
n/N % n/N %
RCT and quasi-RCT
Chimento, 200531 3/27 1/28 0.4
Hart, 200540 0/60 0/60
Ogonda, 200546 28/105 26/109 0.93
Subtotal 31/192 16.1 27/197 13.7
Peto OR [95% CI] 1.26 (0.70 to 2.27), p = 0.45
Comparative studies
Szendrói, 200652 MI/MD 0/24 0/25
Szendrói, 200652 MI/SI 0/24 0/11
Woolson, 200455 0/12 0/21
Wright 200456 0/42 0/42
Subtotal 0/102 0 0/99 00/50).28 One case series reported that 8.5%
(28/331) of participants had a change in limb
length of up to 1 cm but none of the participants
had a change in limb length more than 1 cm.49
Another study reported that 8.8% (88/1000) of
participants had inequality in limb length of more
than 7 mm.51 In a further study, limb length
inequality was noted in 7% (7/100) of participants
with a maximum discrepancy of 5 mm.41
Safety
Blood loss
Table 13 shows the results of studies that reported
the amount of blood loss for patients during the
operation. The reported blood loss varied widely
across studies. Nevertheless, all seven trials, and
eight of the 11 comparative studies favoured the
mini-incision group. The data from the case series
for mini-incision THR were consistent with data
from the trials and comparative studies.
Only two trials31,32 reported SDs and were
therefore suitable for quantitative synthesis. 
The results show that there was significantly less
blood loss in the mini-incision group than in 
the standard incision group (Appendix 10,
Comparison 01:09, WMD –58 ml, 95% CI –74 
to –42, p < 0.00001). This result is broadly 
consistent with further analyses supplemented
with SDs on the basis of reported p-values 
(Figure 5; Appendix 10, Comparison 02:09, 
WMD –57 ml, 95% CI –72 to –42, p < 0.00001).
When supplemented further with dummy SDs 
for the Hart study,40 significant differences
remained, although there was significant
statistical heterogeneity (Appendix 10,
Comparison 03:09, WMD –99 ml, 95% CI 
–112 to –86, p < 0.00001). Using a random
effects model did not change this pattern 
(WMD –86 ml, 95% CI –162 to –10, 
p = 0.03).
Health Technology Assessment 2008; Vol. 12: No. 26
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Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision (p-value)
Outcome:  09 Blood loss (intraoperative, ml)
 
01 RCT
  Charles 2006 (RCT)  
 Chimento  2005  (RCT)
  Chung 2004 (Q-RCT)
  Hart 2005 (Q-RCT)
  Kim 2006 (Q-RCT)
 Ogonda  2005  (RCT)
Subtotal (95% CI)
Test for heterogeneity: 2 = 2.94, df = 4 (p = 0.57), I2 = 0%
Test for overall effect: z = 7.37 (p < 0.00001)
02 Comparative  studies
 Asayama  2006
 Berger  20
 Chen  2006
 Ciminiello  2006
  de Beer 2004
 Howell  2004
 Pilot  2006
  Szendrói 2006 MI/MD
  Szendrói 2006 MI/SI
 Woolson  2004
 Wright  2004
  20  460.00 (184.25)  20  462.50 (184.25)
  28  127.00 (48.00)  32  170.00 (65.00)
  60  136.00 (41.10)  60  200.50 (65.20)
  60  318.80 (0.00)  60  544.40 (0.00)
  70   445.80 (521.95)  70  567.50 (521.95)
109   314.20 (174.78)  110  365.80 (174.78)
347   352
  
  52  217.50 (0.00)  50   247.00 (0.00)
  99  154.00 (443.49)  100  278.00 (443.49)
  51  175.49 (51.90)  95  293.68 (84.50)
  60  201.67 (228.39)  60  191.73 (228.39)
  30  180.00 (69.00)   30  246.70 (99.00)
  50  387.00 (155.00)   57  469.00 (147.00)
  10  699.00 (319.20)  10  540.00 (319.20)
  38  244.00 (100.00)  43  265.00 (114.00)
  38  244.00 (100.00)  43  304.00 (136.00)
  50  603.00 (344.21)  85  507.00 (344.21)
  42  151.80 (53.90)   42  173.20 (57.50)
    –2.50 (–116.70 to 111.70)
  –43.00 (–71.69 to –14.31)
  –64.50 (–84.00 to –45.00)
              Not estimable
–121.70 (–294.62 to –51.22)
  –51.60 (–97.90 to –5.30)
  –56.59 (–71.63 to –41.55)
              Not estimable
–124.00 (–247.24 to –0.76)
–118.19 (–140.36 to –96.02)
      9.94 (–71.79 to 91.67)
  –66.70 (–109.88 to –23.52)
  –82.00 (–139.46 to –24.54)
  159.00 (–120.79 to 438.79)
  –21.00 (–67.60 to 25.60)
  –60.00 (–111.61 to –8.39)
    96.00 (–24.24 to 216.24)
  –21.40 (–45.24 to 2.44)
Study
or subcategory NN Mean (SD) Mean (SD)
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
  1.73
 27.48
 59.48
  0.76
 10.55
100.00
  
1.14
 35.27
  2.60
  9.30
  5.25
  0.22
  7.98
  6.51
  1.20
 30.52
–100 –50 0 50
Mini-incision Standard incision
100
 
FIGURE 5 Meta-analysis of blood loss estimated using trial data supplemented by calculated standard deviations from reported 
p-valuesTwo further comparative studies reported on 
total (rather than intraoperative) blood loss, 
with one (N = 36) favouring mini-incision (318
versus 523 ml, reported p-value <0.05)44 and 
the other (N = 20) slightly favouring standard
incision (796 versus 772 ml, p-value 
unknown).78
Fractures
Intraoperative fractures occurred between 0 
and 2.7% in the mini-incision group and 
between 0.5 and 1.2% in the standard group 
(Table 14; Appendix 10, Comparison 01:11). The
rates varied depending on the source of data.
Three trials (N = 339) reported no cases among
169 in the mini-incision group compared with 
the two among 170 in the standard incision 
group. In contrast, the comparative studies
examining this outcome (N = 790) tended to
favour the standard incision group. 
With respect to postoperative fractures (Table 14;
Appendix 10, Comparison 01:12), there were no
cases reported in the trials examining this
outcome (N = 160) but results from the
comparative studies (N = 326) again favoured the
standard incision group.
Other adverse effects
Infections Infections (including wound, superficial
or deep infections) during the postoperative
period appear to be uncommon in the included
studies with less than 1% across all data sources
and surgical techniques (Table 15 and Figure 6) and
Effectiveness
24
TABLE 14 Intraoperative and postoperative fractures
Study Mini-incision Standard incision Reported p-values
n/N % n/N %
Intra-operative fractures
RCT and quasi-RCT
Hart, 200540 0/60 0/60
Ogonda, 200546 0/109 2/110
Subtotal 0/169 0 2/170 1.2
Peto OR (95% CI) 0.14 (0.01 to 2.18), p = 0.16
Comparative studies
Asayama, 200628 2/52 0/50
Berger, 200429 1/99 1/100
Howell, 200442 2/50 0/57
O’Brien, 200545 2/34 1/53
Szendrói, 200652 MI/MD 0/38 0/43
Szendrói 200652 MI/SI 0/38 0/21
Takahira, 200678 1/10 0/10
Woolson, 200455 2/50 0/85
Subtotal 10/371 2.7 2/419 0.5
Case series
Swanson, 200551 10/1000 1.0
Post-operative fractures
RCT and quasi-RCT
Hart, 200540 0/60 0/60
Sharma, 200677 0/20 0/20
Subtotal 0/80 0 0/80 0
Peto OR (95% CI) Not estimable
Comparative studies
Chen, 200630 3/51 4/95
Ciminiello, 200633 0/60 0/60
de Beer, 200434 1/30 0/30
Subtotal 4/141 2.8 4/185 2.2
Case series
Pipino, 200449 3/331
Siguier, 200450 1/926
Swanson, 200551 3/1000
Subtotal 7/2257 0.3Health Technology Assessment 2008; Vol. 12: No. 26
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4hence with wide confidence intervals around
estimates of differences between the two
approaches which are not clinically plausible.
Nerve injury Reports of postoperative nerve injury
were also rare. Data from the six trials and nine
comparative studies that reported the number of
postoperative nerve injuries (Table 16;
Appendix 10, Comparison 01:14) showed no
statistically significant differences between the
mini-incision group and standard incision group,
although with wide 95% CIs for the trials [Table 16;
Appendix 10, Comparison 01:14, 2/298 (0.7%)
versus 1/302 (0.3%), Peto OR 1.95, 95% CI 0.20 to
18.89, p = 0.56].
Two case series49,51 also provided information on
the number of nerve injuries following mini-
incision surgery at a slightly lower rate (0.4%),
compared with the data from the trials (0.7%) or
the comparative studies (1.7%). 
Vascular injury One trial with 120 participants
reported that there were no events of vascular
injury.58 Also, one case series with 331 participants
which provided information on vascular injuries
reported no events following mini-incision
surgery.49
Thrombosis Five trials and six comparative studies
provided information on DVT (Table 17 and
Figure 7). In all studies where DVT occurred, 
there were slightly fewer events in the mini-
incision groups than in the standard groups 
(0.9% versus 2.5% in the trial, 2.1% versus 4.3%
in the comparative studies), although meta-
analysis of the trial data found no statistically
significant difference (Appendix 10, Comparison
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Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome: 13  Infections
 
01 RCT
 Chimento  2005  (RCT)  0/28  0/32
  Chung 2004 (Q-RCT)  0/60  0/60
  Hart 2005 (Q-RCT)  0/60  0/60
  Kim 2006 (Q-RCT)  1/70  0/70
  Ogonda 2005 (RCT)    2/109    0/110
 Sharma  2006  (Q-RCT)  0/20  0/20
  Zhang 2006 (RCT)  0/60  0/60
Subtotal (95% CI)      407      412
Total events: 3 (Mini-incision), 0 (Standard incision)
Test for heterogeneity: 2 = 0.00, df = 1 (p = 0.99), I2 = 0%
Test for overall effect: z = 1.74 (p = 0.08)
02 Comparative studies
 Asayama  2006  0/52  1/50
  Berger 20  0/99    0/100
 Ciminiello  2006  0/60  0/60
   Howell 2004  0/50  1/57
 O’Brien  2005  0/34  0/53
  Szendrói 2006 MI/MD  0/38  0/43
  Szendrói 2006 MI/SI  0/38  0/21
 Woolson  2004  1/50  0/85
 Wright  2004  0/42  0/42
Total events: 1 (Mini-incision), 2 (Standard incision)
        Not estimable
        Not estimable
        Not estimable
  7.39 (0.15 to 372.38)
  7.53 (0.47 to 121.10)
        Not estimable
        Not estimable
  7.48 (0.78 to 72.16)
  0.13 (0.00 to 6.56)
        Not estimable
        Not estimable
  0.15 (0.00 to 7.78)
        Not estimable
        Not estimable
        Not estimable
14.88 (0.26 to 861.53)
        Not estimable
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
33.44
66.56
100.00
34.14
34.01
31.86
0.01 0.1 1 10
Mini-incision Standard incision
100
FIGURE 6 Meta-analysis of infections01:16, Peto OR 0.39, 95% CI 0.12 to 1.30, 
p = 0.12). 
Three further studies reported on PE (Table 17).
Of these, one comparative study45 reported one
episode of PE in the mini-incision group. 
Resource utilisation
Duration of operation
All nine included trials provided information on
the duration of operation (Table 18). Of these,
three showed that the average duration was
shorter in the mini-incision group,32,43,46 four
showed that it was shorter in the standard incision
group,31,40,58,69 one reported no difference but did
not report any data75 and the ninth only provided
a (non-significant) p-value77 (Table 18). In the
comparative studies, eight30,33,44,45,52,55,56 of the 15
studies reporting this outcome found the
operation shorter on average in the mini-incision
group compared with seven in the standard
incision group.28,29,34,35,42,48,78
The trials reporting SDs tended to be those that
favoured mini-incisions. For this reason, we chose
to estimate SDs for the others using reported 
p-values (calculated SDs). The results suggested a
small difference in favour of mini-incisions for this
analysis (Table 18 and Figure 8; Appendix 10,
Comparison 02:18, WMD –3.70 minutes, 95% CI
–5.67 to –1.74, p = 0.0002). Caution is required,
as this analysis displayed statistical heterogeneity.
Effectiveness
28
TABLE 17 DVT and PE
Study Mini-incision Standard incision Reported p-values
n/N % n/N %
RCT and quasi-RCT
Chimento, 200531 0/28 0/32
Chung, 200432 3/60 5/60
Hart, 200540 0/60 0/60
Ogonda, 200546 0/109 1/110
Zhang, 200658 0/60 2/60
Subtotal 3/317 0.9 8/322 2.5
Peto OR (95% CI) 0.39 (0.12 to 1.30), p = 0.12
Comparative studies
Asayama, 200628 0/52 1/50
De Beer, 200434 0/30 1/30
O’Brien, 200545 0/34 3/53
Szendrói, 200652 MI/MD 2/38 3/43
Szendrói, 200652 MI/SI 2/38 2/21
Woolson, 200455 1/50 2/85
Subtotal 5/242 2.1 12/282 4.3
Case series
Hartzband, 200641 4/100 4.0
PE
RCT and quasi-RCT
Hart 200540 0/60 0/60
Subtotal 0/60 0 0/60 0
Peto OR (95% CI) Not estimable
Comparative studies
Berger, 200429 0/99 0/100
O’Brien, 200545 1/34 0/53
Subtotal 1/133 0.8 0/153 0
Case series
Swanson, 200551a 12/1000 1.2
a Includes both DVT and PE.After applying random effects models, the
differences between mini- and standard incision
surgery were no longer statistically significant
(WMD –2.35, 95% CI –6.86 to 2.16, p = 0.31).
Analyses based on the published data and the 
data supplemented with the dummy SDs are
reported in Appendix 10, Comparisons 01: 18 
and 03:18.
On the assumption that the trials are least biased,
overall, there may be a small difference of around
2–5 minutes in operating time favouring mini-
incision. However, this is not certain and the
difference may not have any practical significance.
Length of hospital stay
The reported length of hospital stay varied from 1
to 23 days (Table 19). Compared with the standard
incision group, five32,46,58,69,77 of the six trials and
seven29,30,35,42,45,74,78 of the 12 comparative studies
that provided information on length of hospital
stay reported shorter average hospital stay in the
mini-incision group. The difference between the
two groups tended to be small or for 1 or 2 days,
except one trial by Zhang and colleagues
reporting the largest difference of more than
6 days.58 The length of stay reported in the case
series was generally consistent with the data on
length of stay for the mini-incision group in the
trials. 
Meta-analysis of the trial data supplemented by
calculated SDs from reported p-values resulted in 
a mean length of stay that was statistically
significantly shorter in the mini-incision group 
but there was significant statistical heterogeneity 
at the 10% level (Figure 9; Appendix 10,
Comparison 02:19, WMD –0.50 days, 95% CI
–0.83 to –0.18, p = 0.002). When a random effects
model was applied, the difference between groups
was no longer statistically significant (WMD –0.34
days, 95% CI –0.94 to 0.25, p = 0.26). Further
analyses based on the published data and the 
data supplemented with the dummy SDs are
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Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  16 DVT (deep venous thrombosis)
01 RCT
 Chimento  2005  (RCT)  0/28  0/32
  Chung 2004 (Q-RCT)  3/60  5/60
  Hart 2005 (Q-RCT)  0/60  0/60
  Ogonda 2005 (RCT)    0/109    1/110
  Zhang 2006 (RCT)  0/60  2/60
Subtotal (95% CI)      317       322
Total events: 3 (Mini-incision), 8 (Standard incision)
Test for heterogeneity: 2 = 1.17, df = 2 (p = 0.56), I2 = 0%
Test for overall effect: z = 1.54 (p = 0.12)
02 Comparative studies
 Asayama  2006  0/52  1/50
   de Beer 2004  0/30  1/30
 O’Brien  2005  0/34  3/53
  Szendrói 2006 MI/MD  2/38  3/43
  Szendrói 2006 MI/SI  2/38  2/21
 Woolson  2004  1/50  2/85
Total events: 5 (Mini-incision), 12 (Standard incision)
    Not estimable
0.59 (0.14 to 2.45)
    Not estimable
0.14 (0.00 to 6.88)
0.13 (0.01 to 2.15)
0.39 (0.12 to 1.30)
0.13 (0.00 to 6.56)
0.14 (0.00 to 6.82)
0.19 (0.02 to 1.95)
0.75 (0.12 to 4.53)
0.52 (0.06 to 4.22)
0.85 (0.08 to 9.02)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
 71.62
9.51
 18.86
100.00
  6.34
  6.35
17.71
30.03
22.07
17.49
0.1 0.2 0.5 1 2 5
Mini-incision Standard incision
10
FIGURE 7 Meta-analysis of DVTEffectiveness
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Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision (p-value)
Outcome:  28 Duration of operation (minutes)
 
01 RCT
  Charles 2006 (RCT)  
  Chimento 2005 (RCT)
  Chung 2004 (Q-RCT)
  Hart 2005 (Q-RCT)
  Kim 2006 (Q-RCT)
  Ogonda 2005 (RCT)
  Sharma 2006 (Q-RCT)
  Zhang 2006 (RCT)    
Subtotal (95% CI)
Test for heterogeneity: 2 = 21.37, df = 5 (p = 0.0007), I2 = 76.6%
Test for overall effect: z = 3.69 (p = 0.0002)
02 Comparative  studies
 Asayama  2006
 Berger  20
 Chen  2006
 Ciminiello  2006
  de Beer 2004
 DiGioia 
 Howell  2004
 Li  2005
 O’Brien  2005
 Pilot  2006
  Szendrói 2006 MI/MD
  Szendrói 2006 MI/SI
 Takahira  2006
 Woolson  2004
 Wright  2004
  20    95.20 (23.29)  20    87.70 (23.29)
  28    70.30 (10.70)  32    70.00 (8.50)
  60    49.00 (9.40)  60     55.10 (17.90)
  60    71.00 (0.00)  60    70.00 (0.00)
  70    52.00 (15.84)  70    61.00 (15.84)
109    60.30 (9.20)  110    65.90 (13.20)
  20      0.00 (0.00)  20      0.00 (0.00)
  60    75.00 (16.60)  60    69.00 (16.60)
427                           432
  50    58.60 (0.00)  50    57.90 (0.00)
  99    72.00 (0.00)  100    66.00 (0.00)
  51    88.41 (17.60)  95    90.85 (17.81)
  60    55.45 (4.91)  60    56.95 (4.91)
  30    46.60 (14.31)  30    44.50 (14.31)
  33  120.00 (0.00)  33  100.00 (0.00)
  50    97.00 (19.00)  57    84.00 (15.00)
  18    91.00 (16.40)  18    97.00 (15.60)
  32    74.00 (15.00)  51    80.00 (10.00)
  10    99.50 (20.25)  10    81.00 (20.25)
  38    84.00 (16.00)   43    93.00 (18.00)
  38    84.00 (16.00)   21  102.00 (12.00)
  10  126.50 (0.00)  10  119.90 (0.00)
  50    97.00 (29.46)  85  105.00 (29.46)
  42    71.40 (11.20)  42    77.70 (13.20)    
    7.50 (–6.94 to 21.94)
    0.30 (–4.64 to 5.24)
  –6.10 (–11.22 to –0.98)
          Not estimable
  –9.00 (–14.25 to –3.75)
  –5.60 (–8.61 to –2.59)
           Not estimable
    6.00 (0.06 to 11.94)
  –3.70 (–5.67 to –1.74)
           Not estimable
           Not estimable
  –2.44 (–8.45 to 3.57)
  –1.50 (–3.26 to 0.26)
    2.10 (–5.14 to 9.34)
            Not estimable
  13.00 (6.45 to 19.55)
  –6.00 (–16.46 to 4.46)
  –6.00 (–11.88 to –0.12)
  18.50 (0.75 to 36.25)
  –9.00 (–16.40 to –1.60)
–18.00 (–25.23 to –10.77)
           Not estimable
  –8.00 (–18.29 to 2.29)
  –6.30 (–11.54 to –1.06)
Study
or subcategory NN Mean (SD) Mean (SD)
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
1.85
15.84
14.76
14.02
42.59
10.94
100.00
5.33
62.47
3.68
4.50
1.76
5.58
0.61
3.52
3.69
1.82
7.04
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FIGURE 8 Meta-analysis of duration of operation time estimated using trial data supplemented by calculated SDs from reported 
p-valuesreported in Appendix 10, Comparisons 01:19 
and 03:19.
Caution is required, since these differences may
reflect the clinical policy of each hospital for
discharge rather than the clinical need of each
patient. For this reason, it may not be appropriate
to place much weight on these values.
Patient-centred measures
Deaths
Two trials31,46 and two comparative studies33,56
provided information on the number of
participants who died during the first 30 days of
the study period (30-day mortality) and also
during the entire study period (long-term
mortality) (Table 20). In terms of 30-day mortality,
one trial reported that two of the 110 patients
(1.8%) in the standard incision group had died in
the early postoperative period (Appendix 10,
Comparison 01:20).46 No deaths were reported
during the early phase of the comparative
studies.33,56
In terms of long-term mortality, two of the 32 trial
participants (6.3%) in the standard incision group
had died during the 2-year period but these
events were reported to be unrelated to surgery.31
One comparative study reported two deaths (2%)
in each of the mini-incision and standard incision
groups over the period of 5 years but similarly
reported that these were secondary to events
Effectiveness
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TABLE 19 Length of hospital stay (days)
Study Mini-incision Standard incision Reported p-values
n/N Valuea n/N Valuea
RCT and quasi-RCT
Charles, 200669 20 5.35 20 5.70 0.501
Chimento, 200531 28 5.8 [4–13] 32 5.5 [3–15] 0.6
Chung, 200432 60 4.41 (1.1) 60 5.34 (1.4) <0.01
Ogonda, 200546 109 3.65 (2.04) 110 3.68 (2.45) 0.94
Sharma, 200677 20 Shorter 20 Longer 0.042
Zhang, 200658 60 7 [5–8] 60 13.5 [12–16] NR
Subtotal 297 302
WMD (95% CI)b –0.50 (–0.83 to –0.18), 
p = 0.002
Comparative studies
Asayama, 200628 52 2.96 (1–6) 50 2.94 (2–4) 0.858
Berger, 200429 100 1.9 100 3.5 >0.05
Chen, 200630 51 11.16 (0.83) 95 12.83 (1.96)
Ciminiello, 200633 60 3.70 [2–7] 60 3.63 [2–5] 0.94
de Beer, 200434 30 5.13 [3–8] 30 5.1 [4–8] 0.894
DiGioia, 200335 33 3.8 33 3.9 0.6
Howell, 200442 50 4.4 (2.9) 57 5.7 (3.1) 0.03
O’Brien, 200545 35 5.4 (2.1) 53 6.2 (2.8)
Panisello, 200674 40 5.6 40 6.7 NR
Takahira, 200678 10 22 10 23.4 NR
Woolson, 200455 50 4.3 85 4.0 0.44
Wright, 200456 42 6.12 42 6.07 0.92
Subtotal 553 655
Case series
Flören, 200639 79 4.7 (2.0)
Hartzband, 200641 100 2.89 [3–5]
Swanson, 200551 1000 3.7 (1.8)
Subtotal 1079
NR, not reported.
a Values are reported as average (SD) [range].
b Based on the analysis using SDs estimated from p-values where relevant data were not reported.unrelated to the hip arthroplasty.56 No deaths
were reported in another comparative study with a
relatively short (6-week) follow-up (Appendix 10,
Comparison 01:21).33
Pain
Postoperative pain was reported using various
measures, including analgesic requirements, pain
scores and the number of patients reporting pain
(Tables 21–23). The available data were mostly
derived from short-term (3 months) results. Five
RCTs31,32,46,69,75 and three comparative
studies28,33,34 reported data on analgesic needs
(Table 21). In all but two69,75 of these studies, the
average analgesic usage was slightly less in the
mini-incision groups but these differences were
small. This difference was not found to be
statistically significant in any of the studies which
performed a statistical test. As the outcome
measures varied between studies and not all
studies reported data amenable to meta-analysis,
only limited quantitative synthesis was possible.
The meta-analyses that were conducted are
reported in Appendix 10, Comparisons
01:22–01:24, and none of these provided any
evidence of a difference between mini- and
standard incision.
In terms of pain scores (short-term), results were
similar with five46,52,75,77 of the six studies with
data favouring the mini-incision groups (Table 22;
Appendix 10, Comparison 01:26). In three studies
which performed a statistical test, this difference
was found to be statistically significant. Results in
terms of the number of patients reporting short-
term pain, derived from three studies,28,33,34 were
Health Technology Assessment 2008; Vol. 12: No. 26
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Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision (p-value)
Outcome:  19 Length of hospital stay (days)
 
01 RCT
  Charles 2006 (RCT)  
 Chimento  2005  (RCT)
  Chung 2004 (Q-RCT)
 Ogonda  2005  (RCT)
 Sharma  2006  (Q-RCT)
  Zhang 2006 (RCT)    
Subtotal (95% CI)
Test for heterogeneity: 2 = 7.94, df = 3 (p = 0.05), I2 = 62.2%
Test for overall effect: z = 3.03 (p = 0.002)
02 Comparative  studies
 Asayama  2006
 Berger  20
 Chen  2006
 Ciminiello  2006
  de Beer 2004
 DiGioia
 Howell  2004
 O’Brien  2005
 Panisello  2006
 Takahira  2006
 Woolson  2004
 Wright  2004
  20  5.35 (1.63)  20    5.70 (1.63)
  28  5.80 (2.20)  32    5.50 (2.20)
  60  4.41 (1.10)  60    5.34 (1.40)
109  3.65 (2.04)  110    3.68 (2.45)
  20  0.00 (0.00)  20    0.00 (0.00)
  60  7.00 (0.00)  60  13.50 (0.00)
297   302
  52    2.96 (0.56)  50    2.94 (0.56)
100    1.90 (5.74)  100    3.50 (5.74)
  51  11.16 (0.83)  95  12.83 (1.96)
  60    3.70 (5.08)  60    3.63 (5.08)
  30    5.13 (0.87)  30    5.10 (0.87)
  33    3.80 (0.77)  33    3.90 (0.77)
  50    4.40 (2.90)  57    5.70 (3.10)
  35    5.40 (2.10)  53    6.20 (2.80)
  40    5.60 (0.00)  40    6.70 (0.00)
  10  22.00 (0.00)  10  23.40 (0.00)
  50    4.30 (2.17)  85    4.00 (2.17)
  42    6.12 (2.27)  42    6.07 (2.27)
–0.35 (–1.36 to 0.66)
  0.30 (–0.82 to 1.42)
–0.93 (–1.38 to –0.48)
–0.03 (–0.63 to 0.57)
       Not estimable
       Not estimable
–0.50 (–0.83 to –0.18)
  0.02 (–0.20 to 0.24)
–1.60 (–3.19 to –0.01)
–1.67 (–2.13 to –1.21)
  0.07 (–1.75 to 1.89)
  0.03 (–0.14 to 0.47)
–0.10 (–0.47 to 0.27)
–1.30 (–2.44 to –0.16)
–0.80 (–1.83 to 0.23)
       Not estimable
       Not estimable
  0.30 (–0.46 to 1.06)
  0.05 (–0.92 to 1.02)
Study
or subcategory NN Mean (SD) Mean (SD)
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 10.30
  8.44
 51.77
 29.49
100.00
 48.52
  0.91
 11.07
  0.69
 11.83
 16.61
  1.77
  2.18
  3.99
  2.43
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FIGURE 9 Meta-analysis of length of stay estimated using trial data supplemented by calculated SDs from reported p-valuesEffectiveness
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TABLE 20 Mortality
Study Mini-incision Standard incision Reported p-values
n/N % n/N %
30-day mortality
RCT
Ogonda, 200546 0/109 2/110
Subtotal 0/109 0 2/110 1.8
Peto OR (95% CI) 0.14 (0.01 to 2.18), p = 0.16
Comparative studies
Ciminiello, 200633 0/60 0/60
Wright, 200456 0/42 0/42
Subtotal 0/102 0 0/102 0
Long-term mortality
RCT
Chimento, 200531 0/28 2/32
Subtotal 0/28 0 2/32 6.3
Peto OR (95% CI) 0.15 (0.01 to 2.45), p = 0.18
Comparative studies
Ciminiello, 200633 0/60 0/60
Wright, 200456 2/42 2/42
Subtotal 2/102 2.0 2/102 2.0
TABLE 21 Short-term pain – analgesic requirement
Study Measure Mini-incision Standard incision Reported p-value
N Average (SD)  N Average (SD)
[range] [range]
RCT and quasi-RCT
Charles, 200669 PCA narcotic  18 22.8 19 19.5 0.105
consumption (mg)
Chimento, 200531 Patient-controlled  28 285 (185) 32 319 (177) 0.3
epidural anaesthesia (ml)
Chung, 200432 Narcotic use (days) 60 2.20 60 2.64 NS
Ogonda, 200546 Volume of morphine  109 42.9 (97.4) 110 45.0 (96.8) 0.89
used (mg)
Rachbauer, 200675 Use of analgesic 60 No difference 60 No difference NR
Comparative studies
Asayama, 200628 Total intravenous  52 92.7 [37–180] 50 94.9 [38–188] NS
narcotic received during 
hospitalisationa (mg)
Ciminiello, 200633 Equianalgesic  60 118 [10.5–450.6] 60 121 [8.6–390.5] 0.77
requirement up to 
6 weeks (mg)
de Beer, 200434 Equianalgesic opioid  30 147.70 [18–337.9] 30 169.3 [23.3–413.3] 0.336
consumption (mg)
NR, not reported; NS, not statistically significant; PCA, patient controlled analgesia.
a Equianalgesic equivalency to morphine.Health Technology Assessment 2008; Vol. 12: No. 26
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TABLE 22 Other short-term pain
Study Measure Mini-incision Standard incision Reported p-value
N Average (SD)  N Average (SD)
Pain score
RCT and quasi-RCT
Charles, 200669 Pain scorea  18 3.9 19 3.7 0.129
Kim, 200643 10-point analogous  70 NR 70 NR >0.05
scale at 2 weeks and 
3 months
Ogonda, 200546 100-mm visual analogue  109 33 (18.0) 110 33.6 (19.6) 0.82
scale in first 7 days 
following discharge
Rachbauer, 200675 Postoperative pain in  60 Lower 60 Higher Sig.
the first week
Sharma, 200677 10-point visual analogue  20 4.05 20 6.25 0.0089
scale at day 1
Comparative studies
Szendrói 200652 Visual analogue scale at  38 1.5 (1.15) 43 2.15 (1.2) 0.028
(MI/MD) day 3
Szendrói, 200652 Visual analogue scale at  38 1.5 (1.15) 21 2.1 (1.3) 0.112
(MI/SI) day 3
Number of patients reporting pain
Comparative studies
Asayama, 200628 Mild pain 52 2 49 3
Ciminiello, 200633 Thigh pain 60 0 60 0
De Beer, 200434 Subcutaneous hematoma, 
mild sciatica and thigh pain 30 0 30 1
Case series
Pipino, 200449 Thigh pain 331 7
NR = not reported; Sig, statistically significant.
a Details unavailable.
TABLE 23 Long-term pain
Study Measure Mini-incision Standard incision Reported p-value
N Value N Value
RCT and quasi-RCT
Kim, 200643 10-point analogous scale at  70 NR 70 NR >0.05
6 months, 1 year and 2 years
Case series
Flören, 200639 Slight or mild pain (no. of patients) 90 10
Hartzband, 200641 Significant thigh pain 
(no. of patients) 100 0
Pipino, 200449 Persistent thigh pain at  331 1
1 year (no. of patients)
NR, not reported.also slightly better for the mini-incision group
(Table 22; Appendix 10, Comparison 01:25).
Only one trial43 and three case series39,41,49
included a measure of long-term pain (Table 23).
The trial did not report the actual pain score
values at 6–24 months postoperatively but
suggested that the two groups did not differ
significantly. The three case series recorded the
number of patients reporting pain, although the
degree of reported pain varied between the
studies.
Return to usual activities
Only one trial75 and one comparative study30
provided information on time to return to usual or
daily activities (Table 24; Appendix 10,
Comparison 01:28). The average time in the mini-
incision group was shorter in both studies. The
one case series reporting this outcome reported a
shorter time to return to usual activities than
comparative study data. However, definitions and
case mix may have differed.
Two further trials31,32 and one comparative
study28 recorded the number of participants
requiring a stick (cane) or other walking aid or
the duration for which participants used such
devices postoperatively (Table 24; Appendix 10,
Comparisons 01:29 and 01:30). Results were
generally more favourable for the mini-incision
group. The number of patients with a limp in 
the mini-incision group within the first 3 months
after operation was significantly fewer in one
study31 but non-significantly higher in another
(Table 24; Appendix 10, Comparison 01:31).28
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TABLE 24 Return to usual activities
Study Measure Mini-incision Standard incision Reported p-value
N Value (SD) N Value (SD)
Time to return to usual activities
RCT and quasi-RCT
Rachbauer, 200675 Time to return to daily activities 60 Shorter 60 Longer NR
Comparative studies
Chen, 200630 Time to return to normal  51 60 (12) 95 116 (11)
activities (days)
Case series
Pipino, 200449 Return to a full normal lifestyle  331 318
at 1–7 years (no. of patients)
Swanson, 200551 Time to begin unrestricted  1000 29.4
normal daily activities (days)
Use of walking aids: short-term
RCT and quasi-RCT
Chimento, 200531 Required a cane at 6 weeks  28 9 32 15 NS
(no. of patients)
Chung, 200432 Use of walking aids (days) 60 21.4 (4.8) 60 24.8 (5.4)
Comparative studies
Asayama, 200628 Use of walking aid at 3 months  52 4 49 4
(no. of patients) 
Limp: short-term (no. of patients)
RCT and quasi-RCT
Chimento, 200531 Persistent limp at 6 weeks 28 6 31 15 0.04
Comparative studies
Asayama, 200628 Very slight limp at 3 months 52 19 49 16 NS
Case series
Siguier, 200450 Limp 926 0
Limp: long-term (no. of patients)
RCT and quasi-RCT
Chimento, 200531 Persistent limp at 1 year 27 0 29 0
NR, not reported; NS, not statistically significant.Health Technology Assessment 2008; Vol. 12: No. 26
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Review:  Minimal incision approaches to total hip replacement
Comparison:  02 Mini-incision versus standard incision (p-value)
Outcome:  33 Harris hip score (3 months)
01 RCT
  Ogonda 2005 (RCT)
  Zhang 2006 (RCT)    
Subtotal (95% CI)
Test for heterogeneity: 2 = 3.32, df = 1 (p = 0.07), I2 = 69.9%
Test for overall effect: z = 0.98 (p = 0.33)
02 Comparative  studies
 Ciminiello  2006
  de Beer 2004
 DiGioia
107  –84.15 (10.56)  108  –83.36 (8.33)    
  60  –91.40 (35.68)  60  –78.50 (35.68)
167   168
  60  –91.02 (12.17)  60  –94.93 (12.17)
  30  –71.10 (9.80)  30  –66.60 (12.20)
  33  –86.29 (11.62)  33  –80.44 (11.62)
  –0.79 (–3.33 to 1.75)
–12.90 (–25.67 to –0.13)
  –1.25 (–3.75 to 1.24)
    3.91 (–0.44 to 8.26)
  –4.50 (–10.10 to 1.10)
  –5.85 (–11.46 to –0.24)
Study
or subcategory NN Mean (SD) Mean (SD)
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
96.18
3.82
100.00
45.29
27.39
27.31
–10 –5 0 5
Mini-incision Standard incision
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FIGURE 10 Meta-analysis of Harris hip score (3 months) estimated using trial data supplemented by calculated SDs from reported
p-values
TABLE 25 Condition-specific quality of life (3 months)
Study Mini-incision Standard incision Reported p-value
N Value (SD)  N Value (SD)
[range] [range]
Harris hip scorea
RCT and quasi-RCT
Ogonda, 200546 107 84.15 (10.56) 108 83.36 (8.33) 0.54
Zhang, 200658  60 91.4 60 78.5 <0.05
Comparative studies
Ciminiello, 200633 60 91.02 [60–100] 60 94.93 [70–100] 0.081
de Beer, 200434 30 71.1 (9.8) 30 66.6 (12.2) 0.193
DiGioia, 200335 33 86.29 [63–96] 33 80.44 [63–95] 0.045
WOMAC osteoarthritis indexb
RCT and quasi-RCT
Charles, 200669 16 91.99 19 89.60 0.690
Ogonda, 200546 107 74.40 (13.88) 108 73.95 (12.90)
Oxford hip scoreb
RCT and quasi-RCT
Ogonda, 200546 107 24.97 (7.33) 108 25.88 (6.29)
Comparative studies
de Beer, 200434 30 26.50 (8.40) 30 28.40 (7.50) 0.494
Merle d’Aubigné-Charnley Scoreb
RCT and quasi-RCT
Hart, 200540 60 16.6 60 14.1 <0.02
a Higher scores reflect better quality of life.
b Higher scores reflect poorer quality of life.Effectiveness
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TABLE 26 Condition-specific quality of life (>3 months)
Study Mini-incision Standard incision Reported p-value
N Value (SD)  N Value (SD)
[range] [range]
Harris hip score
RCT and quasi-RCT
Chimento, 200531 27 94.5 29 94.5 NR
Chung, 200432 60 95.5 60 93.5 NS
Kim, 200643 70 93 [86–100] 70 91 [85–100] 0.7435
Zhang, 200658 60 95.1 60 95.6 >0.05
Comparative studies
Asayama, 200628 52 96.2 50 96.2 NS
Chen, 200630 51 89.71 (3.62) 95 83.78 (8.03)
DiGioia, 200335 33 96 [86–100] 33 94 [79–100] 0.08
Li, 200544 18 92 18 90 >0.05
Woolson, 200455 20 99 [89–100] 14 97 [65–100] 0.43
Wright, 200456 37 86.9 (4.1) 39 84.2 (6.4) 0.042
Case series
Flören, 200639 79 92.3 (7.9)
Swanson, 200551 1000 92 (9)
Merle d’Aubigné-Charnley score
RCT and quasi-RCT
Hart, 200540 60 17.4 60 17.3 NS
NR, not reported; NS, not statistically significant.
Review:  Minimal incision approaches to total hip replacement
Comparison:  02 Mini-incision versus standard incision (p-value)
Outcome:  34 Harris hip score (>3 months)
01 RCT
  Chimento 2005 (RCT)
  Chung 2004 (Q-RCT)
  Kim 2006 (Q-RCT)
  Zhang 2006 (RCT)    
Subtotal (95% CI)
Test for heterogeneity: 2 = 5.92, df = 2 (p = 0.05), I2 = 66.2%
Test for overall effect: z = 1.43 (p = 0.152)
02 Comparative  studies
 Asayama  2006
 Chen  2006
 DiGioia
 Li  2005
 Woolson  2004
 Wright  2004
  27  –94.50 (0.00)  29  –94.50 (0.00)
  60  –95.50 (5.53)  60  –93.50 (5.53)
  70  –93.00 (35.58)  70  –91.00 (35.58)
  60  –95.10 (1.38)  60  –95.60 (1.38)
217   219
  52  –96.20 (0.00)  50  –96.20 (0.00)
  51  –89.71 (3.62)  95  –83.78 (8.03)
  33  –96.00 (4.57)  33  –94.00 (4.57)
  18  –92.00 (2.95)  18  –90.00 (2.95)
  20  –99.00 (7.18)  14  –97.00 (7.18)
  37  –86.90 (4.10)  39  –84.20 (6.40)
       Not estimable
–2.00 (–3.98 to –0.02)
–2.00 (–13.79 to 9.79)
  0.50 (0.01 to 0.99)
  0.35 (–0.13 to 0.83)
       Not  estimable
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–2.00 (–3.93 to –0.07)
–2.00 (–6.90 to 2.90)
–2.70 (–5.10 to –0.30)
Study
or subcategory NN Mean (SD) Mean (SD)
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
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0.16
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FIGURE 11 Meta-analysis of Harris hip score (>3 months) estimated using trial data supplemented by calculated SDs from reported
p-valuesNo studies measured resumption of normal
activities over a longer time span, except one
study which reported no episodes of persistent
limp at 1 year after mini- or standard incision
surgery.31
Condition-specific quality of life
Measurement of condition-specific quality of life
following surgery was assessed using a variety of
instruments, including the Harris hip score,
WOMAC (Western Ontario and MacMaster
Universities Osteoarthritis Index), Oxford hip 
score and Merle d’Aubigné–Charnley score. 
In general, higher scores indicate better quality 
of life. However, for WOMAC and Oxford hip
scores, higher scores indicate poorer quality 
of life. 
The short-term (3 months) results are
summarised in Table 25. Two trials46,58 and three
comparative studies33–35 utilised the Harris hip
score. All but one study33 favoured the mini-
incision group but only two found this to be
statistically significant.35,58
Since only one trial46 reported SDs, we estimated
SDs for the other trial58 using the reported 
p-value for the purpose of quantitative synthesis.
The results showed no statistically significant
difference between the mini- and standard incision
groups (Figure 10; Appendix 10, Comparison
02:33, WMD –1.25, 95% CI –3.75 to 1.24,
p = 0.33). The average Harris hip scores varied
widely across studies, ranging from 67 to 95.
Although not shown in the table, in one case series
study 91% of the 353 participants had a Harris
hip score of 90 or greater (the best possible score
is 100).49
Other studies that examined short-term quality of
life through the WOMAC index46,69 and the
Oxford hip score34,46 found no significant
differences between groups (Table 25;
Appendix 10, Comparisons 01:35 and 01:36).
However, one trial examining the Merle
d’Aubigné–Charnley score reported statistically
significantly higher quality of life in the mini-
incision group compared with the standard
incision group (Table 25; Appendix 10,
Comparison 01:37).40
With respect to the long-term (>3 months) 
results related to condition-specific quality of life
(Table 26), eight of the 10 studies that examined
the Harris hip score tended to favour the mini-
incision group, of which only one non-
randomised study reported a statistically
significant difference.56 The average scores 
varied across studies, although compared with 
the short-term results the scores reported by
studies with longer follow-up appeared to be
higher (reflecting better quality of life), and the
difference between groups was smaller. Only
limited quantitative synthesis was possible due to
insufficient data. The trial data did not provide
any evidence of a difference between groups 
after supplementing with calculated SDs
(Figure 11; Appendix 10, Comparison 02:34,
WMD 0.35, 95% CI –0.13 to 0.83, p = 0.15) or
calculated and dummy SDs (Appendix 10,
Comparison 03:34, WMD 0.27, 95% CI –0.15 to
0.69, p = 0.21). 
Using an alternative measure of condition-specific
quality of life (the Merle d’Aubigné–Charnley
score), one further trial again found no 
statistically significant difference between groups
(Table 26).40
General quality of life
Three studies used components of Short Forms
with 12 (SF-12) and 36 Items (SF-36) to ascertain
general quality of life (Table 27; Appendix 10,
Comparisons 01:39–01:43). Overall, quality of life
scores were similar in both the mini-incision and
standard incision groups. However, in one
comparative study the standard incision group
scored higher (better) in the longer term
(6 months to 1 year) on one test score (SF-36
physical function).36
Although not analysed in the trial report by
Charles and colleagues,69 further patient-level
analysis based on the completed SF-36 data
collected as part of this RCT was performed
(Coyle D, Coyle K, University of Ottawa: 
personal communication, May 2007). This
analysis calculated Short Form with 6 Dimensions
(SF-6D) scores using the algorithm from Brazier
and colleagues.80 Using an analysis of covariance
and adjusting for baseline SF-6D scores, the
results showed no significant differences in the
mean values between the mini-incision group 
and the standard incision group at 3 months 
[0.79 (SD 0.08) versus 0.76 (SD 0.10)] or 2 years
after operation [0.80 (SD 0.08) versus 0.82 (SD
0.09)]. A full description of these analyses is
reported in Appendix 11, including analyses
using different methods of handling missing
values.
Patient satisfaction and scar cosmesis
Six studies using a variety of measures provided
information on patient satisfaction and scar
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01:44–01:46). One trial69 reported that patient
satisfaction scores (details unknown) were slightly
lower in the standard incision group than in the
mini-incision group, although the difference was
not statistically significant. 
Similarly, in three comparative studies36,55,56 the
number of patients dissatisfied with the scar
appearance of incision was higher in the standard
incision group, and one study which performed a
statistical test found this to be significant. It is
worth noting that one of the studies where no
participants rated their scar as ‘unacceptable’55
reported that participants in the mini-incision
group were significantly more likely to rate their
scar as ‘excellent’ compared with the standard
group (12/20 versus 3/14, p = 0.026), despite 
the fact that more scars in the mini-incision 
group in the same study were rated ‘poor’ by
plastic surgeons (MI 6/20 scars versus 
SI 1/14 scars). 
Although not shown in the table, one comparative
study also reported that over 90% of patients were
satisfied with the outcomes irrespective of incision
length (<10, 10–14 or >14 cm), with the highest
satisfaction in the shortest incision (<10 cm)
group, possibly due to less postoperative pain and
better cosmetic appearance.52
One trial examined scar cosmesis in terms of
contraction.46 The results were similar for both
groups. 
Two-incision THR versus single mini-incision or
standard THR
Clinical performance
Revision rates
Table 29 shows the revision rate after two-incision
operations compared with single standard 
incision or single mini-incision operations. One
comparative study which examined this outcome
reported no events after 1 year of follow-up.38
In two case series with 1–1.5 years of follow-up,
0.6% of the participants received a revision
surgery following a two-incision surgery
(5/851;27;1/20037). 
Postoperative dislocation rate
One trial with 30 participants recorded no
postoperative dislocations in either the two-
incision group or single standard incision group.57
Two case series with 1–1.5 years of follow-up
reported that less than 2% of the participants had
postoperative dislocations after a two-incision
surgery (8/851;27 2/10037).
Surrogates for long-term outcomes
Two comparative studies38,53 provided information
on the number of acetabular components (cups)
that were poorly placed. There was no significant
difference between the two-incision group and the
single mini-incision group (8/78 versus 8/78;
Appendix 10, Comparison 04:03). In terms of the
femoral component (stem), there were no
differences between two-incision and single
standard incision surgery based on one trial (0/15
versus 0/15)57 or between two-incision and single
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TABLE 27 General quality of life
Study Measure Mini-incision Standard incision Reported p-value
N Value (SD)  N Value (SD)
[range] [range]
Short-term ( 3 months)
RCT and quasi-RCT
Charles, 200669 SF-36 physical component 16 40.8 19 40.4 0.583
Coylea SF-6D 18 0.79 (0.08) 18 0.76 (0.10)
Ogonda, 200546 SF-12 physical component 107 38.48 (10.20) 108 37.73 (9.48) 0.58
Ogonda, 200546 SF-12 mental component 107 50.61 (11.05) 108 51.11 (10.54) 0.73
Long-term (>3 months)
Comparative studies
Coylea SF-6D 18 0.80 (0.08) 18 0.82 (0.09)
Dorr, 200736 SF-36 physical component 109 54.50 (4.29) 56 56.24 (3.87)
Dorr, 200736 SF-36 mental component 109 60.38 (3.84) 56 60.74 (3.42)
a Coyle D, Coyle K, University of Ottawa: personal communication, May 2007.mini-incision surgery based on the results from
two comparative studies (8/78 versus 7/78;
Appendix 10, Comparison 04:04).38,53 
Two comparative studies (N = 156) reported that
there were no incidents of implant migration.38,53
In one case series, implant migration was 
reported in two out of 175 (1%) and heterotopic 
ossification in two out of 80 (2.5%).37
Limb length inequality
Only one comparative study provided information
on this outcome.38 There was no significant
difference in the proportion of participants who
had inequality in limb length in the two-incision
group compared with the single mini-incision
group (6/39 versus 6/38; Appendix 10,
Comparison 04:06).
Safety
Blood loss
One study57 reported that there was significantly
more intraoperative blood loss in the two-incision
group than in the single standard incision group
(Table 30). In two comparative studies comparing
two-incision surgery with single mini-incision
surgery, one reported significantly less blood loss
in the two-incision group,38 whereas the other
reported significantly more blood loss in the two-
incision group.71 A further comparative study
examining total blood loss reported that there was
significantly more blood loss in the two-incision
group compared with the single mini-incision
group (699 versus 603 ml, p = 0.02).53
Fracture
Two comparative studies reported that there were
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TABLE 28 Satisfaction
Study Measure Mini-incision Standard incision Reported p-value
N Value (SD)  N Value (SD)
[range] [range]
RCT and quasi-RC
Charles, 200669 Satisfaction (score) 18 15.222 19 14.579 0.341
Ogonda, 200546 Scar (cm) 107 8.44 (1.02) 108 13.95 (1.26)
Ogonda, 200546 Scar (mean contraction at  107 11% 108 12% 0.70
6 weeks as % of total 
wound length at the end 
of surgery)
Comparative studies
Dorr, 200736 Not happy with cosmesis  109 0 56 21 0.000
(no. of patients)
Woolson, 200455 Opinion of scar  20 0 14 0 0.026
(Mow, 2005)67 ‘unacceptable’ 
(no. of patients)
Wright, 200456 Disappointed with  37 0 37 5
appearance of incision
(no. of patients)
TABLE 29 Revision rate (number having revision surgery)
Study Two incisions Single incision Reported p-values
n/N % n/N %
Two-incision vs single standard incision
No studies
Two-incision vs single mini-incision
Duwelius, 200738 0/43 0 0/43 0
Two-incision case series
Archibeck, 200427 5/851
Duwelius, 200337 1/200
Subtotal 6/1051 0.6slightly more intraoperative fractures in the two-
incision group than in the single mini-incision
group based on the data from two comparative
studies, but the difference was not statistically
significant (5/78 versus 1/78; Appendix 10,
Comparison 04:09).38,53 In terms of postoperative
fractures, one trial comparing two-incision with
single standard incision surgery reported one case
in each group (1/15 versus 1/15),57 whereas in
another study both postoperative fractures were in
the two-incision group (2/35 versus 0/35)
(Appendix 10, Comparison 04:10).53
Two case series also reported on fractures.
Intraoperative fractures were reported in 6% of
the samples (62/851;27 3/18037), whereas the
proportion of postoperative fractures was less than
1% (2/851;37 3/20027).
Infections
One study reported that there were no incidents of
infections following two-incision or single standard
incision surgery (0/15 versus 0/15).57 Two case
series reported infections in 0.8% of the sample
(7/851;37 1/10027).
Nerve injury
One trial reported one case of nerve injury in the
two-incision group, compared with none in the
single standard incision group (1/15 versus 
0/15).57 Two further studies reported a total of 
10 cases of nerve injury in the two-incision group,
compared with none in the single mini-incision
group (10/78 versus 0/78; Appendix 10,
Comparison 04:12).38,53 All nerve injuries
appeared to relate to the lateral cutaneous nerve
of the thigh, producing a degree of thigh
numbness which could be either temporary or
permanent. Two case series reported that 5% of
the participants having two-incision surgery had
nerve injuries (27/851;37 18/7527).
Resource utilisation
Duration of operation
Duration of operation was reported by one trial
comparing two-incision and single standard
incision surgery57 and two further studies
comparing two-incision and single mini-incision
surgery38,79 (Table 31). Across all these studies the
results were consistently less favourable (longer
operation time) for the two-incision group and
three studies found this to be statistically
significant. Two case series (including one multi-
centre study) also provided information on
operation time, as shown in Table 31.
Length of hospital stay
Length of hospital stay was reported in one trial
comparing two-incision and single standard
incision surgery57 and another three studies
comparing two-incision and single mini-incision
surgery38,71,79 (Table 32). All studies reported
shorter hospital stay for the two-incision group
regardless of the comparator and in three studies
this was found to be statistically significant.
Although not shown in the table, in one multi-
centre case series study where participants were
managed with an accelerated critical pathway after
having two-incision surgery, 69% (249/363) were
discharged home within 24 hours after surgery.37
Patient-centred measures
Pain
Three studies comparing two-incision and single
mini-incision surgery provided information on
postoperative pain using various measures. One
trial with 72 participants reported that time to
discontinue narcotics was shorter for the two-
incision group (details not available).73 The 
second study with 165 participants reported that
narcotic use was significantly less for the two-
incision group (p < 0.05; no further details
available).71 However, the third study reported
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TABLE 30 Blood loss (intraoperative, ml)
Study Two incisions Single incision Reported p-value
N Value (SD)  N Value (SD)
[range] [range]
Two-incision vs single standard incision
Yan, 200557 15 760 [600–1200] 15 650 [500–800] <0.05
Two-incision vs single mini-incision
Duwelius, 200738 43 366 (215) 43 247 (90) 0.001
Greidanus, 200671 66 Less 99 More <0.05
Two-incision case series
No studiesthat the number of patients using a prescription
anti-inflammatory drug was significantly higher in
the two-incision group (20/43 versus 10/43,
p = 0.04).38 The same study also reported that
WOMAC pain scores were lower for the two-
incision group compared with the single mini-
incision group 6 weeks after operation (2 versus
2.5, from graph) but were the same between
groups 1 year after operation (1.6 versus 1.6, from
graph).38
Return to usual activities
Four studies comparing two-incision with single
mini-incision surgery provided information on
patients’ return to usual activities (functional
recovery) after surgery using various measures.
One trial with 72 participants reported that time
to return to normal activities and time to
discontinue ambulatory aids were both longer for
the two-incision group (details not available).73 A
comparative study with 52 participants reported
that there were no significant differences between
the groups in the duration of ambulatory aids use
[28 (7–56) days versus 27 (5–49) days, p = 0.75] or
time to return to driving [32 (8–49) versus 34
(20–56), p = 0.38].47 However, another study with
86 participants reported that the two-incision
group was significantly better in terms of time to
resume driving [13 (2–31) days versus 24 (6–32)
days, p = 0.04] or time to resume shopping 
[14 (3–24) days versus 26 (6–37) days, p = 0.01].38
The fourth trial with 20 participants measured
outcome at 1 year and reported that there was no
significant difference between the groups in the
results of gait analysis performed 1 year after
surgery (details not available).72
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TABLE 31 Duration of operation (minutes)
Study Two incisions Single incision Reported p-value
N Value (SD)  N Value (SD)
[range] [range]
Two-incision vs single standard incision
Yan, 200557 15 100 [90–220] 15 80 [60–150] <0.05
Two-incision vs single mini-incision
Duwelius, 200738 43 93.7 (90) 43 61.7 (60) 0.002
Tanavalee, 200653 35 168 [130–210] 35 113 [90–140] <0.01
Yoon, 200579 118 72 [50–115] 100 52 [35–75] NR
Two-incision case series
Archibeck, 200427 851 148
Duwelius, 200337 – C1 100 90
Duwelius, 200337 – C2 100 62
Duwelius, 200337 – C3a 12 150
Duwelius, 200337 – C3b 88 101
Duwelius, 200337 – C4 75 85
C, study centre; NR, not reported.
TABLE 32 Length of hospital stay (days)
Study Two incisions Single incision Reported p-value
N Value (SD)  N Value (SD)
[range] [range]
Two-incision vs single standard incision
Yan, 200557 15 6 15 13 <0.001
Two-incision vs single mini-incision
Duwelius, 200738 43 1.25 [0.5–2.3] 43 1.9 [0.5–4.3] <0.001
Greidanus, 200671 66 Shorter 99 longer <0.05
Yoon, 200579 118 Shorter 100 longer NR
Two-incision case series
No studies
NR, not reported.Condition-specific quality of life
Table 33 shows results from studies reporting on
the Harris hip score. In terms of the short-term
(3 months) results, one study reported
significantly higher scores (better health) for the
two-incision group compared with the single
standard incision group.57 In another study, scores
in the two-incision group were also better than in
the single mini-incision group, although the
difference appears to be relatively small. 
In terms of the Harris hip scores over the longer
terms (>3 months) (Table 33), the two-incision
group did not differ from the single standard
incision surgery57 or single mini-incision surgery,53
whereas in one study the two-incision group
appeared to be better than the single mini-incision
group.38
General quality of life
Only one study with 86 participants measured
general quality of life.38 This study used the SF-36
physical function and reported that the score in
the two-incision group was higher than that in the
single mini-incision group 6 weeks postoperation
(80 versus 70, estimated from a graph within the
study report), although slightly lower at 1 year
after operation (80 versus 85, estimated from a
graph within the study report). 
Patient satisfaction
One comparative study carried out a self-
administered questionnaire survey to ascertain
perceptions of 26 patients who underwent staged
bilateral THRs with two-incision THR on one hip
and single mini-incision THR (posterior) on the
other hip.47 At a minimum of 6 months after the
second operation, 62% (16/26) of the patients
preferred the single mini-incision approach to the
two-incision approach with their reasons being a
better early recovery (8/16 participants), better
cosmetic results (4/16) or both (4/16). Eight
patients preferred the two-incision approach
because of a better early recovery. None preferred
the cosmetic appearance of two-incision THR, as
they were not satisfied with the presence of the
anterior incision, which was clearly visible during
simple daily activities such as bathing and
changing clothes.
Important subgroup differences for
minimal incision versus standard
techniques
One trial reported subgroup analysis for grossly
obese patients and muscular male patients, for
whom a mini-incision was thought to be more
difficult.46 The mean operative time was
7.5 minutes longer for patients with a BMI of 
>35 (69.5 ± 11.2 minutes) than that for patients
with a BMI of <30 (62.0 ± 11.3 minutes). The
difference was statistically significant (p < 0.001),
irrespective of the incision length. For the
muscular male patients with a mid-thigh
circumference of >55 cm, the mean operative
time (61.4 ± 11.0 minutes) was not found to be
significantly different from that for the less
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TABLE 33 Harris hip score
Study Two incisions Single incision Reported p-value
N Value (SD)  N Value (SD)
Short-term (3 months)
Two-incision vs single standard incision
Yan, 200557 15 89 15 86 <0.05
Two-incision vs single mini-incision
Duwelius, 200738 43 89 43 88 From graph
Two-incision case series
No studies
Long-term (>3 months)
Two-incision vs single standard incision
Yan, 200557 15 93 15 93 >0.05
Two-incision vs single standard incision
Duwelius, 200738 43 94 43 88 From graph
Tanavalee, 200653 35 94.5 (4.7) 35 94.6 (4.5) 0.95
Two-incision case series
Duwelius, 200337 100 90muscular male patients (66.9 ± 13.2 minutes)
(p = 0.17). Caution is required, however, as the
number of patients was small.
One case series of the two-incision procedure also
reported that the incidence of key complications
(fractures, nerve deficits and dislocations) was
nearly two times higher for patients with a BMI of
30 (16.3%) than that for patients with a BMI of
<30 (8.3%) (p = 0.05).27
The same case series of the two-incision 
procedure examined the possible effect of 
surgeon experience on operative time, blood loss
and the prevalence of key complications.27 This
study was a prospective survey of trainee surgeons
who attended corporate-sponsored training on the
two-incision THR. Results from 851 procedures
performed by 159 surgeons following training
show that the mean operative time was
significantly decreased, as the surgeons progressed
from their first case (168 ± 49.6 minutes) to their
tenth case (130 ± 47.1 minutes) (p < 0.05). Blood
loss also decreased non-significantly from the first
(547 ± 377 ml) to tenth (427 ± 260 ml) cases
(p > 0.05). No significant relationship was found
between complication rates and surgeon
experience. Nevertheless, the prevalence of
complications was significantly higher for surgeons
who reported performing less than 50 operations
per year (26.5%), compared with surgeons
performing 50 or more operations per year 
(7.1% for surgeons performing 50–100, 8.6% for
surgeons performing 100–150 and 7.1% for
surgeons performing over 150 operations,
p = 0.0003).
Summary and conclusions of the
evidence for and against the
intervention
Despite the number of studies identified, there
was little evidence of any longer term differences
between incision length. This is primarily due to
the lack of data available. Surrogates for longer
term outcomes also did not provide sufficient
information with which to make judgements about
longer term performance. 
Overall, it appears likely that the mini-incision
approach offers some perioperative advantages
in terms of less blood loss and shorter operative
time, although these may be of limited practical
significance. The mini-incision approach may
also offer a shorter recovery period as identified
by the shorter length of hospital stay and time to
return to usual activities. This quicker recovery is
a key issue in the economic evaluation, the
methods of which are discussed in Chapter 5,
where the impact of this earlier recovery is
measured using QALYs. Patients also appear to
be more satisfied with the operation and the
appearance of the scar (although this latter
finding may be more influenced by the scar’s
location than its size). As indicated above, 
limited data are available for other outcomes 
and the level of uncertainty is such that 
clinically important differences may exist
favouring either treatment. Nevertheless, until
new data become available, it may be sensible to
assume that the two methods are comparable. 
A summary of the effect sizes based on 
meta-analyses of trial data is given in 
Table 34. 
With respect to the two-incision procedure, it is
not possible to draw firm conclusions due to the
small number of studies identified from our
searches and also the poor quality of the data
reported. At best, the data suggest that the 
two-incision procedure may offer a possible
short-term benefit in terms of earlier discharge
from hospital and better quality of life (Harris
hip score) (Table 35). Although there were more
cases of nerve injuries with the two-incision
operation, the CIs were wide and did not rule
out clinically important differences that could
favour either two-incision or single incision
procedures. It is also worth noting that blood loss
and operation time tended to favour single
incision rather than two-incision surgery. As is
the case for single mini-incision THR, any
observed differences in operation duration
following the two-incision procedure, compared
with standard THR, are not likely to be large and
may be of limited practical significance. For
longer term outcomes, there was no discernible
difference by the type of surgical procedures
within the available data. 
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TABLE 34 Summary of the effect size from meta-analysis of the trial data for single mini-incision THR versus standard THR 
Outcome (WMD and Peto OR based on trials) [95% CI] No. of trials 
(No. of comparative studies)
Favours mini-incision
Blood lossa
WMD –56.59 [–71.63 to –41.55], p < 0.00001 7 (11)
Duration of operationa
WMD –3.70 [–5.67 to –1.74], p = 0.0002 9 (15)
Length of hospital staya
WMD –0.50 [–0.83 to –0.18], p = 0.002 6 (12)
Return to usual activities after operation
Time to return to normal activities: no trial data 0 (1)
Use of walking aids (days): WMD –3.40 [–5.23 to –1.57], p = 0.0003 1 (0)
Use of walking aids (N of patients): Peto OR 0.55 [0.20 to 1.53], p = 0.25 1 (1)
Limp: Peto OR 0.31 [0.11 to 0.91], p = 0.03 1 (1)
Patient satisfaction
WMD not estimable 1 (3)
No evidence of a difference or insufficient information
Revision rates
Peto OR 7.96 [0.16 to 402.02], p = 0.30 3 (6)
Postoperative dislocation rates
Peto OR 1.72 [0.43 to 6.92], p = 0.45 6 (11)
Surrogates for long-term outcomes
Implant position (cup): Peto OR 0.93 [0.50 to 1.74], p = 0.83 3 (6)
Implant position (stem): Peto OR 0.70 [0.35 to 1.40], p = 0.31 5 (9)
Implant migration: Peto OR not estimable 1 (1)
Heterotopic ossification: no trial data 0 (2)
Cement quality: Peto OR 1.26 [0.70 to 2.27], p = 0.45 3 (4)
Limb length inequality (number of patients with unequal length)
No trial data 0 (1)
Intraoperative fractures
Peto OR 0.14 [0.01 to 2.18], p = 0.16 2 (3)
Postoperative fractures
Peto OR not estimable 2 (3)
Infections
Peto OR 7.48 [0.78 to 72.16], p = 0.08 7 (9)
Nerve injury
Peto OR 1.95 [0.20 to 18.89], p = 0.56 6 (9)
Vascular injuries
Peto OR not estimable 1 (0)
DVT
Peto OR 0.39 [0.12 to 1.30], p = 0.12 5 (6)
Pulmonary embolism
Peto OR not estimable 1 (2)
30-day mortality
Peto OR 0.14 [0.01 to 2.18], p = 0.16 1 (2)
Long-term mortality
Peto OR 0.15 [0.01 to 2.45], p = 0.18 1 (2)
Analgesic use
Narcotic (days): WMD not estimable 1 (0)
Patient-controlled anaesthesia (mg): WMD –4.41 [–29.18 to 20.36], p = 0.73 3 (0)
Total narcotic received (mg): no trial data 0 (3)
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TABLE 34 Summary of the effect size from meta-analysis of the trial data for single mini-incision THR versus standard THR (cont’d)
Outcome (WMD and Peto OR based on trials) [95% CI] No. of trials 
(No. of comparative studies)
Short-term pain
Pain (no. of patients): no trial data 0 (3)
Pain score: WMD –0.06 [–0.56 to 0.44],p = 0.81 4 (2)
Long-term pain
Pain score: WMD not estimable 1 (0)
Long-term difference in usual activities
Limp: Peto OR not estimable 1 (0)
Short-term condition-specific quality of life
Harris hip scorea: WMD –1.25 [–3.75 to 1.24], p = 0.33 2 (3)
WOMAC: WMD 0.45 [–3.13 to 4.03], p = 0.81 2 (0)
Oxford hip score: WMD –0.91 [–2.74 to 0.92], p = 0.33 1 (1)
Merle d’Aubigné–Charnley score: WMD not estimable 1 (0)
Long-term condition-specific quality of life
Harris hip scorea: WMD 0.35 [–0.13 to 0.83], p = 0.15 4 (6)
Merle d’Aubigné-Charnley score: WMD not estimable 1 (0)
Short-term general quality of life
SF-12 physical component: WMD –0.75 [–3.38 to 1.88], p = 0.58 1 (0)
SF-12 mental component: WMD 0.50 [–2.39 to 3.39], p = 0.73 1 (0)
SF-36 physical function WMD: not estimable 1 (0) 
Long-term general quality of life
SF-36 physical function: no trial data 0 (1)
SF-36 mental function: no trial data 0 (1)
Favours standard incision
No outcomes
a Based on published data supplemented with calculated standard deviations. All other values (WMD and Peto OR) are
based on published data.
TABLE 35 Summary of evidence for two-incisions THR versus single mini-incision or standard THR
Outcome No. of studies
Favours two incisions
Length of hospital stay
2MI vs SI: 1 favours two incisions (significant difference) 1
2MI vs MI: 3 favour two incisions (2 significant difference) 3
Short-term condition-specific quality of life (Harris hip score)
2MI vs SI: 1 favours two incisions (significant difference) 1
2MI vs MI: 1 favours two incisions (no significant difference) 1
No evidence of a difference or insufficient information
Revision rates
2MI vs SI: no studies 1
2MI vs MI: no events 1
Postoperative dislocation rates
2MI vs SI: no events 1
2MI vs MI: no studies 0
Surrogates for long-term outcomes
Implant position (cup):
2MI vs SI: no studies 0
2MI vs MI: 8/78 cases vs 8/78 cases  2
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TABLE 35 Summary of evidence for two incisions THR versus single mini-incision or standard THR (cont’d)
Outcome No. of studies
Implant position (stem): 
2MI vs SI: no events  1
2MI vs MI: 8/78 cases vs 7/78 cases  2
Implant migration:
2MI vs SI: no studies 0
2MI vs MI: no events 2
Limb length inequality
2MI vs SI: no studies 0
2MI vs MI: 6/39 cases vs 6/38 cases 1
Intraoperative fractures
2MI vs SI: no studies 0
2MI vs MI: 5/78 cases vs 1/78 cases 2
Postoperative fractures
2MI vs SI: 1/15 cases vs 1/15 cases 1
2MI vs MI: 2/35 cases vs 0/35 cases 1
Infections
2MI vs SI: no events 1
2MI vs MI: no studies 0
Short-term pain
Narcotics use: 
2MI vs SI, no studies 0
2MI vs MI: 2 favour 2MI (1 significant difference), 1 favours MI (significant difference) 3
Pain score: 
2MI vs SI, no studies 0
2MI vs MI, 1 favours two incisions (no significant difference) 1
Long-term pain (pain score)
2MI vs SI: no studies 0
2MI vs MI: no significant difference 1
Return to usual activities after operation (various measures)
2MI vs SI: no studies 0
2MI vs MI: 1 favours 2MI (significant difference), 1 favours SI (no significant difference), 1 no difference 3
Long-term difference in usual activities (gait analysis)
2MI vs SI: no studies 0
2MI vs MI: no significant difference 1
Long-term condition specific quality of life (Harris hip score)
2MI vs SI: no significant difference 1
2MI vs MI: no significant difference 2
Short-term general quality of life (SF-36)
2MI vs SI: no studies 0
2MI vs MI: 1 favours 2MI (no significant difference) 1
Long-term general quality of life (SF-36)
2MI vs SI: no studies 0
2MI vs MI: 1 favours MI (no significant difference) 1
Favours single incision
Blood loss
2MI vs SI: 1 favours SI (significant difference) 1
2MI vs MI: 1 favours 2MI (significant difference); 1 favours MI (significant difference) 2
Nerve injury
2MI vs SI: 1/15 cases vs 0/15 cases 1
2MI vs MI: 10/78 cases vs 0/78 cases 2
Duration of operation
2MI vs SI: 1 favours SI (significant difference) 1
2MI vs MI: 3 favour MI (2 significant difference) 3 Methods
Search strategies
Studies that reported both costs and outcomes of
single mini-incision and/or two mini-incision
techniques compared with standard THR surgery
for the treatment of arthritis of the hip were
sought from a systematic review of the literature.
No language restrictions to searches were
imposed.
Databases searched were MEDLINE
(1996–February Week 3 2007), EMBASE
(1980–Week 8 2007), MEDLINE In-Process 
(1 March 2007), Science Citation Index 
(1985–2 March 2007), NHS Economic Evaluation
Database (NHS EED) (December 2006), HTA
Database (December 2006) and Health
Management Information Consortium
(1979–March 2006). In addition, recent
conference proceedings and reference lists of all
included studies were scanned to identify
additional potentially relevant studies. Other
sources of information consulted included
references in relevant articles and selected experts
in the field. Full details of the search strategies
used are documented in Appendix 1.
Inclusion and exclusion criteria
To be included, studies had to compare, in terms
of both costs and outcomes, strategies involving
single and/or two mini-incision surgical techniques
with standard THR for the treatment of arthritis
of the hip. Studies were included even if they
made no formal attempt to relate cost to outcome
data in a cost-effectiveness or cost–utility analysis.
One reviewer assessed all abstracts for relevance
and full papers were obtained for those that
appeared potentially relevant.
Data extraction strategy
The following data were extracted for each
included primary study using the framework
provided for abstracts prepared for the NHS
EED:81
1. Study identification information
(a) Author and year.
(b) The interventions studied.
(c) The type of economic evaluation.
(d) The country of origin and currency
reported.
2. The intervention, study design and main outcomes
(a) Fuller description of treatment.
(b) Numbers receiving or randomised to each
intervention.
(c) Outcomes studied.
3. Sources of data
(a) Effectiveness data.
(b) Mortality and co-morbidity (if measured).
(c) Cost data.
(d) Quality of life (if measured).
4. Methods and study perspective
5. Results
(a) Costs.
(b) Benefits.
(c) Incremental cost-effectiveness ratio
(ICER)/cost–utility.
(d) Sensitivity analyses.
6. Additional comments relating to the design and
reporting of the economic evaluation
For reviews of economic evaluations, data were
extracted on the nature of the review
methodology used, the inclusion criteria for
studies, the number of studies identified, the
method of quality assessment for individual
economic evaluations and the conclusions
drawn on the relative efficiency of the
alternative methods.
Quality assessment strategy
One economist assessed included studies using the
NHS EED guidelines for reviewers.81
Data synthesis
No attempt was made to synthesise quantitatively
the primary studies that were identified. Data from
all included studies were instead summarised and
appraised in order to identify common results,
variations and weaknesses between studies. 
Results
Number of studies identified
The results of the literature search are presented
in Table 36. The number of reports retrieved from
the search in the Science Citation Index is the
total after deduplication against the results of the
MEDLINE/EMBASE multi-file search.
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Chapter 4
Systematic review of economic evaluationsTwenty-three papers were selected from the
searches, four of which were assessed for the
systematic review. The remaining 19 papers were
selected for background information or for
possible utilities data. Of the four studies, one82
met the inclusion criteria. One additional
unpublished paper was obtained from a
manufacturer of hip prostheses (Duwelius and
colleagues, Providence St Vincent Medical Center,
Portland, OR, 2006) (henceforth Duwelius, 2006).
Reasons for exclusion of the remaining three were
that one contained no cost information,62 in the
second the procedures followed a care pathway
dissimilar to usual care in the UK NHS 
(standard THR was treated as an inpatient
procedure, whereas minimal incision THR was an
outpatient procedure)83 and the final study
compared standard THR with a ‘do nothing’
approach and not a minimal incision THR
technique.84
Study identification and key elements
Comparators, type of study, dates for collection
and prospective study from sample
The unpublished paper by Duwelius and
colleagues compared single mini-incision and two
mini-incision THR with standard THR on a group
of non-randomised patients in the USA. The study
by Straumann and colleagues, set in Switzerland,
used a model based analysis to assess
consequences to Switzerland of MIS THR
compared with standard THR at the aggregate
level. For the Swiss study, MIS THR was assumed
to include both the single mini-incision and two
mini-incision surgical techniques.82
The unpublished study was classified as a
cost–utility analysis, that is, when the
consequences of programmes are adjusted by
generic health state preference scores to allow the
QALYs gained to be assessed as opposed to the
crude number of years.85 The Swiss study was
classified as a modelling study with a retrospective
costing exercise of standard THR. Effectiveness
data and cost difference between standard and
MIS THR were based on the unpublished US
study by Duwelius and colleagues. Both papers
took a societal perspective, that is, in addition to
hospital and community costs they both took into
account the cost of productivity losses. The
characteristics of the included studies are
presented in Table 37.
The unpublished US study collected effectiveness
data prospectively over the period from 2002 to
2005. The costing was undertaken retrospectively
on the same sample as that used for the
effectiveness study (Duwelius, 2006). In relation to
the Swiss study, the baseline costs were estimated
for the year 2003.
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TABLE 36 Results of searching for studies on cost-effectiveness
Database Hits Selected  for 
screened full assessment
MEDLINE/EMBASE/MEDLINE In-Process multi-file search (after deduplication in Ovid) 56 16
SCI 12 1
NHS NEED 55
HTA database 35 1
HMIC 10 0
Selected from conference abstracts 0 0
Total 118 23
TABLE 37 Characteristics of the included studies
Study Design Sample Follow-up Perspective
Duwelius, 2006  Multi-centre prospective  Two-incision THR: 235 6 weeks Societal
(unpublished) (USA) non-randomised, unmatched  Mini-incision THR: 325
cohort study Standard THR: 31 
Straumann, 200682 Modelling with retrospective  13,101 primary THRs  NA Societal
(Switzerland) costing exercise of standard  performed in Switzerland 
THR in 2003
NA, not applicable.Patient group, study sample and study
design
The sample size of the US study was 591 patients,
although patients were not distributed equally
between the three interventions: 235 patients were
treated using the two mini-incision technique, 
325 using the single mini-incision technique and
31 using standard THR. The study was a multi-
centre unmatched cohort study. Fourteen surgeons
at 10 hospitals provided data on the 591 patients.
It appears that no eligibility criteria were specified
and patients were recruited to each intervention
based on surgeon preference. As a consequence,
significantly different (p  0.05) demographic
characteristics between groups at time of
operation were identified. That is, a trend in
patient selection tending towards younger and
healthier patients was apparent for the two mini-
incision and single mini-incision techniques
(Duwelius, 2006). Patients were followed up for a
maximum of 6 weeks.
In terms of patient groups and study sample, the
paper by Straumann and colleagues is difficult to
quantify.82 This study was a simple model-based
analysis which utilised a retrospective costing
exercise of standard THR. It is assumed, from
published literature, that 13,101 primary THR
operations were performed in Switzerland in
2003. The average hospital cost of a primary THR
was estimated from a single hospital in Zurich.
From the total number of primary THRs
performed, it was assumed that, potentially, 30%
(conservative) or up to 50% (optimistic) of these
might have been performed as an MIS technique.
Therefore, the costs (and potential cost savings) of
the MIS techniques were calculated at the
aggregate level, for rates of 30 and 50%, by
multiplying the cost difference in percentage
terms between standard and MIS THR from the
unpublished US study with the cost of standard
THR (Duwelius, 2006).
The main clinical outcome measures for the
included studies are presented in Table 38.
Methods of economic analysis
Both papers provided details on which items were
included in cost calculations, although no unit cost
data were presented for either. What is not clear is
whether a consistent base-year has been applied to
all costs (Duwelius, 2006). Indirect costs were
calculated for both studies using the human
capital approach (time off paid work). In terms of
summary measures of health benefits, none were
presented for the study by Straumann and
colleagues, which assumed that outcomes were
equal,82 whereas the unpublished US paper
presented QALYs as its main measure of health
benefit (Duwelius, 2006).
Two-way sensitivity analysis was performed in the
paper by Duwelius and colleagues for all costs and
utility values. Further, community costs such as the
cost of an inpatient rehabilitations facility, skilled
nursing facility, home health care, home only (no
rehabilitation) and physician costs were all varied
by +30% and –30% of the base-case values. Wages
and hospital cost-to-charge ratios were also varied
by +10% or –10% of base-case values. Inflation
rates were varied by +5% to –5% of base-case
values to see what effect this might have on results
(Duwelius, 2006). The only sensitivity analysis
performed in relation to the Swiss paper was
changes to the indication rate of minimally
invasive techniques from 30% (assumed to be
conservative) to 50% (optimistic).82
Results
The results of the included studies are shown in
Table 39. In the unpublished US study by Duwelius
and colleagues, total costs including productivity
costs were lowest for the two mini-incision
technique and highest for the standard technique
(two mini-incision, $16,085; single mini-incision,
$16,615; and standard incision, $21,705)
(Duwelius, 2006). When the total cost was broken
down into hospital costs, rehabilitation costs and
indirect costs, the cost for the two mini-incision
and single mini-incision techniques were
consistently lower than standard THR with two
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TABLE 38 Outcome measures used in the included studies
Study End-points
Duwelius, 2006 (unpublished) (USA) Time to walking without support (WWOS)
Psychometric health status (SF-36)
Postoperative recovery (approximated by WWOS, Harris hip score and 
health-related quality of life)
Various complications
Straumann, 200682 None specified (assumed equal)mini-incision remaining the least costly option. It
is unclear whether the differences in costs were
tested for significance and no CIs were reported.
In terms of benefits, 6-week QALYs were
calculated for the three interventions and the
reported incremental effectiveness of the two mini-
incision and single mini-incision techniques
compared with standard incision were 0.037 and
0.023 QALYs gained respectively. The authors
reported that the same patterns of outcomes and
costs were observed after varying input parameters
to test the sensitivity of the base-case assumptions.
No measure of health benefit was included in the
study by Straumann and colleagues.82 Average
hospital costs per patient were higher for standard
THR compared with MIS THR (€13,511 versus
€11,534.40 per patient). At the aggregate level, it
was assumed that by employing MIS in place of
standard THR for 30 or 50% of cases, hospital and
rehabilitation costs would reduce dramatically and
that many millions of euros would be saved over
the 1-year time horizon. In terms of indirect costs,
it was assumed that 36 fewer work days were lost
per employed patient with MIS THR as opposed
to standard THR. From this, it was estimated that
the effective reduction of productivity losses
ranged between €23.8 million and €39.7 million.
Summary of results and discussion
The two studies that met the inclusion criteria of
the review of economics estimated that MIS THR
(including both single and double mini-incision) is
likely to be less costly than standard THR. This is
due to the fact that the unpublished US study
found that length of stay was statistically
significantly shorter for the MIS procedures
(p  0.05). The study also found that the need for
community rehabilitation was also reduced for the
MIS procedures in comparison to standard THR.
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TABLE 39 Cost and outcome data reported in the included studiesa
Study Finding Two Single  Standard
mini-incision mini-incision
Duwelius, 2006  Total cost $16,085 $16,615 $21,705
(unpublished) [£8,042.50] [£8,307.50] [£10,852.50]
(USA)
Price year 2003 Total costs, excluding productivity losses $14,651 $14,825 $19,451
[£7,325.50] [£7,412.50] [£9,725.50]
6-week QALYs 0.053 0.039 0.016
MIS (both single and 
two mini-incision)
Straumann,  Total cost per patient €13,511 €11,534.40
200682 Switzerland [£9,187.48] [£7,843.39]
Price year not  Aggregate hospital cost savings assuming  €7.8 million saving  NA
stated 30% MIS indication rate [£5.3 million saving]
Aggregate hospital cost savings assuming  €12.9 million saving  NA
50% MIS indication rate [£8.8 million saving]
Aggregate community cost savings €10.9 million saving [£7.4 million saving] NA
assuming 50% MIS indication rate for two mini-incision and 
€10.1 million saving [£6.9 million saving] 
for single mini-incision 
Aggregate community cost savings €18.1 million saving [£12.3 million saving]  NA
assuming 50% MIS indication rate for and two mini-incision and 
€16.9 million saving [£11.5 million saving] 
for single mini-incision
Aggregate indirect cost savings assuming  €23.8 million saving NA
30% MIS indication rate [£16.2 million saving]
Aggregate indirect cost savings assuming  €39.7 million saving
50% MIS indication rate [£27 million saving] NA
NA, not applicable.
a Figures in brackets are conversions in UK £ sterling using rates of US$1 ≈ £0.5 and €1 ≈ £0.68.Furthermore, it was reported that short-term
outcomes were improved for the MIS techniques
in comparison with standard THR, although
differences in 6-week QALYs were not statistically
significant (Duwelius, 2006). It should be noted
that a statistically significant difference in terms of
case mix between the groups in the unpublished
US study was found, that is, a trend in patient
selection saw younger and healthier patients being
selected for the two mini-incision and single mini-
incision approaches compared with standard
THR. The authors attempted to compensate for
this bias by using propensity scoring (Duwelius,
2006). As the relative differences in costs and
effects were taken from the unpublished US paper
(Duwelius, 2006) and applied to Swiss data in the
study by Straumann and colleagues,82 it is
unsurprising that the same conclusions in terms of
costs were found. Both studies concluded that the
adoption of MIS techniques in the field of THR
would likely reduce healthcare costs and provide
better short-term outcomes. 
There are numerous issues that should be taken
into account when interpreting the results of the
two described studies, which are, at best,
contentious. In relation to the unpublished US
study, the single most important limitation related
to the case mix of patients recruited to the three
surgical approaches. Patients were non-
randomised and unmatched and, as a result, all
reductions in necessity for postoperative care and
improved outcomes are likely to be affected by the
fact that younger and healthier people were
consistently selected to receive the MIS
techniques. As a result, the fact that these patients
were discharged from hospital sooner, were less
likely to use rehabilitation facilities in the
community and had higher quality of life in terms
of QALYs gained is what one might have expected
if the same patient group were treated using the
standard method. The authors used propensity
scoring when calculating health-related quality of
life to counteract the potential biases that might
arise from differences in case mix, although it is
unclear if this approach would have corrected
possible selection biases. Further limitations of this
study related to the costing method. A
retrospective costing exercise took place which
estimated surgeon costs from the Medicare
unadjusted national average rates for primary
THR, hospital costs from charge data converted to
costs using a hospital cost-to-charge ratio and
rehabilitation costs from inpatient hospital
discharge and Medicare reimbursement schedules.
Bearing in mind the methods used to collect cost
data, it is unknown whether such costs would be
appropriate to the UK and, indeed, to THR
surgery, as charges were converted using 
hospital-level cost-to-charge ratios. Furthermore,
no attempt was made to correct for possible
selection biases and it is unclear whether a
consistent base year was applied to all costs as is
usual good practice when conducting an economic
evaluation. 
In relation to the paper by Straumann and
colleagues,82 little useful information is presented
and this study is not a typical costing exercise. The
paper assumes equal effectiveness in terms of
outcomes and only considers the potential cost
savings from the introduction of minimally
invasive techniques. By applying the definitive cost
difference between minimally invasive THR and
standard THR to the average cost of a standard
THR in Switzerland, the authors are making
several extremely strong assumptions. First, the
authors assume that data from the unpublished US
study are valid, even for the US, and that MIS
THR is likely to have equal or better outcomes
than standard THR. The authors also assume that
US data are likely to be applicable to Switzerland,
despite the vast difference in standard surgical
practice across healthcare systems.
Conclusions
This chapter presents the overall evidence
available on the cost-effectiveness of single mini-
incision and two mini-incision THR compared
with standard THR in the treatment of arthritis of
the hip, based on a systematic review of the
literature. The two cost studies that met the
inclusion criteria for the review of economic
evaluations add little, if any, value to the current
evidence base. Although results claim that MIS
techniques are likely to be cost saving and provide
better outcomes in the immediate postoperative
period, the strong assumptions made by the
authors of the two included studies have probably
produced biased, unreliable results with limited
applicability to the UK. The conclusions drawn
within the two studies are very strong given their
limitations in quality. The measurement and
inclusion of such costs (indirect costs) in an
economic evaluation, however, are contentious. A
well-designed UK-based economic evaluation with
long-term follow-up of costs and outcomes is
warranted to answer questions over the potential
cost-effectiveness of single and two mini-incision
THR in the NHS (even after we consider the
addition to the evidence base of the economic
evaluation conducted as part of this report).
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In this chapter, the data available on costs and
effects are combined in an economic model to
estimate the cost-effectiveness of minimal incision
THR compared with standard THR for the
treatment of arthritic disease of the hip. The results
should be treated with caution, as the model is
constrained by the paucity of data available for
estimating some model parameters. It was not
possible to include the two mini-incision technique
in the model analysis owing to the limited and
poor-quality data available. Conceivably, expert
opinion might have been used to provide some
estimates of the necessary parameters to guide an
economic analysis of the two incision method. This
approach was not adopted, however, as it is believed
that the two mini-incision technique has fallen out
of favour within the orthopaedic community
(Hutchison JD, Department of Surgery, University
of Aberdeen and Munro N, NHS Grampian:
personal communication, April 2007).
The economic evaluation was conducted using a
Markov Model (constructed in TreeAge Pro 2007).
The model estimated the short-term (1-year) long-
term costs and benefits of a cohort of typical
patients for the different surgical procedures. The
long-term model followed a cohort of patients
from their initial operation through their
convalescence (operation state) to their return to
usual activities (defined in the model as a
‘Successful THR state’). The patients may remain
in this state until they die or they suffer a
complication and therefore have a revision
operation or some other form of long-term
patient management if surgery is no longer
considered a viable option. Conceptually, the
patients could move between states within the
model until they all eventually die. For the
purposes of the analysis, however, the cohort of
patients was modelled for a maximum of 40 years
following the initial operation, which represents
the maximum survival for the majority of the
patients. An illustrative representation of the
Markov model can be seen in Figure 12.
Deterministic sensitivity analysis to explore
changes in parameter values or threshold values
was conducted. Many of these deterministic
analyses were combined with partial probabilistic
sensitivity analyses where many, but not all,
parameters within the model were described by a
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Primary THR
Successful THR Non-operative
management
Successful
revision
Revision
All health states
can progress
to Death state
FIGURE 12 Markov model for standard and mini-incision THRprobability distribution. The methods used to
assign these distributions are described below.
Where no distribution was attached to a
parameter, this was because the estimates were
relatively precise or a standard value was used or
insufficient information was available to estimate a
distribution.
Following their initial surgery, patients could move
into one of following states:
● Successful THR state.
● Revision state: where a patient has revision
surgery.
● Successful THR revision state: where patients
following a successful revision operation remain
until they die or have further complications
warranting surgery and/or non-operative
management.
● Non-operative management state: resulting in
long-term non-operative management of the
disease, as surgery is no longer a viable option.
● Death.
A cost per patient for each health state in the
Markov model was calculated using the methods
outlined below. The main cost components in the
model are the initial operative procedure and the
costs of any subsequent revision operation or long-
term non-operative management. It was assumed
that if a patient suffered a complication requiring
a revision procedure, the patient would be
operated on using standard THR regardless of the
method of THR they originally received. Death is
the only state within the model that a patient
cannot leave (i.e. it is an absorbing state). As 
all orthopaedic surgical procedures carry some
risk of complications, the costs of postoperative
complications were included where it was felt likely
that the impact on quality of life or costs would be
substantial. 
The cycle length (the minimum period between
transitions) of the model was set at 1 year, and the
model was run for a maximum of 40 cycles
although analyses using a 1-year time horizon are
also presented as a base case as the most reliable
data related to this period. For the base-case
analysis, it is only the costs and consequences that
patients incur in the first cycle of the model that
were estimated. An outline of the tree structure is
shown in Appendix 13. It was assumed that the
starting age for the model cohort is 68 years based
on the mean age of patients undergoing primary
THR from the National Joint Registry for England
and Wales.3
Estimation of model parameters
Baseline parameters
All baseline parameter values are given in Table 40
and their source and methods used to derive them
are described below. Although many analyses were
conducted for a 1-year time horizon, it is
necessary to explain the methods used in relation
to those analyses where a 40-year time horizon was
considered. For the remainder of this section,
therefore, all model inputs for both the 1- and 
40-year analysis are described. Where quantitative
synthesis was possible, the outputs of the
systematic review of effectiveness (Chapter 3) were
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TABLE 40 Baseline parameter values used in the model
Baseline parameter Value Distribution Values of distribution
Transition probabilities
Operative mortality 0.0091 Log-normal 95% CI 0.0055 to 0.0142
All-cause mortality See sex and age-adjusted UK life table in Appendix 13
Revision rate See 24-year risk of revision in Table 41
Rate of non-operative management following failed THR 0
Other probabilities
Re-operation rate for dislocation 0.01 No distribution
Re-operation rate for deep infection (risk only  0.011 No distribution
included for first 5 years postoperation)
DVT rate 0.0189 Normal 95% CI 0.0111 to 0.0276
PE rate 0.012 Log-normal 95% CI 0.0065 to 0.0202
Operation duration 120 minutes No distribution
Length of stay 8.7 days Log-normal Mean 8.7 days, median 7 dayspresented as Peto ORs for dichotomous variables
and WMDs for continuous variables. For these
data to be incorporated into the model they
needed to be combined with estimates of baseline
rates for one of the interventions. Furthermore,
although it might be argued that such relative
effect sizes are transferable between settings,86 it
was important to ensure that they were applied to
baseline rates that are applicable to the UK, so
that the resultant absolute differences between
interventions were more likely to be applicable to
the UK. 
The baseline annual rate of revision following
standard THR was taken from data provided by
the Swedish National Joint Registry database.87
These data were utilised, as opposed to data from
the UK National Joint Registry database, as they
provided the most precise estimates of long-term
survival of prostheses with the greatest number of
observations. Estimation of the risk of revision was
based on the survival curve for ‘all implants’.
These data provided estimates of the survival of
hip implants up to 24 years post-surgery. The
overall survival of the hip prostheses for standard
THR for each 1-year time period up to 24 years
was estimated from these curves. From these data,
a revision rate for each 1-year cycle length was
calculated. Details of the revision risks for each
year are shown in Table 41. It should be noted that
for those sensitivity analyses that used a 40-year
time horizon, an assumption was made that the
risk of revision after year 24 is constant for the
remaining years at 1.802% per year, the transition
probability at 24 years. For the 1-year time horizon
analysis, it is only the baseline risk of revision at
one year post-surgery and the relative effectiveness
at 1 year that are considered.
No distribution was assigned to the baseline risk of
revision as the number of observations used to
calculate this risk is taken from a very large
national database and the CIs around the point
estimates were narrow. 
In the event that a patient’s THR failed, the
model allowed patients to be treated non-
operatively for the rest of their lives if further
revision surgery is deemed inappropriate. For the
base-case model, however, it was assumed that all
failed THRs will receive revision surgery. The
impact of relaxing this assumption was explored in
later sensitivity analyses. It should be noted that
when patients do enter the non-operative
management state, they are unable to leave this
state unless they die.
As with all surgical procedures requiring general
anaesthetic, death due to complications in the
intraoperative period is a potential risk. The risk
of operative mortality was based on data from the
Trent regional replacement register88 shown in
Table 40. Based on these data, a mortality rate of
0.91% was assumed. The CIs around the point
estimate reported by Fender and colleagues88
assumed a log-normal distribution; therefore,
these data were used to estimate a similar
distribution around this baseline risk. 
As patients progress through the model over time,
annual rates of age-specific general or all-cause
mortality were required. These were taken from
published UK life tables for the years 2003 to
2005.89 The National Joint Registry reports that
60% of all primary THRs are performed on
women; therefore, the all-cause mortality for the
model cohort was weighted to reflect this. Data
relating to the rate of all-cause mortality can be
seen in Appendix 14. As the number of
observations used to calculate this risk is very
large, no distribution was assigned to these rates.
Certain postoperative complications other than
revision have been allowed for within the model
owing to their importance in terms of resource use
and quality of life. These complications have been
subsumed within the initial operation and
successful THR states and, once rectified, patients
would still be classed as successful. The following
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TABLE 41 Cumulative risk of revision estimated from survival curves
Time  Absolute  Time Absolute Time Absolute Time  Absolute Time Absolute 
(years) rate of  (years) rate of  (years) rate of  (years) rate of  (years) rate of 
revision revision revision revision revision
0 0 5 0.028 10 0.073 15 0.136 20 0.197
1 0.007 6 0.035 11 0.085 16 0.147 21 0.204
2 0.013 7 0.042 12 0.097 17 0.163 22 0.211
3 0.017 8 0.05 13 0.113 18 0.174 23 0.218
4 0.02 9 0.06 14 0.124 19 0.186 24 0.222complications have been explicitly included in the
model: risk of re-operation (i.e. not revision) due
to dislocation or wound infection, risk of DVT and
risk of non-fatal PE. The risks of DVT and non-
fatal PE are only factored into the initial operation
and revision states as these complications are only
relevant in the immediate postoperative period.
The Swedish National Joint Registry provided
data on the rate of re-operations and revisions due
to various complications.87 From this, it was
possible to calculate the rate of re-operations on
the hip joint (not including revision procedures).
Two of the most important complications which
might require a re-operation are dislocation and
deep infection. From the Swedish Registry data, 
an annual constant risk of re-operation for
dislocation was estimated as the yearly rates
remained similar over time. Similarly, a constant
rate of re-operation for infection was calculated
from the Swedish data, although this risk was only
included for the first 5 years postoperatively, as
the data suggested that this risk became negligible
after this time point. Again, as with the risk of
revision, no distribution was assigned to these risks
due to the large number of observed events in the
registry data.87 The associated probability, cost and
disutility associated with these complications were
factored into the ‘Initial operation’, ‘Revision’ and
‘Successful THR’ states.
The risks of DVT and non-fatal PE were included
in the model’s operation states (primary THR and
revision) as it was felt that these risks might differ
between standard and mini-incision THR surgery.
The baseline risks of DVT and PE were taken from
the Scottish Intercollegiate Guidelines Network
(SIGN) guidelines for the prophylaxis of venous
thromboembolism (see Table 40).90 From this, a
baseline risk of 1.9% for DVT and a risk of 1.2%
for non-fatal PE were assumed. The CIs around
the point estimate for DVT were based on a
normal distribution and a similar distribution
around this baseline risk was used in the model.
For the PE rate, the CIs suggested a log-normal
distribution, which was therefore used to express
the uncertainty around this point estimate.
Other baseline parameters required for the model
related to operation duration and length of stay.
For standard THR, the baseline length of
operation was assumed to be 120 minutes based
on a previous HTA monograph.91 Average length
of hospital stay was taken from the Hospital
Episodes Statistics Database for the operation code
W37.1 and was assumed to be 8.7 days based on
‘Total prosthetic replacement of the hip joint
using cement, Primary total prosthetic
replacement of hip joint using cement’. This
particular operation code was chosen as it is the
most frequently recorded operation code for THR
(Table 40).92 A distribution for this parameter was
constructed using the median and mean length of
stay for this operation code. Using these two items
of data, the use of alternative distributions was
investigated and a log-normal distribution was
chosen, as it provided a plausible lower estimate of
length of stay and also allowed the possibility of
substantially greater length of stay.
Derivation of relative effect sizes
Data on the relative effect sizes were derived from
the systematic review of effectiveness where
possible. All relative effect sizes are given in
Table 42. It was assumed that the relative effect size
of operative mortality and of all-cause morality for
mini-incision THR compared with standard THR
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TABLE 42 Relative effect sizes used in the model
Parameter Point estimate Limits of 95% CI Distribution
Lower Upper
Transition probabilities 
Operative mortality 1 1 1
All-cause mortality 1 1 1
Revision rate 1 0.1 1.9 Uniform
Rate of non-operative management following failed THR 1 1 1
Other probabilities
Re-operation rate for dislocation 1 0.1 1.9 Uniform
Re-operation rate for deep infection 1 0.1 1.9 Uniform
DVT rate 1 0.1 1.9 Uniform
PE rate 1 0.1 1.9 Uniform
Operation duration (minutes) –3.70 –5.67 –1.74 Normal
Length of stay (days) –0.5 –0.83 –0.18 Normalwas one (Table 42). This assumption was made as it
is unlikely that these risks would differ between
the two operative techniques (Hutchison JD,
Department of Surgery, University of Aberdeen
and Munro N, NHS Grampian: personal
communication, February 2007).
The conclusions that can be drawn from the meta-
analysis reported in Chapter 3 are tenuous, as
data for some outcomes were sparse and the CIs
were implausibly wide. For the base-case model,
therefore, the relative effect sizes from the meta-
analysis were not utilised for several model
parameters. Reliable data relating to the annual
risk of revision, rate of re-operation for both
dislocation and deep infection and risk of DVT
and non-fatal PE were not available but
interpretation of the few data from Chapter 3
suggests a relative effect size of one but with
considerable uncertainty, which was reflected by
the adoption of a uniform distribution for these
parameters (Table 42). This assumption was based
on the interpretation of the findings of the review
of effectiveness and on advice of the
methodological and clinical members of the
research team. The approach was deemed more
appropriate than surveying expert opinion as such
data are themselves arbitrary and may reflect the
biases of those surveyed. 
Other relative effect sizes required for the model
relate to operation duration and length of stay,
which were obtained from data reported in
Chapter 3 (Table 42). Data were suggestive of a
statistically significant reduction in operation time
and length of stay and this was therefore reflected
in the initial operation costs for the two
procedures. For both parameters, a normal
distribution was assigned to represent statistical
uncertainty of the point estimates based on the
95% CIs.
Resource use and costs
The derivations of selected individual resource use
parameters are shown in Tables 43 and 44. A
summary of all resource use parameter values
included in the model can be found in Table 45.
The main cost component included in the model
is the costs associated with the primary THR
operation and the costs of any subsequent revision
operations or re-operations for complications (i.e.
dislocation and/or infection). It is likely that the
main cost differences between standard and mini-
incision THR might result from any extra
specialist equipment or instrumentation required
for mini-incision techniques, any difference in the
duration of surgery and as the possibility of a
shorter hospitalisation period which may be
associated with the mini-incision technique. 
For the primary operation, the cost of a cemented
prosthesis, assumed to be used for both
procedures, was estimated from a number of
manufacturers’ price lists. A cemented prosthesis
was chosen, as data from the Hospital Episodes
Statistics showed that a greater number of THRs
were performed with cemented rather than
uncemented prostheses.92 In relation to
instrumentation costs, it was assumed for standard
THR that this cost would be subsumed in the cost
of the prosthesis based on usual NHS practice. To
perform mini-incision THR, however, an extra
additional instrumentation kit would be necessary.
The one-off cost of this was taken from
manufacturers’ price lists and an estimate of the
lifespan of the instruments, and also an
approximation of the number of times these
instruments would be used in a year was
determined following expert opinion 
(Hutchison JD, Department of Surgery, University
of Aberdeen and Munro N, NHS Grampian:
personal communication, March 2007). An annual
equivalent cost was estimated using a discount rate
Health Technology Assessment 2008; Vol. 12: No. 26
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TABLE 43 Cost of management of DVT during initial hospitalisation period
Management Cost (£) Dose Source
Tests
Ultrasound 38 NRC banding code RBB3 
Other ultrasound
Fibrin D-dimer 1 NRC Speciality code DAP 841 – biochemistry test
Drugs
Heparin 0.36 5000 units/ml BNF
13.68 1000 units/ml/hour for 72 hours BNF
Warfarin 0.11 10 mg on first day BNF
8.10 6 mg warfarin for a further 3 months BNF
Total 61.25of 3.5% which, given expected annual usage, gave
a cost per patient of £12.58. Other costs associated
with the initial operation related to staffing,
overheads (length of stay and theatre costs),
consumables and capital costs. The staff mixes for
both methods of replacement were estimated and
assumed to be the same for the base-case analysis
following clinical opinion (Hutchison JD,
Department of Surgery, University of Aberdeen
and Munro N, NHS Grampian: personal
communication, 2007). The various staff unit costs
were estimated from published sources,93 as were
the unit costs of theatre time and a stay on an
orthopaedic ward.94
The cost of surgery would be incurred in the first
cycle of the model. Other costs would also be
incurred in this cycle related to follow-up visits
and the cost of complications which may occur
following discharge. 
Following guidance from the British Orthopaedic
Association, a patient would attend a consultant
outpatient appointment at 8 weeks and at 1 year.
At this time, both antero-posterior and lateral X-
rays would be performed.95 Following consultation
with clinical experts, the same follow-up for mini-
incision patients was assumed for the base-case
analysis (Hutchison JD, Department of Surgery,
University of Aberdeen and Munro N, NHS
Grampian: personal communication, March 2007).
The cost of an outpatient appointment was
assumed to be £103, taken from published
sources.94 The costs of antero-posterior and lateral
X-rays were assumed to be the same and were
taken from the NHS reference costs. A triangular
distribution was defined for this cost based on the
interquartile range of costs reported for this
imaging modality.96
The costs of complications which might have a
large impact on resource use and quality of life
were also allowed for within the first cycle of the
model. These include the cost of re-operation for
dislocation and deep infection as well as
admissions to hospital as a result of a DVT and/or
PE. Costs for a re-operation (i.e. not revision), for
both dislocation and infection, and the cost of
treatment for PE were taken from NHS reference
costs and, using the methods outlined above in
relation to the cost of an X-ray, triangular
distributions assigned to these costs.96 For a DVT,
it was assumed, based on clinical opinion, that
approximately 5% of those suffering from DVT
would be readmitted to hospital for further
treatment (Hutchison JD, Department of Surgery,
University of Aberdeen and Munro N, NHS
Grampian: personal communication, April 2007).
For these patients, the cost of management was
based on NHS reference costs and a triangular
distribution was defined around the point estimate
to reflect statistical uncertainty.96 For the
remaining patients with a DVT, it was assumed
that they would principally be treated using the
treatment regime recommended by SIGN
(Table 43).97 The cost of tests and medications
required were estimated from NHS reference costs
and the BNF (Table 43).96,98
Following a successful THR operation, regular
reviews past 1 year would be performed. These
include consultant-led outpatient visits including
X-rays (as described above for outpatient
appointments within the first year after surgery) at
5 years following surgery and every subsequent
5 years thereafter.95 These follow-up visits are
assumed to cost the same as those incurred in the
first cycle. The risk and management cost of
complications which may impact on resource use
and quality of life (not including revision) were
subsumed within the relevant states. As described
above for the operation state, these included the
costs of re-operation for both dislocation and deep
infection.
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TABLE 44 Cost of non-operative management for patients following failed THR
Area of resource use Quantity of  Unit cost (£) Annual cost per  Source
resource use patient (£)
Physiotherapy sessions – outpatient Eight sessions per annum 32 256.00 PSSRU
Physiotherapy in the community Three sessions per annum 14 42.00 PSSRU
Medication (assume 270 days  1.2 g daily 0.6 g × 84 tablets = 3.79 24.36 BNF
per year): ibuprofen
GP visits Two per annum 18 36.00 PSSRU
NSAID events 385.00
Total 743.36
NSAID, non-steroidal anti-inflammatory drug; PSSRU, Personal Social Services Research Unit.Health Technology Assessment 2008; Vol. 12: No. 26
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TABLE 45 Cost estimates for each element of total cost 
Parameter Value Distribution Values for  Source
distribution
Estimation of theatre costs (per minute)
Consultant surgeon £1.30 NA NA PSSRU
Consultant anaesthetist £1.32 NA NA PSSRU
Specialist registrar  £0.57 NA NA PSSRU
Nurse – Grade F  £0.40 NA NA PSSRU
Nurse – Grade F £0.40 NA NA PSSRU
Nurse – Grade E  £0.32 NA NA PSSRU
Theatre overheads £19.47 NA NA ISD
Duration of operation for  120 NA NA Hip resurfacing HTA 
standard (minutes) review
Equipment and instrumentation
Cost cemented prosthesis £558.13 NA NA Manufacturer
Cost for MI instrumentation  £12.58 Manufacturer
per patient
Cost of standard instrumentation Subsumed in  NA NA
prosthesis cost
Follow-up cost
Cost of inpatient hospital stay  £411.79 NA NA ISD Scotland
per day
Cost of outpatient visit £103.00 NA NA ISD Scotland
Cost of X-ray £19.00 Triangular IQR: £15–23 NRC Band A (RBA1)
Cost of complications
Revision £7858.00 Triangular IQR: £6129–9121 NRC HRG H71 –
Revisional procedure
to hip
Re-operation for dislocation £1925.00 Triangular IQR: £1263–2304 NRC HRG H40 –
Closed upper limb
fractures or
dislocation
Re-operation for infection £3365.00 Triangular IQR: £1034–4352 NRC HRG H30 –
Infections of bones or
joints
Cost of non-admitted DVT £61.25
Cost of admitted DVT £789.00 Triangular IQR: £612–1610 NRC HRG E21 –
Deep vein thrombosis
<70 without
complications
Cost PE £1326.00 Triangular IQR: £979–2090 NRC HRG D11 –
Pulmonary embolism
without complications
Cost of non-operative  £743.36 NA NA Hip resurfacing HTA 
management review
HRG, Healthcare Resource Group; HTA, Health Technology Assessment; IQR, interquartile range; ISD, Information Services
Division; NA, not applicable; NRC, National Health Service reference costs; PSSRU, Personal Social Services Research Unit.The cost of care for patients who might have a
failed operation would, of course, be dependent
upon the nature of the failure. For those patients
who require a revision surgery, the cost of this was
taken from the NHS reference costs for Healthcare
Resource Group (HRG) H71 (a revisional
procedure to hip). A distribution for this cost was
defined using the same methods described above.
The follow-up of patients after a revision would be
similar to follow-up following primary THR. It was
assumed, however, that during the first year
following revision surgery, an extra outpatient
appointment including X-rays would be performed.
Again, the risk and costs of complications were
factored into the revision state and were assumed
to be the same as after primary THR.
In addition to the cost of revision, a patient might
receive medications and non-operative treatments
for the control and management of hip disease if,
after a failed primary or revision surgery, further
revision surgery is no longer viable, for example as
a result of being unfit for surgery. The cost for a
typical regime of care was defined based on a
previous HTA monograph,91 which identified the
management cost for those people who were
waiting for a THR. The resource usage was used
and costs were updated to 2006 prices (Table 44).
No distributions were assigned to these costs and
this represents a caveat of the costs associated with
the non-operative management state. It should be
noted, however, that the number of patients
entering this state is likely to be extremely small;
therefore, failing to assign distributions to each
component is unlikely to alter the conclusions
between mini-incision and standard THR.
Table 45 outlines cost estimates for each element of
resource use used in the model.
Estimation of quality-adjusted life-years (QALYs)
This section and Table 46 describe the source and
methods used to obtain utility values. All utility
values used for the base-case model are shown in
Table 47. No suitable utility data, required to
estimate QALYs, were identified in either of the
economic evaluations reported in Chapter 4.
Potential utility data were sought from focused
searches of the Harvard Cost Utility Database and
of the literature of quality of life estimates
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TABLE 46 Main findings from papers in relation to quality of life following THR
Study Type of  Baseline Scores for treatment success
THR
3 months 1 year
Dawson, 200199 Revision 0.32 (95% CI 0.29 to 0.36) 0.62 (95% CI 0.59 to 0.65)
Robinson, 1999100 Primary NR 0.99 (IQR 0.006)
Malchau, 2005101 Primary 0.38 (no SD reported) 0.75 (no SD reported)
Ostendorf, 2004a102  Primary 0.35 (SD 0.31) 0.76 (SD 0.27)
Ostenforf, 2004b103 Primary 0.33 (SD 0.32) 0.71 (SD 0.26) 0.75 (SD 0.28)
IQR, interquartile range; NR, not reported; SD, standard deviation.
TABLE 47 Utility values used in the model to estimate QALYs
Utility scores used in the economic model Utility value (SD) Distribution
Primary THR
Preoperative 0.33 (0.32) Beta
Success at 3 months 0.71 (0.26) Beta
Success at 1 year 0.75 (0.28) Beta
Successful THR
Success at 1 year 0.75 (0.28) Beta
Revision
Failure of THR up to 3 months 0.33 (0.32) Beta
Successful revision at 1 year 0.62 (0.015) Beta
Successful THR after revision
Success at 1 year 0.62 (0.015) Beta
Non-operative management  0.33 (0.32) Beta
Dead 0 Nonefollowing standard THR. From these searches, a
number of studies with potentially relevant utility
values which could be used to estimate QALYs
were found. Five European studies with relevant
data were identified as having potentially useful
quality of life data. The results of these studies are
summarised in Table 46.
Results at baseline and 1 year for utility scores
following standard THR were similar across all the
studies apart from one study which based its sample
on revision THR patients.99 Based on the above
data, utilities data were taken from two papers.99,103
The data reported by Ostendorf and colleagues103
was chosen because preoperative and 1-year utility
scores were similar to results from other studies
and also because this was the only study that
reported a utility value at 3 months following
surgery. This paper analysed a prospective cohort
of patients in The Netherlands (n = 161) whose
quality of life was measured at the time when the
patient was placed on a waiting list for THR,
preoperatively and at 3 and 12 months after
surgery. The values used in the model are
reported in Table 47. For the 40-year model, the
utility associated with success post-1 year (for the
successful THR and successful THR after revision
states, respectively) were assumed to be equal to
the 1-year values reported in Table 47. It should be
noted that the disutility associated with a failed
THR requiring revision and also the disutility
associated with re-operations for dislocation were
allowed for within the model. It was assumed that
patients suffering any of these complications would
have a utility score equal to the preoperative score
for 3 months before progressing to the quality of
life score associated with the successful THR or
successful THR after a revision. Following
successful revision surgery, patients were assumed
to have a utility score equal to 0.62 at 1 year (for
the revision state and successful THR after
revision state) (Table 47). This figure was obtained
from a paper by Dawson and colleagues,99 which
analysed the outcomes of 601 revision patients in
the UK using the EQ-5D. For those patients who
progress to the non-operative management state
in the model following failed surgery, it was
assumed that they would have a utility score equal
to the pre-operative quality of life estimate. All
utility scores defined in the model were assigned a
beta distribution in order to reflect uncertainty of
the point estimate (Table 47).
Within the base-case analysis, the above utilities
were applied to both mini-incision THR and
standard THR. The results presented in Chapter 3
indicate that mini-incision THR is associated with
a shorter recovery. Therefore, it was assumed that
patients would return to a utility of 0.71 at
2 months rather than the 3 months assumed for
standard THR. This assumption of a 1-month
earlier recovery represents analyst assumption as it
was not possible to quantify the available data in
relation to ‘time to return to usual activities’. 
A 1-month quicker recovery was a reasonable
starting point given findings from the review of
effectiveness (see Table 24, p. 36) and the
implication of this assumption has been addressed
in a threshold analysis around this estimate (see
the section ‘Results’, p. 65).
Finally, utilities data were also sought from the
Harvard Cost Utility Database in relation to the
disutility associated with DVT and non-fatal PE
following surgery. No suitable data were found and
the effects of these complications on quality of life,
therefore, have not been factored into the
estimation of QALYs.
Assessment of cost-effectiveness
The base-case analysis is based on the costs and
outcomes faced by a cohort of 68-year-old THR
patients (the mean age of patients receiving THR as
stated in the most recent National Joint Registry for
England and Wales report)3 over two time horizons
(1 year and 40 years). For the 40-year model, costs
and effects were discounted at a rate of 3.5%
following current national guidelines.104 Within the
economic model, outcomes are presented as
incremental cost per QALY. Data on these outcomes
are presented in two ways. First, mean costs and
QALYs for the alternative interventions are
presented and incremental cost per additional
QALYs calculated where appropriate. The second
way in which the cost-effectiveness of the alternative
interventions is presented is in terms of cost-
effectiveness acceptability curves (CEACs).105
CEACs have been used to illustrate the effect of
statistical uncertainty caused by the statistical
variability in the model’s parameter estimates.
These curves illustrate the likelihood that an
intervention is cost-effective at various threshold
values for society’s willingness to pay for a QALY. 
Sensitivity analysis and subgroup
analysis
Sensitivity analysis focused on varying assumptions
or parameter values in the base-case model.
Increased resource use associated with mini-
incision THR (1-year time horizon)
It was assumed for the base-case analysis that the
management of patients following mini-incision
Health Technology Assessment 2008; Vol. 12: No. 26
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patients. Following consultation with clinical
experts, it is possible that mini-incision patients
might be followed up more closely than standard
THR patients (Hutchison JD, Department of
Surgery, University of Aberdeen and Munro N,
NHS Grampian: personal communication, March
2007). This sensitivity analysis assumes that an
extra Grade E nurse would be required for the
duration of surgery for mini-incision patients and
also assumes that patients would have an extra
consultant-led outpatient appointment during the
first year after surgery. At this time the usual
antero-posterior and lateral X-rays would be
performed. 
For the base-case analysis, the impact on cost
associated with a shorter hospitalisation period
and reduced operation time was included in the
model. As these differences are very small and
their relevance is uncertain, this sensitivity analysis
also makes the assumption that any differences
were not economically important. 
Use of Peto ORs for dislocation and DVT
reported in review of effectiveness (1- and 
40-year time horizons)
Differences in short- and long-term outcomes
following the two forms of surgery are assumed to
be the same for the base-case analysis (but with
wide CIs) due to the limited data around estimates
produced in the meta-analysis reported in 
Chapter 3. Estimates surrounding the odds of
dislocation and DVT following mini-incision THR
compared with standard THR, although not
statistically significant, were not wholly
implausible, so these were included in this
sensitivity analysis to relax slightly the assumptions
of equal outcomes. The meta-analysis reports a
Peto OR of 1.72 (95% CI 0.43 to 6.92) in relation
to the risk of postoperative dislocation and a Peto
OR of 0.39 (95% CI 0.12 to 1.30) in relation to
DVT (a Peto OR <1 can be interpreted as a lower
odds of a particular event occurring for mini-
incision THR and, conversely, a Peto OR >1
represents a greater likelihood of an event
occurring for mini-incision THR). Log-normal
distributions were assigned to these risks to reflect
uncertainty of point estimates. The analysis was
conducted for a 1- and 40-year time horizons.
Use of alternative utilities data to estimate
QALYs (1- and 40-year time horizons)
Alternative utilities data were identified to
estimate QALYs from a study conducted by
Charles and colleagues.69 Details of the reanalysis
that was performed on the trial results can be
found in detail in Appendix 11. Three analyses
were performed on the data to account for missing
values. For this sensitivity analysis, the reported
utility scores using the ‘last value carried forward’
approach to missing data was used. Utilities data
at baseline, 3 months, 6 months and 1 year were
used to estimate QALYs for standard THR
patients. For mini-incision THR, the mean scores
at each time point for standard THR were
compared in an analysis of covariance adjusting
for baseline SF-6D scores. Table 48 shows the data
used for this analysis, as required by the model. To
estimate results for a 40-year time horizon, it was
necessary to consider the utility that might apply
for revision THR as the utilities data were for
primary THR only. It was assumed for the 40-year
model, therefore, that patients who underwent
revision surgery would have 76% of the utility of
primary THR patients (based on the difference
between a successful primary and revision THR at
1 year from the base-case utility values used). As
for the base-case models, the disutility associated
with re-operations for dislocation was also allowed
for within the model. In the calculation of QALYs,
all utility values were given a beta distribution to
reflect uncertainty of the point estimates and the
reported coefficients of difference for mini-
incision compared with standard THR were
assigned normal distributions to reflect
uncertainty (Table 48).
Assumption that all failed primary THRs go to
non-operative management state and are not
allowed the chance of revision surgery (40-year
time horizon)
This sensitivity analysis assumed that all patients
who failed their initial primary surgery would not
be allowed the opportunity for further surgical
management. These patients were instead treated
non-operatively for the rest of their lives.
50% of failed THRs (primary and revision) go to
non-operative management state and are not
allowed the chance of revision surgery (40-year
time horizon)
Similarly to the above, 50% of those patients who
failed their THR surgery would not be allowed the
opportunity for further surgical management.
These patients were instead treated non-
operatively for the rest of their lives.
25% of failed THRs (primary and revision) go to
non-operative management state and are not
allowed the chance of revision surgery (40-year
time horizon)
This sensitivity analysis assumed that 25% of all
patients who failed their THR surgery would not
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management. These patients were instead treated
non-operatively for the rest of their lives.
Threshold analysis for revision rates for a 40-year
time horizon
A threshold analysis in the form of an implied
valuation was performed around the relative effect
size associated with revision following mini-
incision THR for a 40-year time horizon. The
range of values of the relative effect size for
revision following mini-incision THR were varied
from 1.0 (no difference in relative difference in
revision) to 1.2 (20% relative increase in revision
following mini-incision THR in comparison with
standard THR). In this way, it is possible to
determine the relative increase in revision rates
that mini-incision THR would have to be
associated with to make it the least cost-effective
alternative.
Subgroup analysis
There were no data available on which to conduct
a subgroup analysis.
Results
The results of the deterministic analysis which
reports incremental cost per QALY for the 1-year
analysis are shown in Table 49 and Figure 13.
The ICER is not reported in Table 49 because
standard THR is dominated by mini-incision THR
over a 1-year time horizon (Table 49). To give an
indication as to the flow of the patients through
the model, in a cohort of 1000 patients, for both
standard and mini-incision THR, 967 patients
would move to the successful THR states at the
end of the first cycle whereas seven would move to
the revision states and a total of 26 deaths would
occur within the 1-year time horizon. The results
are the same for both forms of replacement given
the assumptions made around the rates of
complications for the base-case analysis. A cohort
analysis showing how patients move through the
model over the 40-year time horizon for the base-
case analysis is shown in Appendix 15. When
examining the deterministic results for the 1-year
time horizon analysis displayed in Table 49, the
point estimates of the incremental cost-
effectiveness do not provide any indication of the
uncertainty that surrounds the model parameters.
The uncertainty surrounding the precision of
many of the parameter estimates is reflected in the
likelihood that the two surgical interventions are
cost-effective at different threshold values for
society’s willingness to pay for a QALY. Figures 13
and 14 report the CEACs comparing standard and
mini-incision THR in terms of QALYs and the
associated cost-effectiveness plane, respectively.
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TABLE 48 Alternative utility values
Time period Group Mean SD Adjusted difference (SE)
Preoperation Standard 0.61235 0.15764
Mini-incision 0.61235 0.15764
3 months postoperation Standard  0.7632 0.10304
Mini-incision 0.7924 0.08298
Difference 0.045 (0.31)
6 months postoperation Standard  0.8014 0.09470
Mini-incision 0.8001 0.07565
Difference 0.001 (0.030)
1 year postoperation Standard  0.8139 0.11936
Mini-incision 0.7895 0.06912
Difference –0.011 (0.033)
SE, standard error.
TABLE 49 Results of the deterministic model for a 1-year time horizon (QALYs)
Scenario Procedure Cost (£) QALYs Incremental  Incremental  Incremental 
cost (£) QALYs cost per QALY
Base-case (1 year) Mini-incision THR 7064 0.695
Standard THR 7345 0.677 281 –0.018 DominatedEconomic evaluation
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FIGURE 13 CEAC showing society’s willingness to pay for a QALY for the comparison of mini-incision with standard THR surgery
(base-case analysis)
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FIGURE 14 Cost-effectiveness plane for base-case analysisAlthough patients flow through the model in the
same way, it is the decreased cost of mini-incision
THR in comparison with standard THR and the
utility associated with a 1-month quicker recovery
that drives the results. As can be seen from
Figure 13, for the 1-year time horizon analysis
mini-incision THR has >90% chance of being
considered cost-effective for every willingness to
pay threshold presented. The base-case results
show that the reduced cost associated with the
shorter operation and duration of hospital stay is
enough to offset the cost of the extra
instrumentation required for mini-incision THR.
The difference in QALYs is also caused by the
assumption that mini-incision THR patients would
recover from surgery 1 month earlier than standard
THR patients. This is expanded on further in the
sensitivity analyses in the next section. 
Table 50 shows the deterministic results of the
base-case model when it was repeated for a 
40-year time horizon. As can be seen, the results
are similar to those for the 1-year analysis. It is
only when we look at the stochastic analysis,
however, that the importance of the 40-year
analysis becomes apparent. The 40-year analysis
allows a greater amount of uncertainty into the
model and, although many outcomes assume no
difference in effects, the extremely wide CIs
around the point estimates reduce the probability
that mini-incision THR is the most cost-effective
alternative from around 95% to 55% for all
threshold values considered.
Sensitivity analyses
Threshold analysis around time to return to usual
activities (base-case model)
The base-case analysis assumed a 4-week quicker
recovery following mini-incision THR, although
the absolute difference is unknown. A threshold
analysis was performed to explore the impact of
quicker return to usual activities following mini-
incision THR (Table 51). From Table 51, it can be
seen that even if there was no difference in time to
return to usual activities following mini-incision
THR in relation to standard THR, standard THR
is still dominated because of the higher cost
associated with it.
Increased resource use associated with mini-
incision THR (1-year time horizon)
The first sensitivity analysis focused on increasing
the hospital resource usage of mini-incision
surgery in comparison with standard THR surgery
and by relaxing assumptions on cost savings in
relation to the slightly shorter length of stay and
operation time estimates (Figures 15 and 16). 
Here mini-incision THR is, again, more effective
then standard THR, due to the assumption of
earlier recovery for these patients, but is also more
costly by approximately £200 with an ICER of
approximately £11,000.
Threshold analysis around time to return to usual
activities (1-year time horizon and increased
resource use model)
In a further sensitivity analysis, for the scenario
where mini-incision THR is associated with
increased resource use, a threshold analysis around
time to return to usual activities was performed.
This analysis showed that if mini-incision THR
was associated with a 2-week reduction in time to
return to usual activities, as opposed to the 4-week
quicker recovery assumed for the base-case
analysis, then the ICER is approximately £22,000.
When time to return to usual activities is reduced
further to 1 week, the ICER increases to £44,000
(Table 52 and Figure 17).
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TABLE 50 Results of the deterministic model for a 40-year time horizon (QALYs)
Scenario Procedure Cost (£) QALYs Incremental  Incremental  Incremental 
cost (£) QALYs cost per QALY
Base-case (40 years) Mini-incision THR 11,618 8.480
Standard THR 11,899 8.463 281 –0.017 Dominated
TABLE 51 Threshold analysis of impact of earlier return to usual activities following mini-incision THR (base-case analysis)
Reduction in time to return to usual activities following minimal-incision THR (weeks)
0123456
Change in QALYs 0 0.00436 0.0087 0.0131 0.0175 0.0218 0.0262
Change in costs (£) –281 –281 –281 –281 –281 –281 –281
ICER Dominated Dominated Dominated Dominated Dominated Dominated DominatedEconomic evaluation
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FIGURE 15 CEAC showing society’s willingness to pay for a QALY for the comparison of mini-incision with standard THR surgery
(increased resource use with mini-incision THR, 1-year time horizon)
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FIGURE 16 Cost-effectiveness plane for increased resource usage analysisUse of Peto ORs reported for dislocation and
DVT from review of effectiveness
This analysis used the point estimates of the Peto
OR for DVT and re-operation due to dislocation
from the meta-analysis conducted as part of the
systematic review of effectiveness in Chapter 3. As
is apparent in Table 53, the results did not differ
greatly from the base-case analysis. Although there
is a high management cost associated with
dislocation, the baseline risk is small, hence the
increase in the rate of dislocation apparent for
mini-incision THR patients impacts little on
results. Further, as the Peto OR for DVT favoured
mini-incision THR, some of the increased cost
associated with an increase in re-operations for
dislocations would be offset by the reduction in
cost for the treatment of patients suffering from
DVT. As would be expected, the QALY gain
following mini-incision surgery is slightly reduced
due to the assumptions made around quality of
life following a dislocation. Again, this reduction
in quality of life is small because of the low
baseline risk of dislocation and because of the
short time horizon of this analysis. At all threshold
values for society’s willingness to pay for a QALY,
mini-incision THR still has >95% chance of being
considered cost-effective. 
When this analysis was repeated for the 40-year
time horizon, standard THR is still dominated by
mini-incision THR (Table 54) but the magnitude of
the difference in cost and QALYs is reduced. This
is because the longer time horizon allows more
uncertainty into the model and also allows a
greater number of mini-incision patients to suffer
the costs and consequences associated with a re-
operation for dislocation in comparison with
standard THR. This would be as expected given
the point estimates of the OR for re-operation due
to dislocation used for this analysis which slightly
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TABLE 52 Threshold analysis of impact of earlier return to usual activities following mini-incision THR (increased resource usage
analysis)
Reduction in time to return to usual activities following minimal-incision THR (weeks)
0123456
Change in QALYs 0 0.00436 0.0087 0.0131 0.0175 0.0218 0.0262
Change in costs (£) 192 192 192 192 192 192 192
ICER (£) Dominated 43,991 21,996 14,664 10,998 8,798 7,331
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FIGURE 17 Threshold analysis of impact of earlier return to usual activities (increased resource usage analysis)favours standard THR. As the baseline risk of
dislocation is low, however, it is not enough to
offset the benefits of mini-incision surgery in
terms of earlier return to usual activities in the
immediate postoperative period, the driver of
QALY results. The important point to note in
relation to the probabilistic sensitivity analysis
results for the 40-year model is that the probability
that mini-incision THR would be considered cost-
effective is approximately 55% for all threshold
values (markedly reduced from the 95% chance in
the 1-year analysis). This is because this model
allows a much greater amount of uncertainty into
the analysis. 
Use of alternative utilities data to estimate
QALYs (1- and 40-year analysis)
Alternative utilities data were identified from a
study by Charles and colleagues.69 Again, standard
THR is dominated by mini-incision THR in this
analysis which differs little from the base-case
results (Table 53). The difference in cost between
the two interventions remained the same as the
base-case analysis; however, QALYs following mini-
incision THR were slightly higher at 1 year. This is
because the utility scores reported at 3 and
6 months were slightly higher for mini-incision
THR than standard THR (Table 48) and the net
effect of this was that QALYs at 1 year following
mini-incision THR were higher. 
This analysis was repeated for the 40-year time
horizon and is one of the few analyses where
standard THR is not dominated by mini-incision
THR, although the ICER reported is extremely
high (approximately £259,000). The difference in
cost between the two interventions remained the
same as in the base-case analysis; however, on
average, QALYs following standard THR were
very slightly higher at 40 years. This is because the
difference in utilities at 1 year reported in the data
from Charles and colleagues69 (Table 48) was
slightly lower for mini-incision and it was this
difference in utility that was applied to the
successful THR and successful THR after revision
states, the states in the model in which patients
would likely spend the most amount of time. The
mean utility for standard THR was, therefore,
higher than that for minimally invasive THR,
leading to a greater number of QALYs following
standard THR over the 40-year time horizon.
Finally, the point estimate of QALYs for both
standard and mini-incision THR for the 
40-year analysis using alternative utility data are
higher than those reported in the 1-year base-case
analysis because the utility score associated with
failure from the alternative utilities data was
higher than (approximately double) that of the
base-case utility score for failed THRs (Table 54). 
Assumptions around the number of failed THR
patients (primary and revision) moving to the
non-operative management state and not being
allowed the chance of revision surgery (40-year
time horizon)
Results of the sensitivity analyses that made
assumptions around the number of failed THR
patients going to the non-operative management
state for the rest of their lives, as opposed to being
given the chance of revision surgery, did not differ
greatly from those of the base-case analysis. As
would be expected, patients in both arms of the
model experienced reduced QALYs over the 
40-year time horizon, compared with the 1-year
time horizon base-case analysis, for each of the
three sensitivity analyses that were performed (one
assuming all failed patients went to the non-
operative management state, one assuming 50%
and one assuming 25%). This is as would be
expected given the low quality of life associated
with the model’s non-operative management state.
Similarly in relation to cost, although patients
incurred costs in terms of long-term pain and
non-operative management over the 40-year
period, the high costs associated with revision
surgery were more likely to be avoided and, as a
result, reduced the cost estimates for both forms of
surgery for each of the analyses (Table 54).
Threshold analysis for revision rates for a 40-year
time horizon
A threshold analysis was conducted on the relative
difference in revisions following mini-incision
THR compared with standard THR. This analysis
showed that if society were willing to pay £30,000
for a QALY, mini-incision THR would have to be
associated with a 7.5% increase in revisions for it
to be no longer considered cost-effective. 
Summary of evidence on 
cost-effectiveness
Available data on the effectiveness of single mini-
incision THR in comparison with standard THR
were explicitly synthesised in an economic model.
Synthesised data from the systematic review of
effectiveness in relation to revision, risk of
dislocation and infection and the risks of DVT and
PE were extremely tenuous and were therefore not
included in the model owing to the implausibly
wide CIs reported. In general, however, the results
suggested a relative effect size of one. It was
assumed, therefore, that these outcomes would be
Economic evaluation
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8equal but with considerable uncertainty around
the point estimates. In the base case of this model,
and most of the sensitivity analyses, standard THR
was dominated (i.e. no more effective but more
costly by approximately £300) by mini-incision
THR (with approximately a 95% likelihood of
being cost-effective depending on the cost per
QALY threshold considered for the 1-year base-
case analysis). Standard THR only appeared to be
less costly when it was assumed that follow-up after
mini-incision THR would be more intensive than
after standard THR. Nevertheless, if society were
willing to pay £30,000 for an additional QALY, the
likelihood that mini-incision surgery would be the
most cost-effective alternative was still high at
approximately 75%. The use of alternative utility
values were explored for both a 1- and 40-year
time horizons. The analysis conducted over a 
40-year time horizon was one of the few analyses
where standard THR was not dominated by mini-
incision THR. The slight added effectiveness of
standard THR in relation to mini-incision THR
did not, however, alter the probabilistic sensitivity
analysis results significantly. Relaxing assumptions
with regard to equal long- and short-term
complications following surgery, and increasing
the time horizon of the analysis to 40 years, did
not alter the deterministic results significantly but
did make results of the stochastic analyses more
uncertain as, when employing the 40-year time
horizon, the likelihood that mini-incision THR
would be considered cost-effective varied between
50 and 60% for threshold values for society’s
willingness to pay of up to £50,000. The exception
to this was the analysis that used alternative utility
values, where standard THR was more costly but
more effective than mini-incision THR. The
incremental cost per QALY for standard THR
compared with mini-incision THR, however, was
nearly £260,000. Furthermore, the likelihood that
mini-incision THR would be considered cost-
effective was over 50% for all threshold values for
society’s willingness to pay for a QALY up to
£50,000. A threshold analysis around revisions for
the 40-year time horizon model showed that if
society were willing to pay £30,000 for a QALY,
mini-incision THR would have to be associated
with a 7.5% increase in revisions for it to be no
longer considered cost-effective. 
Results of the economic evaluation should be
treated with caution because very few useable and
reliable data were available in relation to costs for
the two modes of surgery and the risk of long-
term complications following mini-incision THR
in comparison with standard THR.
Economic evaluation
72Quality of life for the family and
carers
Quality of life issues related to THR relate to pain,
mobility (e.g. limp, use of walking aids) and return
to normal activities. There are a number of
specific scores which measure condition-specific
quality of life, encapsulating a range of issues,
such as the Harris hip score. Finally, there are
general quality of life measures such as the SF-12,
the SF-36 and the EQ-5D. 
The information on pain (either short-term within
3 months of the operation or long-term pain
resulting in disability) was not well reported, but
there were no overall differences between patients
receiving a mini-incision or a standard incision.
There were either no differences in mobility or
time to return to normal activities or the data
favoured mini-incision. 
Similarly, few studies reported significant
differences between the two groups in condition-
specific measures, but where there were such
differences, they favoured the mini-incision group
both in the short term (less than 3 months) and
over a longer period (e.g. 1–5 years). Measures of
general quality of life did not favour either group. 
Patients also preferred the shorter scars resulting
from MIS.
In summary, it seems reasonable to conclude that
patients had a marginally better quality of life
after MIS, but long-term information is not
available. This conclusion might also be
overturned if there was evidence of a higher need
for revision surgery in the long term. 
Although no information was available on the
quality of life of family and carers, better quality of
life for the individual with hip disease would most
likely reduce the burden of care for their carers
and hence improve their own quality of life. 
Financial impact for the patient
and others
An earlier return to mobility and normal activity
following MIS would be expected to result in
economic benefits both for themselves (e.g. earlier
return to work) and for carers in reducing the
need for time spent caring for the patient.
However, there were no data available to support
this inference. 
It is unlikely that minimal incision approaches will
be employed in all patients due to variations in
individual patients’ habitus, the variable
complexity of reconstruction between cases and
the variable experience of different surgeons. 
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Chapter 6
Implications for other partiesTraining
Relatively few orthopaedic surgeons in the UK are
currently undertaking formal mini-incision THR.
However, there is a trend to reduce incision size,
which could be seen as a development of standard
practice rather than a new technique which
requires specific training. 
Nevertheless, it would be prudent to advise that
widespread adoption of this technique should be
in the context of ongoing quality assurance
processes relating to individual surgeons’ practices.
These might include audit and feedback from the
National Joint Registry/Scottish Arthroplasty
Project. Several studies addressed the issue of a
learning curve for surgeons not familiar with this
technique,32,42,48,52,55 whereas others only included
patients from surgeons who were considered to be
experienced.31,40,46,56 However, there was no
consensus as to how many procedures would be
sufficient to ensure a reasonable level of skill. It
seems reasonable to propose, however, that initial
training in mini-incision operations should occur in
high-volume orthopaedic centres, and that surgeons
performing THRs should perform a minimum
number annually to maintain their expertise. 
A further point to note is that if the use of MIS
increases, this may reduce the number of cases of
standard THRs available for the training of junior
surgeons. Proficiency in mini-incision is achieved
by performing the procedure and is, generally, not
amenable to being taught on a training course
(Hutchison JD, Department of Surgery, University
of Aberdeen and Munro N, NHS Grampian:
personal communication, April 2007). Generally,
an orthopaedic surgeon would need to be
proficient in the standard technique before
modifying it to a mini-incision technique. We
estimate that around two in five patients may be
suitable for the mini-incision procedure (see the
next section) and therefore not available for
training in standard THR techniques. In addition,
training in computer-aided navigation and robotic
guidance might further reduce the necessary
number of standard THRs available for the
training of junior surgeons. 
Training may also be provided by companies who
are commercially motivated to sell their own 
THR appliances, and who may also supply THR
‘kits’ consisting of specially adapted retractors,
light sources and so on in order to boost their
sales. The desirability of this for the NHS is
unclear. 
Fair access and equity issues
Currently, MIS is variably utilised within the NHS,
due to uncertainty about its safety and efficacy and
the potential need for special training. However, it
should be remembered that this operation is not
suitable for all patients, particularly those who are
obese, very muscular or with severe osteoporosis.
This is for technical reasons related to operative
difficulty, need for adequate operative access and a
higher chance of complications in certain
populations. 
Estimates of the proportion of THR patients who
might be suitable for this operation are not
available, but around 6% of all THRs are currently
performed via a mini-incision. Three studies
included information about the proportions of
patients potentially suitable for MIS. In one study,
patients were selected for MIS based on their
upper thigh or hip girdle girth:45 32/51 patients
(63%) were considered to be small enough to be
suitable for mini-incision THR. In another study,55
where patients were selected for mini-incision
THR based on body habitus (lower BMI), 50/135
patients (37%) received mini-incision THR.
Finally, in a third study,52 where the surgeons
intended to use mini-incision THR, but then
extended the incision length if required during
the operation, 38/102 (37%) were successfully
restricted to an incision of less than 10 cm, 43/102
(42%) had an intermediate incision length of
10–14 cm and 21/102 (21%) finally had an incision
length of more than 14 cm. Interestingly, the final
incision length correlated with increasing body
habitus (mean BMI 26, 28 and 29.5, respectively).
Hence, in an unselected population, just under
40% might be found to be suitable for mini-
incision THR. 
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Chapter 7
Implications for the NHSSecond, the need for training and a need to
maintain professional competence by performing
a minimum number of operations may restrict the
centres providing this technique to those with
specialised hip surgeons. This may limit access to
mini-incision operations by patients served by
other centres. 
Budgetary impact on the NHS
Given that the NHS operation costs of a mini-
incision THR may be similar to those of standard
incision, it would seem likely that increasing the
numbers of THRs carried out via mini-incisions
would not result in any appreciable change in
NHS costs. However, this would depend on there
being no significant increase in the need for
revision surgery: long-term data for this outcome
are lacking. It would be important to obtain long-
term follow-up data for all THRs performed in the
NHS, for example through the National Joint
Registry.3
The use of two-incision
approaches
Little evidence was available on the effectiveness
of the two-incision approaches to minimal incision
THR and it was not possible to estimate cost-
effectiveness or budget impact of adopting these
approaches. The generally accepted view among
surgeons is that they have never been widely used
and the conflicting evidence from the current
report supports this stance.
Implications for the NHS
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inimal incision THR continues a general
trend towards the use of less invasive
approaches in other surgical specialities. This
study aimed to examine the clinical and cost-
effectiveness of single mini-incision and two mini-
incision procedures for THR compared with
standard THR. The rationale behind the need for
this research is that shorter incisions (usually
10 cm or less) may result in less muscle dissection,
which may in turn lead to reduced morbidity and
quicker recovery. On the other hand, shorter
incisions may reduce visualisation at operation,
leading to a potential risk of suboptimal
placement of the prostheses, which may then lead
to a higher rate of revisions than might be
expected with standard THR. Failure of THR
requiring replacement (revision) carries serious
implications and so longer term performance is a
major factor in the choice of method for THR. In
addition to uncertainty about the relative
effectiveness (including their effect on
complication rates) of these minimally invasive
techniques, there is also uncertainty about the
relative costs of these procedures. In particular it
was unclear whether the potential reduction in
length of hospital stay would compensate for any
increased cost of equipment. 
Main results
The results of the review of clinical effectiveness
suggest that single mini-incision procedures
appear comparable to single standard incision
procedures in terms of safety and quality of life
following surgery. Single mini-incision surgery
appeared to be associated with a small reduction
in the loss of blood and operation time. The
clinical and economic relevance of these results is
uncertain and a matter for judgement. Recovery
appears more rapid after MIS (although the
magnitude of the reduction in time to return to
usual activities is uncertain). This is reflected in a
reduced hospital stay and quicker return to usual
activities. 
However, comparisons of longer term data and, in
particular, revision rates, were inconclusive
because of the small amount of data available and
the limited duration of follow-up. The number of
revisions observed during the follow-up periods
was very small. For example, revision rates derived
from the trial data were 0.5% (1/197) for mini-
incision procedures compared with 0% (0/198) for
standard incision procedures. The corresponding
Peto OR was, as a result, 7.96 (95% CI 0.16 to
402.02). Clearly, such a wide CI is beyond the
limits of clinical plausibility.
With respect to the two-incision procedure, the
results are inconclusive and conflicting. Two-
incision surgery is technically more complex than
single-incision surgery and this may be reflected in
a higher mean intraoperative blood loss and
longer operation time (two of the three studies
reporting on blood loss and all four studies
reporting on operation time, found this difference
to be statistically significant). On the other hand,
the procedure may offer a shorter hospital stay
and higher postoperative quality of life, compared
with single mini-incision or standard incision
procedures. However, data are sparse so these
findings must be treated with caution. This
operation has not been taken up with any
enthusiasm by orthopaedic surgeons in the UK
(Hutchison JD, Department of Surgery, University
of Aberdeen and Munro N, NHS Grampian:
personal communication, May 2007). After a
further focused search of the most recent
literature, there is little sign that the two-incision
approach is being taken up any further than the
current very small proportion in the UK. Further,
there appears to be a decreasing trend in
enthusiasm in the international literature.
Only two economic evaluations were identified
that considered a comparison of minimally
invasive approaches (Duwelius, 2006).82 One of
these, the unpublished US study, involved a
comparison of two mini-incisions with single mini-
incision and standard THR (Duwelius, 2006). The
second study was a crude modelling exercise based
on the results of the first study.82 Neither study
was methodologically robust and their results are
unlikely to inform decision-makers.
Results of the economic evaluation conducted
suggest similar costs and effects for mini-incision
THR and standard incision THR. On average,
mini-incision THR was found to be slightly less
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Discussioncostly than standard incision THR. This result is
driven by the assumption that operation time and,
more importantly, length of stay, are reduced and
that little additional specialised equipment and
instrumentation are required. In addition, an
assumption around quicker return to usual
activities following mini-incision THR results in
the new intervention being slightly more effective
than standard THR. Analyses were conducted over
two time horizons (1 and 40 years). For both the
short- and long-term analyses, the deterministic
results were similar. It is only when we look at the
stochastic analysis, however, that the importance
of the 40-year analysis becomes apparent. The 
40-year model allows a greater amount of
uncertainty into the models’ input parameters and
when this is translated into the probability that
mini-incision THR might be cost-effective, a
reduction is seen in this rate from 95% to
approximately 55% for all threshold values
considered for society’s willingness to pay for a
QALY. Only here does the current huge level of
uncertainty in relation to long-term outcomes
become apparent. It was not possible to
incorporate data to estimate the cost-effectiveness
of two mini-incision THR as data are too sparse to
allow any meaningful analysis to be conducted.
Furthermore, no analysis by subgroup was
performed due to the lack of data available.
Table 50 (p. 67) shows the deterministic results of
the base-case model when it was repeated for a 
40-year time horizon. As can be seen, the results
are similar to those of the 1-year analysis. 
The published results on subgroup differences do
appear to indicate longer operation time for
grossly obese patients (BMI >35) compared with
patients with a BMI of <30 for the single incision
procedures (irrespective of incision length).46
Another study for the two-incision procedure also
appears to indicate higher complication rates for
obese patients (BMI >30) and also a training
effect whereby operative time, blood loss and
complication rates are higher with low-volume
surgeons.27
Assumptions, limitations and
uncertainties
The relatively small differences found between
minimal and standard incision THR may be
explained by a number of factors. First, THR with
standard-length incision (usually 25–40 cm) has
already been proved to be very successful in
relieving pain and disability.106 Moreover, some
surgeons may have been using a progressively
shorter incision in standard THR for many
years.107 Indeed, most of the included studies
reported using average incision length of around
20 cm or less for the standard incision group.
Hence measurable improvements with further
shortening of incisions to less than 10 cm might
be expected to be relatively small. 
Nevertheless, given that minimal incision THR is
a relatively new technique compared with standard
THR, it is possible that the number of
complications may increase, as minimal incision
THR is generalised from surgeons with a special
interest in this area to the wider community of
surgeons who have a relatively low annual activity
level for THR. It may also be possible that clinical
performance of minimal incision THR will
improve, as more surgeons gain proficiency in this
technique. Further consideration is therefore
required regarding the potential impact of this
learning effect. Our searches identified 14
ongoing trials (of which four had been
abandoned) and their results would represent a
significant contribution to the area (Appendix 6). 
Second, there is no consensus as to what
constitutes a minimally invasive THR. The
National Joint Registry has used a definition of
incision length of 10 cm. However, it has been
argued by some that reduction in the dissection of
soft tissue is more important with the less invasive
approaches rather than incision length itself.107,108
Yet it is not always clear within the included
studies whether the deep dissection was
sufficiently different between the mini-incision and
standard incision groups. Of note, the cadaver
study by Mardones and colleagues109 comparing
the two-incision technique with a single mini-
incision technique reported that the degree of
damage to the abductor muscle was actually
greater with the two-incision incision technique.
Third, for most of the complications specified in
the review, events were rare, while the sample size
of the trials tended to be relatively small.
Therefore, there was little information available.
Most often, there were no clear differences, but
confidence intervals were wide.
There is little research into the predictors of long-
term success from short-term measures. We chose
implant position (poor placement of cup or stem)
and cement quality. It is possible that
radiostereometry may be useful in this respect, but
long-term research will be required to assess its
value. The hypothesis is that if radiostereometry
shows that the implant is stable at 2 years, it
Discussion
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term surveillance may be required. If this
hypothesis is proven, radiostereometry could be
used to identify those patients whose implants are
unstable (and hence require long-term
surveillance) and discharge the rest from follow-
up. This is a researchable question. 
The study has largely been concerned with THR
for patients with osteoarthritis. Since the incidence
of osteoarthritis increases with age, the majority of
participants in the studies included in the
systematic review of effectiveness were in the older
age groups. Therefore, the applicability of
findings to younger age groups is uncertain.
Although it might be expected that apart from
younger patients possibly being more muscular or
having previous trauma or childhood hip disease
with subsequent deformity, and hence being less
suitable for minimal incision approaches, there is
no reason to expect the relative performance of
the two approaches to be different in younger
patients. The study also did not consider hip
resurfacing. This operation is gaining popularity
and is more commonly performed on a younger
population.3 The review also excluded studies that
focused solely on patients with trauma and
osteoporosis, who are also likely to have
significantly different characteristics. 
Because minimally invasive THR may be
contraindicated in some patients (e.g. obese,
muscular or having severe osteoporosis), it is
plausible to expect a difference in the outcome of
the THR on the basis of the type of patients. We
had therefore planned analysis within subgroups
as specified in Chapter 2. In the event, this was
not performed due to the lack of data available.
This is a common problem with any subgroup
analyses and we acknowledge that the initial
specification of subgroups represents an ideal.
Indeed, amongst six31,32,40,46,58,75 of the nine
included trials that reported inclusion and
exclusion criteria, patients were excluded from the
trials for reasons such as weight, BMI, age,
anaemia, neurological deficits and having
‘difficult’ hips requiring complex reconstruction
(e.g. post-fracture). 
The review of effectiveness and the subsequent
economic evaluation were limited by the amount
and quality of research on mini-incision THR. Our
searches identified few high-quality RCTs. In most
of the studies identified, the sample sizes were
small and the duration of follow-up was short.
Although the results from the review appear to
show some short-term benefits for minimal
incision THR, many of the complications arising
from THR occur over a longer time span and, for
these outcomes, data are lacking. Further expert
opinion might have been used but it is unclear if
estimates of relative effectiveness would be any
more robust than those used here. Nevertheless,
this might represent a potential weakness of the
report. According to current NICE guidance on
the selection of prostheses for primary THR,106
the most recent available evidence shows that the
best prostheses have revision rates of 10% or less
at 10 years after surgery. Based on this evidence,
NICE recommended that, wherever possible, the
NHS should use implants and techniques that can
be expected to last for 10 years or more. 
Due to the small number of RCTs identified, the
review of effectiveness included a number of non-
randomised prospective comparative studies. The
data from these comparative studies and the trials
were not formally combined in the meta-analyses
but their data were broadly consistent with those
from the trials. However, in terms of dislocation
rates, the results from the comparative studies
suggested a trend towards lower rates following
minimal incision as opposed to a trend towards
standard THR based on data from the trials. In
neither case was the difference statistically
significant.
Data identified as part of the review of
effectiveness were not always reported in a form
amenable to meta-analysis. For continuous
variables, means and SDs for both minimally
invasive and standard THR were not always
reported. More importantly, there seemed to be a
tendency for these to be provided where the
estimate was in a particular direction (e.g.
duration of operation). For this reason, we chose
to estimate missing data by imputing the standard
error of the mean difference for individual studies
on the basis of available information on p-values.
This approach made the assumption that SDs are
the same in both arms of the trial. Where
information on p-values was also unavailable,
‘dummy’ SDs were imputed as the weighted means
of SDs reported in the other studies which did
report data on the same outcome or where they
could be imputed from p-values.
In addition to problems with obtaining data
amenable to meta-analysis, there are also some
concerns about the usefulness of some of the
meta-analyses that could be conducted. There was
evidence of statistical heterogeneity in the trial
data on length of hospital stay. As reported above,
when using a fixed effects approach length of stay
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compared with standard THR. When data were
reanalysed using a random effects model instead
of a fixed effects model the difference in length of
hospital stay was no longer statistically significant.
It also needs to be borne in mind that length of
hospital stay may be influenced by hospital policy
for discharge rather than the clinical needs of
each patient. Statistical heterogeneity was also
evident in the trial data on operation time. The
results from a fixed effects approach favoured the
mini-incision approach but when a random effects
model was applied, the difference in operation
time was no longer statistically significant. Caution
is therefore required in interpreting these
findings. 
The studies included in the review of effectiveness
also varied in terms of surgeon experience
(learning curve effect) and operative approach
used (e.g. posterior, anterior). Lack of
standardisation in outcome measurements was also
evident, particularly in terms of quality of life such
as postoperative pain and functional recovery, and
some outcomes were assessed in only one or two
reports. This made comparison across studies
difficult.
There are also possible uncontrolled factors
influencing the outcomes of THR. For example,
aggressive rehabilitation programmes may offer a
shorter recovery period regardless of incision
length.110 Patients’ awareness of incision length
may be another factor influencing outcomes:
although blinding the patients to the incision size
is difficult, patients who are aware of a smaller
incision may recover slightly more quickly than
those who are not.111
As with any economic evaluation, a number of
assumptions have been made, mostly in response
to the very limited data available. For example,
results from the meta-analysis conducted as part of
the review of effectiveness in relation to long-term
outcomes such as revision were so limited that they
were not used in the economic evaluation. As a
result, it has been assumed for the base-case
analysis that differences in complications are equal
following both forms of surgery (but with wide
CIs). Although this is a strong assumption to
make, it was deemed appropriate given that no
statistically significant differences were found in
the outcomes of interest and that any differences
that did exist would likely be small. Nevertheless,
further long-term data following mini-incision
THR are essential. This being said, the baseline
risks of complications from long-term Swedish
Registry data are so small that only large
differences in relative complications following
mini-incision THR in comparison with standard
THR would greatly alter the cost-effectiveness
results. A threshold analysis around revisions
showed that if society were willing to pay £30,000
for a QALY, mini-incision THR would have to be
associated with a 7.5% increase in revisions for it
to be no longer considered cost-effective. Given
the likely absolute rate of revisions for standard
THR, this is approximately equal to one more
revision for every 200 procedures performed.
In the economic model, estimates of the absolute
effectiveness of minimal incision THR for many
parameters were based on combining relative
effect sizes for the differences between minimal
incision THR with estimates for the absolute
effectiveness of standard THR. One of the main
sources of data on the relative effectiveness of
standard THR was the Swedish Registry. Although
it is true that there are likely to be some
differences between Scandinavian and UK
populations, long-term UK specific data are
lacking, The National Joint Registry for England
and Wales is a recent innovation and their most
recent report contains, for the main, a maximum
follow-up of 3 years, and only a crude calculation
of the risk of revision can be calculated.
Furthermore, there is little information about
postoperative complications. The Swedish Registry
is internationally recognised as being the original
and most respected database reporting the
outcomes for THR. It is applicable to this study in
that it covers a north European population with a
predominantly public healthcare system.
Traditionally, implant choice was more similar to
that in the UK than in some countries with an
emphasis on cemented implants (although this is
starting to change a little in the UK). The
advantage of such registry data in comparison with
studies from individual hospitals or surgeons is
that they may be more representative, and the
large number of patients included, allow estimates
for outcomes to be identified with greater
precision. Unfortunately, at this time we are not
aware of any formal publication comparing the
two populations covered by the National Joint
Registry for England and Wales and the Swedish
Registry. 
One area where data are lacking relates to the rate
at which failed primary and revision THR patients
might receive non-operative treatment as opposed
to further revision surgery. It was assumed that
there would be no difference in this rate following
both modes of surgery. If, in the future,
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costs and consequences of this will have to be
addressed. 
The main cost drivers in the model are the
reduced hospital length of stay and operation
duration assumed to be associated with minimal
incision THR. These estimates were taken from
the review of effectiveness and, as stated
previously, these estimates are uncertain. When
the analysis was repeated but with the alternative
assumption that there were no economically
important differences in operation time or length
of stay, mini-incision THR became more costly
than standard THR by approximately £200 per
patient. Further data relevant to the UK are
needed to judge whether any differences in length
of hospitalisation and operation exist and, if they
do exist, whether they are economically important. 
In addition to limitations in estimates of the
relative effect sizes, there are also concerns about
the limited cost and utilities data available. In the
case of costs, no high-quality economic evaluations
have been conducted, so a bottom-up costing of
the two forms of surgery was attempted. However,
it was not possible to include all relevant elements
of the operation cost. For example, certain cost
elements in relation to hospital resource use, such
as consumables, instrumentation and equipment
costs, were not available and therefore not
included in the calculation of operation cost.
Nonetheless, it is likely that such elements would
be similar for both mini-incision and standard
THR procedures and that their inclusion would
not greatly alter the estimated difference in cost
between the two procedures. Furthermore, in
terms of operating room instrumentation, it has
been assumed in this report that only a specialised
minimally invasive instrumentation kit would be
required in addition to the standard THR
instrumentation kit. Nevertheless, it is plausible
that further additional instrumentation and
equipment might be used depending on the
preference of the surgeon and the particular
surgical centre. In such instances, these elements
of cost would need to be accounted for. With
respect to utilities few useable data were available
relevant to the comparison of mini-incision to
standard THR, although data from one RCT were
used for a sensitivity analyses. The trial, however,
was very small, so estimates are subject to
considerable imprecision. Some exploration of the
likely importance of any difference in health state
utilities was provided by the threshold analysis
which was conducted. For the base-case analysis,
mini-incision THR remained a less costly but more
effective alternative than standard THR provided
that it was assumed that it was associated with a
quicker recovery. In the analysis which assumed
that mini-incision THR is associated with more
intensive resource usage, then recovery would
need to be on average 1.5 weeks sooner before the
incremental cost per QALY was £30,000. 
It was not possible to conduct any subgroup
analysis around model estimates. Consequently, it
is not possible to assess the suitability of minimal
incision THR techniques to particular patient
demographics and operative approaches and
hence the applicability of results to all groups is
limited.
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● Compared with standard THR, minimal
incision THR has small perioperative
advantages in terms of blood loss and operation
time. It may offer a shorter hospital stay and
quicker recovery. It appears to have a similar
procedure cost to standard THR, but evidence
on its longer term performance is very limited. 
● There is no evidence of differences between
patients receiving minimal incision and
standard incision THRs in postoperative
complication rates and self-reported quality of
life.
● The use of single mini-incision THR continues
a trend within the NHS towards the use of
minimally invasive procedures. Given the
similarities between minimal incision and
standard THR, the adoption of minimal
incision THR would involve relatively small
changes compared with the adoption of other
minimally invasive procedures.
● The main uncertainty is the related long-term
performance of minimal incision THR.
● A 7.5% difference in revision rates would be
required for minimal incision THR for it no
longer to be considered cost-effective at a
£30,000 threshold.
● It is plausible that the longer term outcomes
following minimal incision THR will be similar
to those of standard THR. Therefore, there is
no current evidence to suggest that its use
should be restricted.
● Due to the difficulty in obtaining adequate
visualisation of the hip, minimal incision THR
may be technically more difficult. It is this lack
of visualisation that has led to concerns that the
risk of revision and dislocation may be higher
than with standard THR. Appropriate training
is needed for both patient selection and
technical aspects of the procedure.
● Few data were identified relevant to the two
minimal incision THR approach. Given its
current low use within the NHS, these data
provide no basis to suggest that this approach
should be further adopted. 
● Standard THR remains an effective treatment.
As the apparent short-term benefits of minimal
incision THR are modest, the quality of an
individual operation should not be
compromised purely to conform to an arbitrary
limit in terms of wound size.
● The increase in minimal incision THRs
performed may reduce the number of cases of
standard THRs available for the training of
junior surgeons. Generally, an orthopaedic
surgeon would need to be proficient in the
standard technique before modifying it to a
mini-incision technique and, when it is taken
into account that further training might be
required in computer aided navigation and
robotic guidance, this might reduce still further
the necessary number of standard THRs
required for training. 
Implications for patients and
carers
● The use of minimal incision THR could provide
advantages to patients in terms of reduced time
under anaesthetic and possibly less time in
hospital. The shorter incision and reduced
muscle dissection also result in a quicker
recovery. It would be natural for patients to
want to obtain these benefits but they should be
aware that the longer term outcomes are
uncertain. 
● The use of minimal incision THR is not suitable
for all patients. It is generally not
recommended for those who are obese or
heavily muscled and for those with significant
deformity or severe osteoporosis.
● Compared with standard THR, minimal
incision THR is a relatively new and evolving
technique. As a consequence, the procedure
may not be practised by all surgeons who
perform THR.
Implications for research
● An important issue that needs to be addressed
formally by the orthopaedic community relates
to definitional issues around minimally invasive
techniques. Currently, there is little consensus
across studies, making the evaluation of such
techniques especially difficult. 
● The main difficulty about making a decision to
use minimal incision THR is lack of reliable
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Conclusionsinformation on longer term outcomes,
especially revision and other long-term
complications. 
● Securing reliable information on longer term
outcomes is not straightforward. The ideal
design would be a sufficiently large RCT with
follow-up for at least 5 years. However,
differences in long-term performance are not
likely to be large and so a big trial would be
needed to provide sufficiently precise estimates,
and this may not be feasible and/or worth the
cost. If such a trial were to be conducted,
however, it would be recommended that an
economic evaluation be conducted as part of it.
● Data from national registers, such as the
National Joint Registry and the Scottish
Arthroplasty Project, would certainly be useful
for assessing short-term complications and
operator issues, such as related to training and
learning. Registers can include large numbers
of procedures and hence give relatively precise
estimates; however, registers would be less
satisfactory than large RCTs for assessing
differences in long-term outcome because the
selection bias inherent in a register is likely to
obscure or exaggerate any true differences
between minimal incision THR and standard
THR.
● This lack of understanding of long-term
outcomes translates into uncertainty about
longer term costs. Such costs related to minimal
incision and standard THRs, therefore, would
likely be enhanced by reliable data from high-
quality RCTs.
● The need for long-term observation is a major
impediment for assessing developments in hip
and other joint replacement; research to fund
reliable surrogate outcomes that can be
measured earlier should therefore be
encouraged, for example collection of data in
relation to implant position, cement quality and
radiostereometry.
● Further research around the use of robotic
guidance and computer navigation techniques
to improve positioning of the implants may also
be worthwhile. 
● Further research is required in relation to the
operative approach from different locations (i.e.
posterior, anterior).
● Direct measurements of health state utilities to
reflect potential differences in pain, mobility,
return to normal activities and general quality
of life are required to supplement the available
evidence base from RCTs so that the economic
evaluation of minimal incision THR can be
made more robust.
● If two minimal incision THR is to be adopted
widely, high-quality RCTs comparing two
minimal incision with standard THR are
necessary. Given that this technique has
generally fallen out of favour within the UK
orthopaedic community and, as a consequence,
has a low use within the NHS, such trials are
unlikely to be considered worthwhile.
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Search strategies used to identify
reports of clinical effectiveness of
minimally invasive hip arthroplasty
MEDLINE (1966–February Week 3 2007),
EMBASE (1980–2007 Week 8) 
(MEDLINE In-Process 1 March 2007)
Ovid multi-file search. 
URL: http://gateway.ovid.com/athens
1 Arthroplasty, Replacement, Hip/
2 Total Hip Prosthesis/ use emez 
3 Hip Prosthesis/ 
4 (hip adj3 (arthroplast$ or replace$ or
prosthes$ or implant$)).tw. 
5 or/1-4 
6 Osteoarthritis,Hip/su
7 exp Arthritis/su 
8 (osteoarthritis or arthritis).tw. 
9 hip.tw,hw. 
10 (7 or 8) and 9 
11 or/6,10 
12 Hip Joint/su use mesz
13 Hip/su use mesz 
14 Hip Surgery/ use emez 
15 (arthroplast$ or replace$ or prosthes$ or
implant$).tw. 
16 (12 or 13 or 14) and 15 
17 5 or 11 or 16 
18 Surgical procedures,minimally invasive/ 
19 Robotics/ 
20 Video-assisted Surgery/ 
21 (minimal$ adj3 (invasiv$ or access$ or
surg$)).tw. 
22 ((small or single or double or mini or one or
two) adj3 incision$).tw. 
23 computer aid$.tw. 
24 robotic$.tw.
25 (key hole or keyhole).tw. 
26 (less adj5 invasiv$).tw. 
27 or/18-26
28 17 and 27 
29 humans/ 
30 animals/ or nonhuman/ 
31 30 not (29 and 30) 
32 28 not 31 
33 remove duplicates from 32 
Science Citation Index (1985–2 March 2007),
Biosis (1985–1 March 2007)
Web of Knowledge. URL:
http://wok.mimas.ac.uk/ 
#1 TS=(hip SAME arthroplast*)
#2 TS=(hip SAME replace*)
#3 TS=(hip SAME prosthes*)
#4 TS=(hip SAME implant*)
#5 TS=(hip SAME (surgery or surgical))
#6 #1 or #2 or #3 or #4 or #5
#7 TS=(minimal* SAME (invasiv* or access* or
surg*))
#8 TS=((small or single or double or mini or
one or two) SAME incision*)
#9 TS=(robotic* or computer-aid*)
#10 #7 or #8 or #9
#11 #6 and #10
Cochrane Library (Issue 1, 2007)
URL: http://www3.interscience.wiley.com/
cgi-bin/mrwhome/106568753/HOME
#1 MeSH descriptor Arthroplasty, Replacement,
Hip, this term only 
#2 MeSH descriptor Hip Prosthesis, this term
only 
#3 MeSH descriptor Osteoarthritis, Hip, this
term only with qualifier: SU 
#4 MeSH descriptor Arthritis explode all trees
with qualifier: SU 
#5 MeSH descriptor Hip Joint, this term only
with qualifier: SU 
#6 MeSH descriptor Hip, this term only with
qualifier: SU 
#7 (arthroplast* or replace* or prosthes* or
implant*) 
#8 (((#5 OR #6 ) AND #7)
#9 (hip near/3 (arthroplast* or replace* or
prosthes* or implant*)) 
#10 (osteoarthritis or arthritis) and (hip) 
#11 (hip) 
#12 (#4 AND #11) 
#13 (#1 OR #2 OR #3 OR #8 OR #9 OR #10
OR #12) 
#14 MeSH descriptor Surgical Procedures,
Minimally Invasive, this term only 
#15 MeSH descriptor Robotics, this term 
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Appendix 1
Search strategies#16 MeSH descriptor Video-Assisted Surgery,
this term only 
#17 (minimal* near/3 (invasiv* or access* or
surg*)) or ((small or single or double or
mini or one or two) near/3 incision*) or
(computer aid*) or (robotic* or key hole or
keyhole) or (less near/3 invasiv*) 
#18 (#14 OR #15 OR #16 OR #17) 
#19 (#13 AND #18) 
National Research Register (Issue 4, 2006)
URL: http://www.update-software.com/National/
1 MeSH Arthroplasty, Replacement, Hip
2 MeSH Hip Prosthesis
3 MeSH Osteoarthritis, Hip QUALIFIERS SU
4 MeSH Arthritis QUALIFIERS SU EXPLODE 1
5 MeSH Hip Joint QUALIFIERS SU
6 MeSH Hip QUALIFIERS SU
7 (arthroplast* or replace* or prosthes* or
implant*)
8 ((#5 or #6) and #7)
9 (hip near/3 (arthroplast* or replace* or
prosthes* or implant*)) 
10 ((osteoarthritis OR arthritis) AND hip)
11 hip
12 (#4 and #11)
13 (#1 OR #2 OR #3 OR #8 OR #9 OR #10
OR #12)
14 MeSH Surgical Procedures, Minimally Invasive
15 MeSH Robotics
16 MeSH Video-Assisted Surgery
17 (minimal* near (invasiv* or access* or surg*)
18 (small or single or double or mini or one or
two) near incision*) 
19 (computer aid*) 
20 (robotic* or key hole or keyhole) 
21 (less near invasiv*)
22 #14 or #15 or #16 or #17 or #18 or #19 or
#20 or #21
23 #13 and #22
Clinical Trials (December 2006)
URL: http://clinicaltrials.gov/ct/gui/c/r
Hip and minimally and (arthroplasty or
replacement)
Current Controlled Trials (December 2006) 
URL: http://www.controlled-trials.com/
Hip and Minimal% and (arthroplast% or replac%
or implant% or prosthes% or surg%)
Cost-effectiveness and economic
evaluations
Search strategies used to identify
reports of cost-effectiveness and
economic evaluations of minimally
invasive hip arthroplasty
MEDLINE (1966–February Week 3 2007),
EMBASE (1980–Week 8 2007) 
(MEDLINE In-Process 1 March 2007)
Ovid multi-file search. URL:
http://gateway.ovid.com/
1 Arthroplasty, Replacement, Hip/ 
2 Total Hip Prosthesis/ use emez 
3 Hip Prosthesis/ 
4 (hip adj3 (arthroplast$ or replace$ or
prosthes$ or implant$)).tw. 
5 or/1-4 
6 Osteoarthritis,Hip/su 
7 exp Arthritis/su 
8 (osteoarthritis or arthritis).tw. 
9 hip.tw,hw. 
10 (7 or 8) and 9 
11 or/6,10 
12 Hip Joint/su use mesz 
13 Hip/su use mesz 
14 Hip Surgery/ use emez 
15 (arthroplast$ or replace$ or prosthes$ or
implant$).tw. 
16 (12 or 13 or 14) and 15 
17 5 or 11 or 16 
18 Surgical procedures,minimally invasive/ 
19 Robotics/ 
20 Video-assisted Surgery/ 
21 (minimal$ adj3 (invasiv$ or access$ or
surg$)).tw. 
22 ((small or single or double or mini or one or
two) adj3 incision$).tw. 
23 computer aid$.tw. 
24 robotic$.tw. 
25 (key hole or keyhole).tw. 
26 (less adj5 invasiv$).tw. 
27 or/18-26 
28 17 and 27 
29 exp "costs and cost analysis"/ 
30 economics/ 
31 exp economics,hospital/
32 exp economics,medical/ 
33 economic,pharmaceutical/ 
34 exp budgets/
35 exp models, economic/ 
36 exp decision theory/ 
37 ec.fs. use mesz 
38 monte carlo method/ 
39 markov chains/ 
40 exp quality of life/ 
41 "Value of Life"/ 
Appendix 1
9442 cost of illness/ 
43 exp health status indicators/ 
44 cost$.ti.
45 (cost$ adj2 (effective$ or utilit$ or benefit$ or
minimis$)).ab
46 economics model$.tw. 
47 (economics$ or pharmacoeconomic$ or
pharmo-economic$).ti. 
48 (price$ or pricing$).tw. 
49 (financial or finance or finances or financed).tw.
50 (value adj2 (money or monetary)).tw. 
51 quality adjusted life.tw. 
52 disability adjusted life.tw. 
53 (qaly? or qald? or qale? or qtime? or daly?).tw. 
54 (euroqol or euro qol or eq5d or eq 5d).tw. 
55 (hql or hqol or h qol or hrqol or hr qol).tw. 
56 (hye or hyes).tw. 
57 (health adj3 (indicator? or status or utilit?)).tw. 
58 markov$.tw. 
59 monte carlo.tw. 
60 (decision$ adj2 (tree? or analy$ or model$)).tw. 
61 or/29-60 
62 28 and 61
63 Remove duplicates from 62
Science Citation Index (1985–2 March 2007)
Web of Knowledge URL: http://wok.mimas.ac.uk/ 
#1 TS=(hip SAME arthroplast*)
#2 TS=(hip SAME replace*)
#3 TS=(hip SAME prosthes*)
#4 TS=(hip SAME implant*)
#5 TS=(hip SAME (surgery or surgical))
#6 #1 or #2 or #3 or #4 or #5
#7 TS=(minimal* SAME (invasiv* or access* or
surg*))
#8 TS=((small or single or double or mini or
one or two) SAME incision*)
#9 TS=(robotic* or computer-aid*)
#10 #7 or #8 or #9
#11 #6 and #10
#12 TS=economic*
#13 TS=cost*
#14 TS=(price* OR pricing*)
#15 TS=(financial or finance*)
#16 TS=(decision* SAME (tree* OR analy* or
model*))
#17 TS=markov*
#18 TS=monte carlo
#19 TS=(health SAME (indicator* or status or
utilit*))
#20 TS=quality of life
#21 TS=quality adjusted life
#22 TS=disability adjusted life
#22 TS=(qaly* or qald* or qale* or qtime* or
daly*)
#23 TS=(euroqol* or euro qol* or eq5d or eq 5d)
#24 TS=(hql or hqol or h qol or hrqol or hr qol)
#25 TS=(hye or hyes)
#26 #12 or #13 or #14 or #15 or #16 or #17
or #18 or #19 or #20 or #21 or #22 or
#23 or #24 or #25
#17 #11 and #26
NHS EED (December 2006)
URL: http://www.york.ac.uk/inst/crd/nhsdhp.htm
#1 MeSH Arthroplasty, Replacement, Hip
EXPLODE 1 2
#2 MeSH Hip Prosthesis EXPLODE 1
#3 hip
#4 arthroplasty OR replac* OR prosthes* OR
implant*
#5 #3 And #4
#6 #1 OR #2 OR #5
Search strategy for additional search
for utilities, cost data and revision rates
for total hip arthroplasty
MEDLINE (1995–January Week 5 2007),
EMBASE (1995–2007 Week 5) (MEDLINE 
In-Process 8 February 2007)
Ovid multi-file search URL:
http://gateway.ovid.com/athens
1 Arthroplasty, Replacement, Hip/
2 Total Hip Prosthesis/ use emez 
3 Hip Prosthesis/ 
4 (hip adj3 (arthroplast$ or replace$ or
prosthes$ or implant$)).tw. 
5 or/1-4 
6 Hip Joint/su use mesz 
7 Hip/su use mesz 
8 Hip Surgery/ use emez 
9 (arthroplast$ or replace$ or prosthes$ or
implant$).tw. 
10 (6 or 7 or 8) and 9
11 5 or 10 
12 exp quality of life/
13 "Value of Life"/ 
14 cost of illness/ 
15 exp health status indicators/ 
16 quality adjusted life.tw.
17 disability adjusted life.tw. 
18 (qaly? or qald? or qale? or qtime? or 
daly?).tw. 
19 (euroqol or euro qol or eq5d or eq 5d).tw. 
20 (hql or hqol or h qol or hrqol or hr qol).tw. 
21 (hye or hyes).tw. (70)
22 (health adj3 (indicator? or status or 
utilit?)).tw. 
23 markov$.tw. 
24 monte carlo.tw. 
25 (decision$ adj2 (tree? or analy$ or 
model$)).tw. 
26 or/12-24
27 11 and 26
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29 limit 28 to yr="1995 - 2007" 
30 remove duplicates from 29
31 (case reports or letter).pt. 
32 30 not 31 
33 exp "costs and cost analysis"/ 
34 economics/ 
35 exp economics,hospital/ 
36 exp economics,medical/ 
37 economics,pharmaceutical/ 
38 exp budgets/ 
39 exp models, economic/ 
40 exp decision theory/ 
41 ec.fs. use mesz 
42 monte carlo method/ 
43 markov chains/ 
44 cost$.ti. 
45 (cost$ adj2 (effective$ or utilit$ or benefit$ or
minimis$)).ab. 
46 economics model$.tw. (16)
47 (economics$ or pharmacoeconomic$ or
pharmo-economic$).ti. 
48 (price$ or pricing$).tw. 
49 (financial or finance or finances or
financed).tw. 
50 (value adj2 (money or monetary)).tw.
51 or/33-50
52 11 and 51
53 united kingdom/ use emez 
54 exp great britain/ use mesz 
55 53 or 54
56 52 and 55
57 remove duplicates from 56
58 exp prosthesis failure/ 
59 prosthesis-related infection/ use mesz 
60 prosthesis infection/ use emez 
61 hip prosthesis/ae 
62 follow-up studies/ use mesz 
63 follow-up/ use emez 
64 10 year$.ti. 
65 ten year$.ti. 
66 (11 year$ or eleven year$).ti
67 (12 year$ or twelve year$).ti. 
68 (13 year$ or thirteen year$).ti. 
69 (14 year$ or fourteen year$).ti. 
70 (15 year$ or fifteen year$).ti. 
71 (20 year$ or twenty year$).ti. 
72 cohort studies/ 
73 or/58-63,72
74 11 and 73
75 ((failed or failure) adj3 (prosthes$ or
arthroplast$ or operat$)).tw. 
76 ((re operat$ or reoperat$ or revision) adj
rate$).tw. 
77 (follow up or long term or longterm).ti. 
78 or/64-71,75-77
79 74 and 78
80 79 not 31
81 limit 80 to english language 
82 limit 181to yr="1995 - 2007" 
83 remove duplicates from 82
84 32 or 57 or 83
General searches
Search strategies used to identify
reports of clinical or cost effectiveness
of minimally invasive hip arthroplasty 
HMIC (1979–January 2007)
URL: http://gateway.ovid.com/
1 joint replacement surgery/ 
2 arthroplasty/ 
3 hip.tw,hw. 
4 (1 or 2) and 3 
5 (hip adj3 (arthroplast$ or replac$ or
prosthes$)).tw. 
6 4 or 5 
7 hip joint replacement/ 
8 6 or 7 
9 minimally invasive therapy/ 
10 (minimal$ adj3 (invasiv$ or access$ or
surg$)).tw. 
11 ((small or single or double or mini or one or
two) adj3 incision$).tw. 
12 or/9-11 
13 8 and 12
DARE and HTA Databases (December 2006)
NHS Centre for Reviews and Dissemination 
URL: http://nhscrd.york.ac.uk/welcome.htm
#1 MeSH Arthroplasty, Replacement, Hip
EXPLODE 1 2
#2 MeSH Hip Prosthesis EXPLODE 1
#3 hip
#4 arthroplasty OR replac* OR prosthes* OR
implant*
#5 #3 And #4
#6 #1 OR #2 OR #5
National Registries consulted
AOA National Joint Replacement Registry
(Australian). URL:
http://www.dmac.adelaide.edu.au/aoanjrr/index.j
sp
Canadian Joint Replacement Registry. URL:
http://secure.cihi.ca/cihiweb/dispPage.jsp?cw_pag
e=services_cjrr_about_e
Danish Hip Arthroplasty Registry. URL:
http://www.dhr.dk/ENGLISH.htm
European Arthroplasty Register. URL:
http://www.ear.efort.org/
Finnish Arthroplasty Registry. URL:
http://www.nam.fi/english/publications/
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96Norwegian Arthroplasty Register. URL:
http://www.haukeland.no/nrl/
Romanian Arthroplasty Register. URL:
http://www.rne.ro/site/
Scottish Arthroplasty Project. URL:
http://www.arthro.scot.nhs.uk/
Swedish National Hip Arthroplasty Regstry. 
URL: http://www.jru.orthop.gu.se/
New Zealand National Joint Registry. 
URL: http://www.cdhb.govt.nz/NJR/
UK National Joint Registry. URL:
http://www.njrcentre.org.uk/
Conference Proceedings Abstracts:
Amercian Academy of Orthopaedic Surgeons
(AAOS)
2003 Annual Meeting, San Fransisco, CA, 
March 2003.
2004 Annual Meeting, New Orleans, LA, 
March 2004.
2005 Annual Meeting, Washington, DC, 
February 2006.
2006 Annual Meeting, Chicago, IL, March 2006.
American Association of Hip and Knee Surgeons
(AAHKS)
15th Annual Meeting, Dallas,TX, November 2005.
16th Annual Meeting, Dallas,TX, November 2006.
American Orthopaedic Assocation (AOA)
117th Annual Meeting, Boston, MA, June 2004.
118th Annual Meeting, Huntington Beach, CA,
June 2005.
119th Annual Meeting, San Antonio, TX, June
2006.
Association of Bone and Joint Surgery (ABJS): 
57th Annual Meeting, Carmel, CA, June 2005
58th Annual Meeting, Buenos Aires, April 2006
British Hip Society
Annual Meeting, Belfast, February 2003.
Annual Meeting, Sheffield, March 2004.
Annual Meeting, Wrightington Hospital, 
March 2005.
Annual Meeting, Edinburgh, March 2006.
British Orthopaedic Association (BOA)
Annual Congress, Manchester, September 2004.
Annual Congress, Birmingham, September 2005.
Annual Congress, Glasgow, September 2006.
Hip Society and AAHKS
9th Annual Combined Open Meeting, 
New Orleans, LA, February 2003.
10th Annual Combined Open Meeting 2004 
San Fransisco, CA, March 2004.
11th Annual Combined Open Meeting 2005
Washington, DC, February 2005.
12th Annual Combined Open Meeting 2006
Chicago, IL, March 2006. 
International Society for Technology in
Arthoplasty (ISTA)
18th Annual Symposium, Kyoto, October 2005.
19th Annual Symposium,Washington,DC, October
2006.
Mid-American Orthopaedic Association
22nd Annual Meeting, La Quinta April 2004.
23rd Annual Meeting, Amelia Island, FL, April
2005.
24th Annual Meeting, San Antonio, TX, April
2006.
Journals (full-text search)
Journal of Arthroplasty (2000–February 2007)
Science Direct. URL: www.sciencedirect.com/
Journal of Bone and Joint Surgery, American
Volume (2000–March 2007)
URL: http://www.ejbjs.org/
Journal of Bone and Joint Surgery, British Volume
(2000–February 2007)
URL: www.jbjs.org.uk/
Clinical Orthopaedics and Related Research
(2000–February 2007) 
Ovid Journals. URL:
http://gateway.ovid.com/athens
Hip* and (minimal* or MIS or incision*)
Websites searched for other evidence-based
reports and background information
American Academy of Orthopaedic Surgeons.
URL: http://www.aaos.org/
American Association of Hip and Knee Surgeons.
URL: http://www.aahks.org/
British Hip Society. URL:
http://www.britishhipsociety.com/
British Orthopaedic Association. URL:
http://www.boa.ac.uk/
Depuy International (Johnson & Johnson). URL:
http://jnjgateway.com/
Smith and Nephew. URL:
http://www.smithnephew.com/
Styker. URL: http://www.stryker.com/
Zimmer. URL: http://www.zimmer.co.uk/ 
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for the treatment of arthritic disease of the hip
Assessor initials: __________ Date assessed: __________
Study identifier 
(surname of first author + year of publication)
Type of study
Q1. Is the study (circle one number) Yes Unclear No
1. a randomised controlled trial, or 
2. a comparative study (at least 2 groups) or 
3. a case series/cohort study?
4. other Go to
Design: FU: next question Exclude
Participants in the study Yes Unclear No
Q2. Are some or all of the participants in the study adults with 
arthritis (excluding osteoporosis, fracture or tumour)?
Go to
next question Exclude
Interventions in the study Yes Unclear No
Q3. Did some or all of the participants receive minimally 
invasive primary total hip replacement (and not revision 
surgery or hip resurfacing or computer modelling surgery)?
Go to
next question Exclude
Outcomes in the study Yes Unclear No
Q4. Does the study report short-term and/or long-term 
outcome data on the patients that underwent the 
intervention(s)?
For case series/cohort studies only rare complications and long-term  Include Exclude
outcomes are to be collected.
Final decision (subject to clarification of ‘unclear’ points) Include Unclear Exclude
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Appendix 2
Study eligibility formMinimally invasive hip arthroplasty versus conventional hip arthroplasty
for the treatment of arthritic disease of the hip
Reviewer ID: Date: __________________
Study
Study ID: Country: RCT 
Quasi-RCT 
Funding: government/private/manufacturer/other (specify) Cohort study (Comparative) 
Additional information on study design (e.g. prospective/ Cohort study (one-group) 
retrospective, method of randomisation): Unclear 
Participants
Recruitment dates: ___________________________
Number of eligible patients: __________________Number of patients randomised: _____________
Criteria for Inclusion:
Criteria for Exclusion: 
Intervention
Surgical technique No of Patients
Intervention 1
Intervention 2
Intervention 3
Comments: (i.e. operator information, specialised equipment used, length of incision)
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Appendix 3
Data extraction formPatient Characteristics
Specify Intervention 1 Intervention 2 Intervention 3 Overall
Age (years)
Sex (M/F)
Body weight (kg)
Height
BMI
Muscular patient* (%)
Significant bone deformity* (%)
Severe osteoporosis* (%)
Emergency case (%)
Follow-up period: __________________________ Number of patients lost to follow-up: _______________
Comments:
* Note details on how assessed
Indications for total hip replacement 
Specify Intervention 1 Intervention 2 Intervention 3 Overall
Total (No.)
Arthritis
• Degenerative arthritis 
(osteoarthritis)
• Rheumatoid arthritis
Deformity
Appendix 3
102Operative approach 
Specify Intervention 1 Intervention 2 Intervention 3 Overall
Total (No.)
Operative method performed?
• Anterolateral
• Lateral
• Posterolateral
• Transtrochanteric
Type and name of 
prosthesis used?
Cemented or uncemented 
procedure?
Short-term Outcomes 
Intra-operative Intervention 1 Intervention 2 Intervention 3
Duration of operation (min)
Operating theatre throughput
Blood loss
Opposite method initiated (pre-operative) 
Intra-operative fracture
Conversion (intra-operative)
Post-operative
Dislocation
Infection (specify, e.g. wound)
Nerve injury
Vascular injury
Deep vein thrombosis
Peri-prosthetic fracture
30 day mortality
Length of hospital stay
Health Technology Assessment 2008; Vol. 12: No. 26
103
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.Post-operative pain (specify)
Time to return to usual activities (days)
Implant position (radiographic analysis)
Other
Long-term Outcomes Intervention 1 Intervention 2 Intervention 3
Functional result (Harris hip, Mayo and 
Charnley scores)
Pain relief
Revision rates
Time to revision (months)
Health related quality of life
Long term pain
Limb length inequality
Mortality
Surrogates for long-term outcomes
• Implant migration (radiostereometry anal)
• Heterotopic ossification
• Component orientation
• Cement quality
Other (e.g. patient perception/satisfaction)
Additional information/Other comments
Contact with Author
Date: ………/………/……… Signature: ……………………………………
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(Verhagen et al., 1998)26
Reviewer ID: Date:
Question Yes No Unclear
1. Was a method of randomisation performed? 
Adequate approaches to sequence generation
• Computer-generated random tables
• Random number tables
Inadequate approaches to sequence generation
• Use of alternation, case record numbers, birth dates or week days
2. Was the treatment allocation concealed?
Adequate approaches to concealment of randomisation
• Centralised or pharmacy-controlled randomisation
• Serially numbered identical containers
• On-site computer based system with a randomisation sequence 
that is not readable until allocation
• Other approaches with robust methods to prevent foreknowledge 
of the allocation sequence to clinicians and patients
Inadequate approaches to concealment of randomisation
• Use of alternation, case record numbers, birth dates or week days
• Open random number lists
• Serially numbered envelopes
3. Were the groups similar at baseline regarding the most important 
prognostic indicators?
4. Were the eligibility criteria specified?
5. Was the outcome assessor blinded?
6. Was the care provider blinded?
7. Was the patient blinded?
8. Were point estimates and measures of variability presented for 
the primary outcome measures?
9. Did the analysis include an intention-to-treat analysis?
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Appendix 4
Quality assessment form – RCTsIncluded studies (full-text papers)
Archibeck, 2004
Archibeck MJ, White RE Jr. Learning curve for the 
two-incision total hip replacement. Clin Orthop 2004;
429:232–8.
Asayama, 2006
Asayama I, Kinsey TL, Mahoney OM. Two-year
experience using a limited-incision direct lateral
approach in total hip arthroplasty. J Arthroplasty 2006;
21:1083–91.
Berger, 2004
Berger RA. Mini-incision total hip replacement using an
anterolateral approach: technique and results. Orthop
Clin North Am 2004;35:143–51.
Chen, 2006
Chen J, Chen W, Zhou J, Huang H. Clinical research
and following results on the minimal incision and
traditional total hip arthroplasty. Fudan Xuebao
(Yixueban) 2006;33:257–82.
Chimento, 2005
Primary reference
Chimento GF, Pavone V, Sharrock N, Kahn B, Cahill J,
Sculco TP. Minimally invasive total hip arthroplasty: 
a prospective randomized study. J Arthroplasty 2005;
20:139–44.
Secondary reference
Sculco TP, Jordan LC, Walter WL. Minimally invasive
total hip arthroplasty: the Hospital for Special Surgery
experience. Orthop Clin North Am 2004;35:137–42.
Chung, 2004
Chung WK, Liu D, Foo LS. Mini-incision total hip
replacement – surgical technique and early results.
J Orthop Surg 2004;12:19–24.
Ciminiello, 2006
Primary reference
Ciminiello M, Parvizi J, Sharkey PF, Eslampour A,
Rothman RH. Total hip arthroplasty: is small incision
better? J Arthroplasty 2006;21:484–8.
Secondary reference
Rothman RH, Ciminiello M, Parvizi J. Total hip
arthroplasty: does incision length matter. Annual
Meeting of the American Academy of Orthopaedic
Surgeons, Washington, DC, March 2005. Paper No. 137.
De Beer, 2004
de Beer J, Petruccelli D, Zalzal P, Winemaker MJ.
Single-incision, minimally invasive total hip
arthroplasty: length doesn't matter. J Arthroplasty 2004;
19:945–50.
DiGioia, 2003
Primary reference
DiGioia AM III, Plakseychuk AY, Levison TJ, 
Jaramaz B. Mini-incision technique for total hip
arthroplasty with navigation. J Arthroplasty 2003;
18:123–8.
Secondary references
DiGioia AM III. Mini incision supported by navigation.
Annual Meeting of the American Academy of
Orthopaedic Surgeons, San Francisco, March 2003.
Symposia (ORS1).
Hafez MA, Seel MJ, Jaramaz B, DiGioia AM III.
Navigation in minimally invasive total knee arthroplasty
and total hip arthroscopy. Oper Tech Orthop 2006;
16:207–10.
Dorr, 2007
Primary reference
Dorr L, Thomas D, Long W, Polatin P, Sirianni L.
Psychologic reasons for patients preferring minimally
invasive total hip arthroplasty. Clin Orthop 2007;
458:94–100.
Secondary reference
Inaba Y, Dorr LD, Wan Z, Sirianni L, Boutary M.
Operative and patient care techniques for posterior
mini-incision total hip arthroplasty. Clin Orthop 2005;
441:104–14.
Duwelius, 2007
Primary reference
Duwelius PJ, Burkhart RL, Hayhurst JO, Moller H,
Butler JB. Comparison of the 2-incision and mini-
incision posterior total hip arthroplasty technique.
J Arthroplasty 2007;22:48–56.
Secondary reference
Duwelius PJ. Two-incision minimally invasive total hip
arthroplasty: techniques and results to date. Instr Course
Lect 2006;55:215–22.
Duwelius, 2003
Primary reference
Duwelius PJ, Berger RA, Hartzband MA, Mears DC.
Two-incision minimally invasive total hip arthroplasty:
operative technique and early results from four centers.
J Bone Joint Surg Am 2003;85A:2240–2.
Secondary references
Berger RA, Duwelius PJ. The two-incision minimally
invasive total hip arthroplasty: technique and results.
Orthop Clin North Am 2004;3:163–72.
Berger RA. Total hip arthroplasty using the minimally
invasive two-incision approach. Clin Orthop 2003;
417:232–41.
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Appendix 5
List of included studiesDuwelius PJ, Berger RA. The two-incision minimally
invasive total hip arthroplasty: technique and results.
Semin Arthroplasty 2004;15:99–107.
Duwelius PJ. Two-incision minimally invasive total hip
arthroplasty: techniques and results to date. Instr Course
Lect 2006;55:215–22.
Flören, 2006
Flören M, Lester DK. Durability of implant fixation
after less-invasive total hip arthroplasty. J Arthroplasty
2006;21:783–90.
Hart, 2005
Primary reference
Hart R, Stipcak V, Janecek M, Visna P. Component
position following total hip arthroplasty through a
miniinvasive posterolateral approach. Acta Orthop Belg
2005;71:60–4.
Secondary reference
Hart R, Stipcak V, Janecek M, Visna P. Radiological
study of THA after mini-incision technique. Hip Int
2005;15:98–101.
Hartzband, 2006
Hartzband MA. Posterolateral mini-incision total hip
arthroplasty. Oper Tech Orthop 2006;16:93–101.
Howell, 2004
Howell JR, Masri BA, Duncan CP. Minimally invasive
versus standard incision anterolateral hip replacement:
a comparative study. Orthop Clin North Am 2004;
35:153–62.
Kim, 2006
Kim Y-H. Comparison of primary total hip
arthroplasties performed with a minimally invasive
technique or a standard technique. J Arthroplasty
2006;21:1092–8.
Li, 2005
Li Z, Shi Z, Guo W, Zhang N, Sun W. Preliminary
experiences in minimally invasive and mini-incision
surgery total hip arthroplasty for late osteonecrosis of
the femoral head. Chung Kuo Hsiu Fu Chung Chien Wai
Ko Tsa Chih 2005;19:710–13 (in Chinese).
O’Brien, 2005
O’Brien DA, Rorabeck CH. The mini-incision direct
lateral approach in primary total hip arthroplasty. 
Clin Orthop 2005;441:99–103.
Ogonda, 2005
Primary reference
Ogonda L, Wilson R, Archbold P, Lawlor M, 
Humphreys P, O’Brien S, et al. A minimal-incision
technique in total hip arthroplasty does not improve
early postoperative outcomes. A prospective, randomized,
controlled trial. J Bone Joint Surg Am 2005;87:701–10.
Secondary references
Lawlor M, Humphreys P, Morrow E, Ogonda L,
Bennett D, Elliott D, et al. Comparison of early
postoperative functional levels following total hip
replacement using minimally invasive versus standard
incisions. A prospective randomized blinded trial. 
Clin Rehabil 2005;19:465–74.
Bennett D, Ogonda L, Elliott D, Humphreys L,
Beverland DE. Comparison of gait kinematics in
patients receiving minimally invasive and traditional hip
replacement surgery: a prospective blinded study. Gait
Posture 2006;23:374–82.
Pagnano, 2006
Pagnano MW, Trousdale RT, Meneghini RM, 
Hanssen AD. Patients preferred a mini-posterior THA
to a contralateral two-incision THA. Clin Orthop 2006;
453:156–9.
Pilot, 2006
Pilot P, Kerens B, Draijer WF, Kort NP, ten Kate J,
Buurman WA, et al. Is minimally invasive surgery less
invasive in total hip replacement? A pilot study. Injury
2006;37:S17–23.
Pipino, 2004
Pipino F. CFP prosthetic stem in mini-invasive total hip
arthroplasty. J Orthop Traumatol 2004;5:165–71.
Siguier, 2004
Siguier T, Siguier M, Brumpt B. Mini-incision anterior
approach does not increase dislocation rate: a study of
1037 total hip replacements. Clin Orthop 2004;
426:164–73.
Swanson, 2005
Swanson TV. Early results of 1000 consecutive, posterior,
single-incision minimally invasive surgery total hip
arthroplasties. J Arthroplasty 2005:20:26–32.
Szendrói, 2006
Szendrói M, Sztrinkai G, Vass R, Kiss J. The impact of
minimally invasive total hip arthroplasty on the
standard procedure. Int Orthop 2006;30:167–71.
Tanavalee, 2006
Tanavalee A, Jaruwannapong S, Yuktanandana P,
Itiravivong P. Early outcomes following minimally
invasive total hip arthroplasty using a two-incision
approach versus a mini-posterior approach. Hip Int
2006;16:S17–22.
Teet, 2006
Teet JS, Skinner HB, Khoury L. The effect of the 
“mini” incision in total hip arthroplasty on component
position. J Arthroplasty 2006;21:503–7.
Woolson, 2004
Primary reference
Woolson ST, Mow CS, Syquia JF, Lannin JV,
Schurman DJ. Comparison of primary total hip
replacements performed with a standard incision 
or a mini-incision. J Bone Joint Surg Am 2004;86A:
1353–8.
Secondary reference
Mow CS, Woolson ST, Ngarmukos SG, Park EH, 
Lorenz HP. Comparison of scars from total hip
replacements done with a standard or a mini-incision.
Clin Orthop 2005;441:80–5.
Wright, 2004
Wright JM, Crockett HC, Delgado S, Lyman S, 
Madsen M, Sculco TP. Mini-incision for total hip
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108arthroplasty: a prospective, controlled investigation with
5-year follow-up evaluation. J Arthroplasty 2004;
19:538–45.
Yan, 2005
Yan Z-Q, Chen Y-S, Yang Y, Li W-J, Chen Z-R, 
Zhang G-J. Two-incision minimal invasive approach for
total hip replacement. Acta Acad Med Shanghai 2005;
32:557–60 (in Chinese).
Zhang, 2006
Zhang XL, Wang Q, Jiang Y, Zeng BF. Minimally
invasive total hip arthroplasty with anterior incision.
Chung Hua Wai Ko Tsa Chih 2006;44:512–15 
(in Chinese). 
Included studies (abstracts only)
Charles, 2006
Charles MN, Fejbel RJ, Kim P. Minimally invasive
surgery of the hip – a randomized pilot study. Annual
Meeting of the Canadian Orthopaedic Association,
Toronto, June 2006. Poster 88.
Greidanus, 2006
Greidanus NV, Garbuz DS, Masri BA, Duncan CP,
Callaghan JJ, Hozack WJ. Comparative cohort study of
2-incision versus 1-incision MIS THA. Annual Meeting
of the American Academy of Orthopaedic Surgeons,
Chicago, March 2006. Paper No. 200.
Pagnano, 2007a
Pagnano MW, Meneghini RM, Kaufman K, Colemam-
Wood K, Berg E, Hanssen AD. No benefit of the 
2-incision technique over miniposterior total hip
arthroplasty: a comprehensive gait analysis and strength
testing study. J Arthroplasty 2007;22:301.
Pagnano, 2007b
Pagnano MW, Leone J, Hanssen AD, Trousdale RTM,
Berg E. A prospective randomized clinical trial shows
that 2-incision total hips do not recover quicker than
miniposterior total hips. J Arthroplasty 2007;22:303.
Panisello, 2006
Panisello JJ, Canales V, Herrera A, Mateo J, Peguero A.
Effectiveness of mini-incision technique in primary hip
replacement. J Bone Joint Surg Br 2006;88B:63.
Rachbauer, 2006
Rachbauer F, Rosiek R, Nogler M, Kessler O. 
The benefits of the direct anterior approach in
minimally invasive THA. Annual Meeting of the
American Academy of Orthopaedic Surgeons, Chicago,
March 2006. Paper No. 202.
Sharma, 2006
Sharma S, Bharma MS. A prospective randomised pilot
study to compare early post-operative recovery after
conventional versus minimal incision posterior
approach for total hip joint replacement. J Bone Joint
Surg Br 2006;88B:243.
Takahira, 2006
Takahira N, Uchiyama K, Takasi S, Katano M, 
Itoman M. Prospective comparison study of clinical data
between the minimal incision and conventional incision
in total hip arthroplasty. 19th Annual Symposium of the
International Society for Technology in Arthroplasty,
New York, October 2006. Abstract A9-3.
Yoon, 2005
Yoon TR, Moon E, Rowe SM, Jung ST, Seo HY, Lee JY.
Minimally invasive total hip arthroplasty: comparison
between one-incision and two-incision technique.
Annual Meeting of the American Academy of
Orthopaedic Surgeons, Washington, DC, March 2005.
Paper No. 147.
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Appendix 6
List of ongoing trials
Title of trial Contact Project details
Minimally invasive surgery
of the hip: a randomised
study
Dr Paul Kim
Division of Orthopedics
501 Smyth Road 
Ottawa
Ontario K1H 8L6, Canada
Email: pkim@Ottawahospital.on.ca
A pilot trial compares minimally invasive THR via a
modified lateral approach with a standard lateral
(Hardinge) approach with 12-week follow-up. Variables
measured included in-hospital length of stay, incidence of
surgical complications and validated pain and function
scores
Intended number of participants: 40
Poster presented at the Canadian Orthopaedic
Association meeting, June 2006, Ontario:
Charles MN, Feibel RJ and Kim P , Minimally invasive
surgery of the hip – a randomised pilot study
Clinical evaluation
comparing minimally
invasive and standard skin
incisions in cementless total
hip arthroplasty using the
Bimetric Hip System with
the 38 mm M2A cup.
Clinical evaluation of
incision size in total hip
replacement
Mr James Calder
North Hampshire Hospital NHS
Trust
Aldermaston Road
Basingstoke
Hants RG24 9NA, UK
Email: james.calder@imperial.ac.uk
The trial has now ended recruiting and is evaluating
general health scores, hip scores, patient satisfaction,
blood loss, length of stay, time to discharge and
postoperative X-rays. Follow-up is still ongoing
Minimally invasive surgery
in total hip arthroplasty: the
2-incision technique versus
conventional total hip
arthroplasty. A prospective,
randomised, controlled trial
Dr Dr Jakob van Oldenrijk
Academic Medical Center (AMC)
Department of Orthopedics
P .O. Box 22660
Meibergdreef 9
1100 DD Amsterdam
The Netherlands
Email: J.vanoldenrijk@amc.uva.nl
The trial is in progress, without any substantial evidence
to publish yet. Switched from a two-incision technique to
the anterolateral (Rottinger) MIS in March 2006 and
conducting a prospective non-blinded RCT comparing
this technique with the lateral transgluteal technique
The patient recruitment period was planned from March
2006 to March 2008, with 1-year follow-up. Planned
outcome measures include operation time, blood loss,
fractures, dislocation, perioperative complications, length
of hospital stay, short- and long-term pain, radiographic
evaluation, function scores (e.g. Harris hip score,
WOMAC), revision rates, health-related quality of life
(e.g. SF-36) and patient satisfaction
Intended number of participants: 100
continuedAppendix 6
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Title of trial Contact Project details
Effectiveness of computer-
navigated minimally invasive
total hip surgery compared
with conventional total hip
arthroplasty: design of a
randomised controlled trial
Inge Reininga
University Medical Centre
Groningen 
Department of Orthopaedic
Surgery
P .O. Box 30001
9700 RB Groningen
The Netherlands
Email: i.reininga@orth.umcg.nl
The trial compares computer-navigated minimally
invasive THR (the Smith–Petersen anterior approach)
with a conventional technique (the posterolateral
approach). Patient recruitment was planned from March
2007 to May 2008. The main focus is cost-effectiveness
analysis besides the clinical follow-up for 6 months.
Planned outcome measures include perioperative
complications, gait analysis, implant position
(radiographic analysis) and self-reported functional status
and health-related quality of life
Intended number of participants: 110
The trial protocol was recently published:
Reininga IHF, Wagenmakers R, van den Akker-Scheek J,
Stant AD, Groothoff JW, Bulstra SK, et al., Effectiveness
of computer-navigated minimally invasive total hip
surgery compared to conventional total hip arthroplasty:
design of a randomised controlled trial’ (protocol), BMC
Musculoskeletal Disorders 2007;8:4(11 January 2007)
A randomized controlled
trial utilising RSA for a
comparison of minimally
invasive surgery (MIS) vs
standard exposure in
primary total hip
arthroplasty with the
ProfemurZ modular
femoral stem
Dr Michael Gross
QEII Health Sciences Centre
Halifax
Nova Scotia B3H 3A7
Canada
Tel. 902-473-6811
Email: mgross@eastlink.ca
The trial compares minimally invasive and standard THR
using the direct lateral approach. It is recruiting patients
and will have preliminary clinical results in 1 year from
January 2007. Hip function will be assessed using Harris
hip score, Oxford-12 and WOMAC. The primary
outcome will be implant micromotion (RSA analysis).
The RSA part of the study has a 2-year follow-up 
Intended number of participants: 100
Protocol: Dr Michael Gross (Principal Investigator), 
A randomised controlled trial utilising RSA for a
comparison of Minimally Invasive Surgery (MIS) vs
standard exposure in primary total hip arthroplasty with
the ProfemurZ modular femoral stem
Randomised, prospective,
post-market surveillance
study comparing the
outcomes of minimally
invasive and conventional
surgical procedures in
subjects requiring primary
total hip arthroplasty
(THA) for osteoarthritis
Dr S Young
South Warwickshire General
Hospitals NHS Trust
Lakin Road
Warwich CV34 5BW, UK
Email: skyoung@uk-
consultants.co.uk
The project is in its very early stages and there are no
results available; being coordinated at DePuy
Comparison of two
minimally invasive hip
arthroplasties in a
randomised trial
Associate Professor Per Rotbøll
Nielsen 
H:S Tværfaglige Smertecenter
Neurocentret
H:S Rigshospitalet
Blegdamsvej 9
DK-2100 København Ø 
Denmark
Email: rotboell@rh.dk
The trial has just started and will be collecting data for
next 15 months. The research team has a contract that
forbids them from providing further information
continuedHealth Technology Assessment 2008; Vol. 12: No. 26
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Title of trial Contact Project details
Single versus dual incision
minimally invasive hip
arthroplasty
Professor Bo Nibvrant
Perth Orthpaedic Institute
Gate 3, Verdun Street
Nedlands
Perth 6009, Australia
Email: bo.nivbrant@uwa.edu.au
The trial data are still in process; no further information
available
Minimally invasive total hip
replacement (prospective
randomised, multi-centre
study of synergy total hip
system comparing the
effectiveness and safety of
minimally invasive THR
arthroplasty vs standard
surgery)
Mr Simon Scott
Aintree Trust
University Hospital Aintree
Lower Lane
Liverpool L9 7AL, UK
Email: wicksyontour@hotmail.com
The trial has had the funding withdrawn by the company
Is minimally invasive total
hip replacement clinically
advantageous, safe and cost
effective compared to
conventional total hip
arthroplasty?
Dr David Beard
Nuffield Department of
Orthopaedic Surgery (NDOS)
University of Oxford
Windmill Road
Oxford OX3 7LD, UK
Email: david.beard@orthopaedic-
surgery.oxford.ac.uk
The trial was suspended before it became live (in the
pilot stage) because the two incision method proposed
for one arm of the trial was found to have an obvious
and unacceptable complication rate (four out of 10
patients); it is no longer performed in the hospital;
funding was returned
Does a small incision at the
time of total hip
replacement surgery confer
any advantage to patients
by comparison to a
standard incision?
Mr John Timperley
Exeter Hip Unit
Princess Elizabeth Orthopaedic
Hospital
RA & E
Barrack Road
Exeter EX2 5DW, UK
Email: john.timperley@virgin.net
The trial was abandoned at an early stage, as the
research team felt there were sufficient data available in
the world literature that proves that the size of incision
is not the important factor in determining outcome or
cost-effectiveness
A prospective randomised
control trial comparing two
different surgical
approaches for minimally
invasive total hip
replacement
Mr H Apthorp
Conquest Hospital
The Ridge
St Leonard’s on Sea
East Sussex TN37 7RD, UK
The trial has been put on hold, as the research team are
worried that they are getting significantly better results
with their posterior approaches compared with anterior
approaches
Image guidance for
minimally invasive hip
replacement
Professor Dave Hawkes
Radiological Sciences
5th Floor, Thomas Guy House
Guy’s Hospital
St Thomas’ Hospital
London SE1 9RT, UK
Email: david.hawkes@kcl.ac.uk
No available data at the time of writing
Comparison of the clinical
effectiveness and cost-
effectiveness of the MIS
anterolateral approach 
(MIS Watson Jones, G3)
versus anterolateral mini or
posterolateral mini
approaches in primary total
hip arthroplasty
James Latteier
Vancouver General Hospital
Vancouver
British Colombia V5Z 1L8
Canada
Email: jlatteier@arthritisresearch.ca
No available data at the time of writingHealth Technology Assessment 2008; Vol. 12: No. 26
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Appendix 7
Detailed quality assessment score for the 
included trials and comparative studies (see Table 6)
Study Q1a Q1b Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9
One incision
RCT and quasi-RCT
Charles, 200669a YUUY NYYYNN
Chimento, 200531 YYN Y YYUUYY
Chung, 200432 YNN U YYNNYY
Hart, 200540 YNN U YYNUNY
Kim, 200643 YNNY NY YYNU
Ogonda, 200546 YYN Y YYYYYU
Rachbauer, 200675a YUUY YUUUNU
Sharma, 200677a YUU NNYYYUU
Zhang, 200658 YYYY YYYUYY
Comparative studies
Asayama, 200628 NNNN YY YYNY
Berger, 200429 NNNU NUUUNU
Chen, 200630 NNNU YNUUYU
Ciminiello, 200633 NNNY YNNNNU
de Beer, 200434 NNNY YNNNY Y
DiGioia, 200335 NNNY YY NNNY
Dorr, 200736 NNNY NUNNY Y
Howell, 200442 NNNN YNNNYU
Li, 200544 NNNY YY UNY Y
O’Brien, 200545 NNNN YUUNY Y
Panisello, 200674a NNNY NUUUNU
Pilot, 200648 NNNN NNNNNY
Szendrói, 200652 NNNN YY NYY Y
Takahira, 200678a NNNU NUUUNU
Teet, 200654 NNNU YY UUYU
Woolson, 200455 NNNN YY UNY Y
Wright, 200456 NNNN YUUNYU
Two incisions
RCT and quasi-RCT
Pagnano, 2007a72a YYU YN UUU NU
Pagnano, 2007b73a YYU YN UUU NU
Yan, 200557 YUUY YUUUYU
Comparative studies
Duwelius, 200738 NNNY YNNNNU
Greidanus, 200671a NNNY NUUUNU
Pagnano, 200647 NNNY YUNNNY
Tanavalee, 200653 NNNN YY UNYU
Yoon, 200579a NNNU NUUUNU
N, no; U, unclear; Y, yes.
a Abstract only.In the following tables:
• continuous data: total N, mean (SD), [range]
• dichotomous data: n/N
• abbreviations: FU, follow-up; MD, midi-incision; MI, mini-incision; 2MI, 2 mini-incision; NR, not
reported; NS, not statistically significant; SI, standard incision.
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c
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n
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c
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d
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Appendix 10
Results of meta-analyses
Comparison 01: Single mini-incision versus single standard incision
(reported means and SDs)
1/27 0/29
0/60 0/60
0/110 0/109
   197     198
2/50 0/52
1/60 0/60
0/18 1/18
0/38 0/43
0/38 0/21
0/37 0/39
7.96 (0.16 to 402.02)
      Not estimable
      Not estimable
7.96 (0.16 to 402.02)
7.85 (0.48 to 127.30)
7.39 (0.15 to 372.38)
0.14 (0.00 to 6.82)
      Not estimable
      Not estimable
      Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  01 Revision rate (number having revision surgery)
01 RCT
 Chimento  2005  (RCT)
 Hart  2005  (Q-RCT)
 Ogonda  2005  (RCT)
Subtotal (95% CI)
Total events: 1 (Mini-incision), 0 (Standard incision)
Test for heterogeneity: not application
Test for overall effect: z = 1.04 (p = 0.30)
02 Comparative studies
 Asayama  2006
 Ciminiello  2006
 Li  2005
 Szendrói  2006  MI/MD
 Szendrói  2006  MI/SI
 Wright  2004
Total events: 3 (Mini-incision), 1 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
100.00
100.00
49.74
25.13
25.13
0.001 0.01 0.1 1 10 100 1000
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2/28 0/32
0/60 0/60
1/60 1/60
1/70 1/70
1/109 1/110
0/20 0/20
   347     352
0/52 1/50
0/99 0/100
0/51 0/95
0/60 0/60
0/33 0/33
0/34 0/53
0/38 0/43
0/38 0/21
1/73 4/54
0/50 1/85
0/42 1/42
8.84 (0.54 to 145.71)
     Not estimable
1.00 (0.06 to 16.18)
1.00 (0.06 to 16.15)
1.01 (0.06 to 16.24)
     Not estimable
1.72 (0.43, 6.92)
0.13 (0.00 to 6.56)
     Not estimable
     Not estimable
     Not estimable
     Not estimable
     Not estimable
     Not estimable
     Not estimable
0.21 (0.03 to 1.24)
0.20 (0.00 to 11.83)
0.14 (0.00 to 6.82)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  02 Postoperative dislocation rates
01 RCT
 Chimento  2005  (RCT)
 Chung  2004  (Q-RCT)
 Hart  2005  (Q-RCT)
 Kim  2006  (Q-RCT)
 Ogonda  2005  (RCT)
 Shama  2006  (Q-RCT)
Subtotal (95% CI)
Total events: 5 (Mini-incision), 3 (Standard incision)
Test for heterogeneity: 2 = 1.75, df = 3 (p = 0.63), I2 = 0%
Test for overall effect: z = 0.76 (p = 0.45)
02 Comparative studies
 Asayama  2006
 Berger  2004
 Chen  2006
 Ciminiello  2006
 DiGioia  2003
 O’Brien  2005
 Szendrói  2006  MI/MD
 Szendrói  2006  MI/SI
 Teet  2006
 Woolson  2004
 Wright  2004
Total events: 1 (Mini-incision), 7 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
24.72
25.05
25.08
25.15
100.00
13.04
61.74
12.17
13.05
0.01 0.1 1 10 100
Mini-incision Standard incision
  0/60    0/60
  6/70    5/70
16/105 19/109
     235       239
  0/52    0/50
  0/60    0/60
  4/38    2/43
  4/38    3/21
15/50 13/85
  0/42    0/42
     Not estimable
1.22 (0.36 to 4.15)
0.85 (0.41 to 1.76)
0.93 (0.50 to 1.74)
     Not estimable
     Not estimable
2.33 (0.44 to 12.21)
0.70 (0.14 to 3.60)
2.43 (1.03 to 5.73)
     Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  03 Implant position (cup, number poorly placed)
01 RCT
 Chung  2004  (Q-RCT)
 Kim  2006  (Q-RCT)
 Ogonda  2005  (RCT)
Subtotal (95% CI)
Total events: 22 (Mini-incision), 24 (Standard incision)
Test for heterogeneity: 2 = 0.24, df = 1 (p = 0.62), I2 = 0%
Test for overall effect: z = 0.21 (p = 0.83)
02 Comparative studies
 Asayama  2006
 Ciminiello  2006
 Szendrói  2006  MI/MD
 Szendrói  2006  MI/SI
 Woolson  2004
 Wright  2004
Total events: 23 (Mini-incision), 18 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
25.77
74.23
100.00
17.39
17.86
64.74
0.1 0.2 0.5 1 2 5 10
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1/28 1/32
0/60 0/60
6/60 7/60
4/70 4/70
3/105 8/109
   323     331
0/52 0/50
0/60 0/60
0/30 0/30
1/34 3/53
2/38 2/43
2/38 1/21
4/73 4/54
6/50 3/85
0/42 0/42
1.15 (0.07 to 18.88)
      Not estimable
0.84 (0.27 to 2.65)
1.00 (0.24 to 4.15)
0.40 (0.12 to 1.34)
0.70 (0.35 to 1.40)
     Not estimable
     Not estimable
     Not estimable
0.54 (0.07 to 4.19)
1.14 (0.15 to 8.42)
1.11 (0.10 to 12.27)
0.72 (0.17 to 3.06)
3.86 (0.96 to 15.59)
        Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  04 Implant postion (stem, number poorly placed)
01 RCT
 Chimento  2005  (RCT)
 Chung  2004  (Q-RCT)
 Hart  2005  (Q-RCT)
 Kim  2006  (Q-RCT)
 Ogonda  2005  (RCT)
Subtotal (95% CI)
Total events: 14 (Mini-incision), 20 (Standard incision)
Test for heterogeneity: 2 = 1.28, df = 3 (p = 0.73), I2 = 0%
Test for overall effect: z = 1.01 (p = 0.31)
02 Comparative studies
 Asayama  2006
 Ciminiello  2006
  De Beer 2004
 O’Brien  2005
 Szendrói  2006  MI/MD
 Szendrói  2006  MI/SI
 Teet  2006
 Woolson  2004
 Wright  2004
Total events: 15 (Mini-incision), 13 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
6.17
36.85
23.95
33.04
100.00
14.45
15.07
10.44
29.03
31.02
0.1 0.2 0.5 1 2 5 10
Mini-incision Standard incision
0/60 0/60
   60     60
1/60 0/60
      Not estimable
      Not estimable
7.39 (0.15 to 372.38)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  05 Implant migration
01 RCT
  Hart 2005 (Q-RCT)
Subtotal (95% CI)
Total events: 0 (Mini-incision), 0 (Standard incision)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative studies
 Ciminiello  2006
Total events: 1 (Mini-incision), 0 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
100.00
0.001 0.01 0.1 1 10 100 1000
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   0     0
0/33 3/33
0/10 1/10
      Not estimable
0.13 (0.01 to 1.27)
0.14 (0.00 to 6.82)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  06 Heterotopic ossification (number with ossification)
01 RCT
Subtotal (95% CI)
Total events: 0 (Mini-incision), 0 (Standard incision)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative studies
 DiGioia  2003
 Takahira
Total events: 0 (Mini-incision), 4 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
74.41
25.59
0.1 0.2 0.5 1 2 5 10
Mini-incision Standard incision
  3/27    1/28
  0/60    0/60
28/105 26/100
     192       197
  0/24    0/25
  0/24    0/11
  0/12    0/21
  0/42    0/42
3.00 (0.40 to 22.53)
     Not estimable
1.16 (0.63 to 2.15)
1.26 (0.70 to 2.27)
     Not estimable
     Not estimable
     Not estimable
     Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  07 Cement quality (number with poor quality)
01 RCT
 Chimento  2005  (RCT)
 Hart  2005  (Q-RCT)
 Ogonda  2005  (RCT)
Subtotal (95% CI)
Total events: 31 (Mini-incision), 27 (Standard incision)
Test for heterogeneity: 2 = 0.78, df = 1 (p = 0.38), I2 = 0%
Test for overall effect: z = 0.76 (p = 0.45)
02 Comparative studies
 Szendrói  2006  MI/MD
 Szendrói  2006  MI/SI
 Woolson  2004
 Wright  2004
Total events: 0 (Mini-incision), 0 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
8.52
91.48
100.00
0.1 0.2 0.5 1 2 5 10
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   0     0
0/52 0/50
      Not estimable
      Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  08 Limb length inequality (number with unequal lengths)
01 RCT
Subtotal (95% CI)
Total events: 0 (Mini-incision), 0 (Standard incision)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative studies
 Asayama  2006
Total events: 0 (Mini-incision), 0 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
0.1 0.5 1 2 10
Mini-incision Standard incision
  20  460.00 (0.00)  20  462.50 (0.00)
  28  127.00 (48.00)  32  170.00 (65.00)
  60  136.00 (41.10)  60  200.50 (65.20)
  60  318.80 (0.00)  60  544.40 (0.00)
  70  445.80 (0.00)  70  567.50 (0.00)
109  314.20 (0.00)   110  365.80 (0.00)
347   352
  52  217.50 (0.00)  50  247.00 (0.00)
  99  154.00 (0.00)  100  278.00 (0.00)
  51  175.49 (51.90)  95  293.68 (84.50)
  60  201.67 (0.00)   60  191.73 (0.00)
  30  180.00 (69.00)  30  246.70 (99.00)
  50  387.00 (155.00)  57  469.00 (147.00)
  10  699.00 (0.00)  10  540.00 (0.00)
  38  244.00 (100.00)  43  265.00 (114.00)
  38  244.00 (100.00)  43  304.00 (136.00)
  50  603.00 (0.00)  85  507.00 (0.00)
  42  151.80 (53.90)  42  173.20 (57.50)
        Not estimable
–43.00 (–71.69 to –14.31)
–64.50 (–84.00 to –45.00)
        Not estimable
        Not estimable
        Not estimable
–57.71 (–73.84 to –41.58)
        Not estimable
        Not estimable
–118.19 (–140.36 to –96.02)
        Not estimable
–66.70 (–109.88 to –23.52)
–82.00 (–139.46 to –24.54)
        Not estimable
–21.00 (–67.60 to 25.60)
–60.00 (–111.61 to –8.39)
        Not estimable
–21.40 (–45.24 to 2.44)         
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  09 Blood loss (intraoperative, ml)
01 RCT
  Charles 2006 (RCT)
  Chimento 2005 (RCT)
  Chung 2004 (Q-RCT)
  Hart 2005 (Q-RCT)
  Kim 2006 (Q-RCT)
  Ogonda 2005 (RCT)
Subtotal (95% CI)
Test for heterogeneity: 2 = 1.48, df = 1 (p = 0.22), I2 = 32.2%
Test for overall effect: z = 7.01 (p < 0.00001)
02 Comparative studies
 Asayama  2006
 Berger  2004
 Chen  2006
 Ciminiello  2006
  de Beer 2004
 Howell  2004
 Pilot  2006
 Szendrói  2006  MI/MD
 Szendrói  2006  MI/SI
 Woolson  2004
 Wright  2004
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 
31.60
 68.40
100.00
 37.19
  9.81
  5.54
  8.42
  6.87
 32.18
–100 –50 0 50 100
Mini-incision Standard incision
N Mean (SD) N Mean (SD)Appendix 10
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28  378.00 (151.00)  32  504.00 (205.00)
60  613.30 (0.00)  60  853.70 (0.00)
88   92
51  369.51 (65.05)  95  509.63 (117.39)
18  318.00 (223.00)  18  523.00 (210.70)
38  744.00 (260.00)  43  708.00 (221.00)
38  744.00 (260.00)  21  771.00 (235.00)
10  796.00 (0.00)  10  772.00 (0.00)
–126.00 (–216.41 to –35.59)
        Not estimable
–126.00 (–216.41 to –35.59)
–140.12 (–169.72 to –110.52)
–205.00 (–346.73 to –63.27)
    36.00 (–69.82 to 141.82)
  –27.00 (–157.14 to 103.14)
        Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  10 Blood loss (total, ml)
01 RCT
  Chimento 2005 (RCT)
  Hart 2005 (Q-RCT)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: z = 2.73 (p = 0.008)
02 Comparative studies
 Chen  2006
 Li  2005
 Szendrói  2006  MI/MD
 Szendrói  2006  MI/SI
 Takahira  2006
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
100.00
85.21
3.72
6.67
4.41
–1000 –500 0 500 1000
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
0/60 0/60
0/109 2/110
   169     170
2/52 0/50
1/99 1/100
2/50 0/57
2/34 1/53
0/38 0/43
0/38 0/21
1/10 0/10
2/50 0/85
        Not estimable
  0.14 (0.01 to 2.18)
  0.14 (0.01 to 2.18)
  7.25 (0.45 to 117.60)
  1.01 (0.06 to 16.26)
  8.67 (0.53 to 141.36)
  3.27 (0.31 to 34.22)
     Not estimable
     Not estimable
  7.39 (0.15 to 372.38)
15.18 (0.85 to 270.70)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  11 Fractures: intraoperative
01 RCT
 Hart  2005  (Q-RCT)
 Ogonda  2005  (RCT)
Subtotal (95% CI)
Total events: 0 (Mini-incision), 2 (Standard incision)
Test for heterogeneity: not applicable
Test for overall effect: z = 1.41 (p = 0.16)
02 Comparative studies
 Asayama  2006
 Beger  2004
 Howell  2004
 O’Brien  2005
 Szendrói  2006  MI/MD
 Szendrói  2006  MI/SI
 Takahira  2006
 Woolson  2004
Total events: 10 (Mini-incision), 12 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
100.00
100.00
17.09
17.18
17.03
24.09
8.63
15.98
0.01 0.1 1 10 100
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0/60 0/60
0/20 0/20
   80     80
3/51 4/95
0/60 0/60
1/30 0/30
     Not estimable
     Not estimable
     Not estimable
1.44 (0.29 to 7.03)
     Not estimable
7.39 (0.15 to 372.38)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  12 Fractures: postoperative
01 RCT
 Hart  2005  (Q-RCT)
 Sharma  2006  (Q-RCT)
Subtotal (95% CI)
Total events: 0 (Mini-incision), 0 (Standard incision)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative studies
 Chen  2006
 Chiminiello  2006 
  de Beer 2004
Total events: 4 (Mini-incision), 4 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
85.92
14.08
0.01 0.1 1 10 100
Mini-incision Standard incision
0/28 0/32
0/60 0/60
0/60 0/60
1/70 0/70
2/109 0/110
0/20 0/20
0/60 0/60
   407     412
0/52 1/50
0/99 0/100
0/60 0/60
0/50 1/57
0/34 0/53
0/38 0/43
0/38 0/21
1/50 0/85
0/42 0/42
      Not estimable
      Not estimable
      Not estimable
  7.39 (0.15 to 372.38)
  7.53 (0.47 to 121.10)
      Not estimable
      Not estimable
  7.48 (0.78 to 72.16)
  0.13 (0.00 to 6.56)
      Not estimable
      Not estimable
  0.15 (0.00 to 7.78)
      Not estimable
      Not estimable
      Not estimable
14.88 (0.26 to 861.53)
      Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome: 13  Infection
01 RCT
 Chimento  2005  (RCT)
 Chung  2004  (Q-RCT)
 Hart  2005  (Q-RCT)
 Kim  2006  (Q-RCT)
 Ogonda  2005  (RCT)
 Sharma  2006  (Q-RCT)
 Zhang  2006  (RCT)
Subtotal (95% CI)
Total events: 3 (Mini-incision), 0 (Standard incision)
Test for heterogeneity: 2 = 0.00, df = 1 (p = 0.99), I2 = 0%
Test for overall effect: z = 1.74 (p = 0.08)
02 Comparative studies
 Asayama  2006
 Berger  2004
 Ciminiello  2006
 Howell  2004
 O’Brien  2005
 Szendrói  2006  MI/MD
 Szendrói  2006  MI/SI
 Woolson  2004
 Wright  2004
Total events: 1 (Mini-incision), 2 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
33.44
66.56
100.00
34.14
34.01
31.86
0.01 0.1 1 10 100
Mini-incision Standard incisionAppendix 10
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1/20 0/20
0/28 0/32
0/60 0/60
0/60 0/60
1/70 1/70
0/60 0/60
   298     302
0/52 0/50
0/51 2/95
0/33 0/33
0/34 0/53
2/38 3/43
2/38 0/21
1/10 0/10
1/50 1/85
0/42 0/42
   348     432
7.39 (0.15 to 372.38)
      Not estimable
      Not estimable
      Not estimable
1.00 (0.06 to 16.15)
        Not estimable
1.95 (0.20 to 18.89)
      Not estimable
0.21 (0.01 to 3.93)
      Not estimable
      Not estimable
0.75 (0.12 to 4.53)
4.85 (0.26 to 89.99)
7.39 (0.15 to 372.38)
1.75 (0.10 to 31.21)
      Not estimable
1.16 (0.36 to 3.76)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  14 Nerve injury
01 RCT
 Charles  2006  (RCT) 
 Chimento  2005  (RCT)
 Chung  2004  (Q-RCT)
 Hart  2005  (Q-RCT)
 Kim  2006  (Q-RCT)
 Zhang  2006  (RCT)
Subtotal (95% CI)
Total events: 2 (Mini-incision), 1 (Standard incision)
Test for heterogeneity: 2 = 0.67, df = 1 (p = 0.41), I2 = 0%
Test for overall effect: z = 0.58 (p = 0.56)
02 Comparative studies
 Asayama  2006
 Chen  2006
 DiGioia  2003
 O’Brien  2005
 Szendrói  2006  MI/MD
 Szendrói  2006  MI/SI
 Takahira  2006
 Woolson  2004
 Wright  2004
Subtotal (95% CI)
Total events: 6 (Mini-incision), 6 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
33.49
66.51
100.00
16.14
42.28
16.10
8.94
16.54
100.00
0.01 0.1 1 10 100
Mini-incision Standard incision
0/60 0/60
   60     60
   0     0
      Not estimable
      Not estimable
      Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  15 Vascular injury
01 RCT
  Zhang 2006 (RCT)
Subtotal (95% CI)
Total events: 0 (Mini-incision), 0 (Standard incision)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative studies
Subtotal (95% CI)
Total events: 0 (Mini-incision), 0 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
0.1 0.5 0.2 1 5 21 0
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       0/28                      0/32
       3/60                      5/60
       0/60                      0/60
       0/109                    1/110
       0/60                      2/60
          317                       322
       0/52                      1/50
       0/30                      1/30
       0/34                      3/53
       2/38                      3/43
       2/38                      2/21
       1/50                      2/85
        Not estimable
     0.59 (0.14 to 2.45)
        Not estimable
     0.14 (0.00 to 6.88)
     0.13 (0.01 to 2.15)
     0.39 (0.12 to 1.30)
     0.13 (0.00 to 6.56)
     0.14 (0.00 to 6.82)
     0.19 (0.02 to 1.95)
     0.75 (0.12 to 4.53)
     0.52 (0.06 to 4.22)
     0.85 (0.08 to 9.02)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  16 DVT (deep venous thrombosis)
01 RCT
 Chimento  2005  (RCT)
 Chung  2004  (Q-RCT)
 Hart  2005  (Q-RCT)
 Ogonda  2005  (RCT)
 Zhang  2006  (RCT)
Subtotal (95% CI)
Total events: 3 (Mini-incision), 8 (Standard incision)
Test for heterogeneity: 2 = 1.17, df = 2 (p = 0.56), I2 = 0%
Test for overall effect: z = 1.54 (p = 0.12)
02 Comparative studies
 Asayama  2006
  de Beer 2004
 O’Brien  2005
 Szendrói  2006  MI/MD
 Szendrói  2006  MI/SI
 Woolson  2004
Total events: 5 (Mini-incision), 12 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
 
71.62
  9.51
 18.86
100.00
  6.34
  6.35
 17.71
 30.03
 22.07
 17.49
0.1 0.5 0.2 1 10 5 2
Mini-incision Standard incision
       0/60                      0/60
          60                         60
       0/99                      0/100
       1/34                      0/53 
        Not estimable
        Not estimable
        Not estimable
12.92 (0.23 to 717.46)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  17 Pulmonary embolism
01 RCT
 Hart  2005  (Q-RCT)
Subtotal (95% CI)
Total events: 0 (Mini-incision), 0 (Standard incision)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative studies
 Berger  2004
 O’Brien  2005
Total events: 1 (Mini-incision), 0 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
 
100.00
0.001 0.1 0.01 1 1000 100 10
Mini-incision Standard incisionAppendix 10
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  20    95.20 (0.00)  20    87.70 (0.00)
  28    70.30 (10.70)  32    70.00 (8.50)
  60    49.00 (9.40)  60    55.10 (17.90)
  60    71.00 (0.00)  60    70.00 (0.00)
  70    52.00 (0.00)  70    61.00 (0.00)
109    60.30 (9.20)  110    65.90 (13.20)
  20      0.00 (0.00)  20      0.00 (0.00)
  60    75.00 (0.00)  60    69.00 (0.00)
427   432
  50    58.60 (0.00)  50    57.90 (0.00)
  99    72.00 (0.00)  100    66.00 (0.00)
  51    88.41 (17.60)  95    90.85 (17.81)
  60    55.45 (0.00)  60    56.95 (0.00)
  30    46.60 (0.00)  30    44.50 (0.00)
  33  120.00 (0.00)  33  100.00 (0.00)
  50    97.00 (19.00)  57    84.00 (15.00)
  18    91.00 (16.40)  18    97.00 (15.60)
  32    74.00 (15.00)  51    80.00 (10.00)
  10    99.50 (0.00)  10    81.00 (0.00)
  38    84.00 (16.00)  43    93.00 (18.00)
  38    84.00 (16.00)  21  102.00 (12.00)
  10  126.50 (0.00)  10  119.90 (0.00)
  50    97.00 (0.00)  85  105.00 (0.00)
  42    71.40 (11.20)  42    77.70 (13.20)
        Not estimable
    0.30 (–4.64 to 5.24)
  –6.10 (–11.22 to –0.98)
        Not estimable
        Not estimable
  –5.60 (–8.61 to –2.59)
        Not estimable
        Not estimable
  –4.42 (–6.72 to –2.13)
        Not estimable
        Not estimable
  –2.44 (–8.45 to 3.57)
        Not estimable
        Not estimable
        Not estimable
  13.00 (6.45 to 19.55)
  –6.00 (–16.46 to 4.46)
  –6.00 (–11.88 to –0.12)
        Not estimable
  –9.00 (–16.40 to –1.60)
–18.00 (–25.23 to –10.77)
        Not estimable
        Not estimable
  –6.30 (–11.54 to –1.06)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  18 Duration of operation (minutes)
01 RCT
  Charles 2006 (RCT)
  Chimento 2005 (RCT)
  Chung 2004 (Q-RCT)
  Hart 2005 (Q-RCT)
  Kim 2006 (Q-RCT)
  Ogonda 2005 (RCT)
  Sharma 2006 (Q-RCT)
  Zhang 2006 (RCT)
Subtotal (95% CI)
Test for heterogeneity: 2 = 4.51, df = 2 (p = 0.10), I2 = 55.7%
Test for overall effect: z = 3.77 (p = 0.0002)
02 Comparative studies
 Asayama  2006
 Berger  2004
 Chen  2006
 Ciminiello  2006
  de Beer 2004
 DiGioia  2003
 Howell  2004
 Li  2005
 O’Brien  2005
 Pilot  2006
 Szendrói  2006  MI/MD
 Szendrói  2006  MI/SI
 Takahira  2006
 Woolson  2004
 Wright  2004
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 
21.64
 20.16
 
58.19
100.00
 
16.97
 
14.31
  5.61
 17.77
 
11.19
 11.75
 
22.39
–10 –5 0 5 10
Mini-incision Standard incision
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  20    5.35 (0.00)  20    5.70 (0.00)
  28    5.80 (0.00)  32    5.50 (0.00)
  60    4.41 (1.10)  60    5.34 (1.40)
109    3.65 (2.04)  110    3.68 (2.45)
  20    0.00 (0.00)  20    0.00 (0.00)
  60    7.00 (0.00)  60  13.50 (0.00)
297   302
  52    2.96 (0.00)  50    2.94 (0.00)
100    1.90 (0.00)  100    3.50 (0.00)
  51  11.16 (0.83)  95  12.83 (1.96)
  60    3.70 (0.00)  60    3.63 (0.00)
  30    5.13 (0.00)  30    5.10 (0.00)
  33    3.80 (0.00)  33    3.90 (0.00)
  50    4.40 (2.90)  57    5.70 (3.10)
  35    5.40 (2.10)  53    6.20 (2.80)
  40    5.60 (0.00)  40    6.70 (0.00)
  10  22.00 (0.00)  10  23.40 (0.00)
  50    4.30 (0.00)  85    4.00 (0.00)
  42    6.12 (0.00)  42    6.07 (0.00)
        Not estimable
        Not estimable
–0.93 (–1.38 to –0.48)
–0.03 (–0.63 to 0.57)
        Not estimable
        Not estimable
–0.60 (–0.96 to –0.24)
        Not estimable
        Not estimable
–1.67 (–2.13 to –1.21)
        Not estimable
        Not estimable
        Not estimable
–1.30 (–2.44 to –0.16)
–0.80 (–1.83 to 0.23)
        Not estimable
        Not estimable
        Not estimable
        Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  19 Length of hospital stay (days)
01 RCT
  Charles 2006 (RCT)
  Chimento 2005 (RCT)
  Chung 2004 (Q-RCT)
  Ogonda 2005 (RCT)
  Sharma 2006 (Q-RCT)
  Zhang 2006 (RCT)
Subtotal (95% CI)
Test for heterogeneity: 2 = 5.56, df = 1 (p = 0.02), I2 = 82.0%
Test for overall effect: z = 3.29 (p = 0.001)
02 Comparative studies
 Asayama  2006
 Berger  2004
 Chen  2006
 Ciminiello  2006
  de Beer 2004
 DiGioia  2003
 Howell  2004
 O’Brien  2005
 Panisello  2006
 Takahira  2006
 Woolson  2004
 Wright  2004
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 63.71
 36.29
100.00
 73.69
 11.80
 14.51
–4 –2 0 2 4
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
       0/109                    2/110
          109                       110
       0/60                      0/60
       0/42                      0/42
     0.14 (0.01 to 2.18)
     0.14 (0.01 to 2.18)
        Not estimable
        Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  20 Death (30 days)
01 RCT
  Ogonda 2005 (RCT)
Subtotal (95% CI)
Total events: 0 (Mini-incision), 2 (Standard incision)
Test for heterogeneity: not applicable
Test for overall effect: z = 1.41 (p = 0.16)
02 Comparative studies
 Ciminiello  2006
 Wright  2004
Total events: 0 (Mini-incision), 0 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
100.00
100.00
0.01 0.1 1 100 10
Mini-incision Standard incisionAppendix 10
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       0/28                      2/32
          28                         32
       0/60                      0/60
       2/42                      2/42
     0.15 (0.01 to 2.45)
     0.15 (0.01 to 2.45)
        Not estimable
     1.00 (0.14 to 7.36)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  21 Death (long term)
01 RCT
  Chimento 2005 (RCT)
Subtotal (95% CI)
Total events: 0 (Mini-incision), 2 (Standard incision)
Test for heterogeneity: not applicable
Test for overall effect: z = 1.33 (p = 0.18)
02 Comparative studies
 Ciminiello  2006
 Wright  2004
Total events: 2 (Mini-incision), 2 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
100.00
100.00
100.00
0.01 0.1 1 100 10
Mini-incision Standard incision
  18    22.80 (0.00)  19    19.50 (0.00)
  28  285.00 (185.00)  32  319.00 (177.00)
109    42.90 (97.40)  110    45.00 (96.80)
155   161
          Not estimable
–34.00 (–125.96 to 57.96)
  –2.10 (–27.82 to 23.62)
  –4.41 (–29.18 to 20.36)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  22 Short-term patient-controlled anaesthesia (mg)
01 RCT
  Charles 2006 (RCT)
  Chimento 2005 (RCT)
  Ogonda 2005 (RCT)
Subtotal (95% CI)
Test for heterogeneity: 2 = 0.43, df = 1 (p = 0.51), I2 = 0%
Test for overall effect: z = 0.35 (p = 0.73)
02 Comparative studies
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
7.26
 92.74
100.00
–100 –50 0 50 100
Mini-incision Standard incision
N Mean (SD) N Mean (SD)Health Technology Assessment 2008; Vol. 12: No. 26
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  0    0
52      92.70 (0.00)  50      94.90 (0.00)
60    118.00 (0.00)  60    121.00 (0.00)
30    147.70 (0.00)  30    169.30 (0.00)
        Not estimable
        Not estimable
        Not estimable
        Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  23 short-term total narcotic received (mg)
01 RCT
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative studies
 Asayama  2006
 Ciminiello  2006
  de Beer 2004
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
60      2.20 (0.00)  60      2.64 (0.00)
60 60
        Not estimable
        Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  24 Short-term narcotic (days)
01 RCT
  Chung 2004 (Q-RCT)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative studies
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
–100 –50 0 50 100
Mini-incision Standard incision
N Mean (SD) N Mean (SD)Appendix 10
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            0                           0
       2/52                      3/49
       0/60                      0/60
       0/30                      1/30
       Not estimable
   0.62 (0.10 to 3.71)
       Not estimable
   0.14 (0.00 to 6.82)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  25 Short-term pain (N of patients)
01 RCT
Subtotal (95% CI)
Total events: 0 (Mini-incision), 0 (Standard incision)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative  studies
 Asayama  2006
 Ciminiello  2006
  de Beer 2004
Total events: 2 (Mini-incision), 4 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
 82.75
 17.25
0.1 0.5 0.2 1 10 25
Mini-incision Standard incision
  18  3.94 (0.00)  19  3.68 (0.00)
  70  0.00 (0.00)  70  0.00 (0.00)
109  3.30 (1.80)  110  3.36 (1.96)
  20  4.05 (0.00)  20  6.25 (0.00)
217   219
  38  1.50 (1.15)  43  2.15 (1.20)
  38  1.50 (1.15)  21  2.10 (1.30)
        Not estimable
        Not estimable
–0.06 (–0.56 to 0.44)
        Not estimable
–0.06 (–0.56 to 0.44)
–0.65 (–1.16 to –0.14)
–0.60 (–1.27 to 0.07)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  26 Short-term pain (score)
01 RCT
  Charles 2006 (RCT)
  Kim 2006 (Q-RCT)
  Ogonda 2005 (RCT)
  Sharma 2006 (Q-RCT)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.24 (p = 0.81)
02 Comparative studies
 Szendrói  2006  MI/MD
 Szendrói  2006  MI/SI
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
100.00
 62.80
 37.20
–4 –2 0 2 4
Mini-incision Standard incision
N Mean (SD) N Mean (SD)Health Technology Assessment 2008; Vol. 12: No. 26
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 70  0.00 (0.00)  70  0.00 (0.00)
 70    70
        Not estimable
        Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  27 Long-term pain (score)
01 RCT
  Kim 2006 (Q-RCT)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative studies
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
   0     0
  51  60.00 (12.00)  95  116.00 (11.00)
         Not estimable
–56.00 (–59.97 to –52.03)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  28 Time to return to normal activity (days)
01 RCT
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative studies
 Chen  2006 
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
–100 –50 0 50 100
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
       9/28                    15/32
          28                         32
       4/52                      4/49
     0.55 (0.20 to 1.53)
     0.55 (0.20 to 1.53)
     0.94 (0.22 to 3.95)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  29 Use of walking aids: short-term (N of patients)
01 RCT
  Chimento 2005 (RCT)
Subtotal (95% CI)
Total events: 9 (Mini-incision), 15 (Standard incision)
Test for heterogeneity: not applicable
Test for overall effect: z = 1.15 (p = 0.25)
02 Comparative  studies
 Asayama  2006
Total events: 4 (Mini-incision), 4 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
100.00
100.00
100.00
0.1 0.5 0.2 1 10 25
Mini-incision Standard incisionAppendix 10
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  60  21.40 (4.80)  60  24.80 (5.40)
  60    60
  –3.40 (–5.23 to –1.57)
  –3.40 (–5.23 to –1.57)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  30 Use of walking aids (days)
01 RCT
  Chung 2004 (Q-RCT)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: z = 3.65 (p = 0.0003)
02 Comparative studies
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
100.00
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
       6/28                    15/31
          28                         31
     19/52                    16/49
    0.31 (0.11 to 0.91)
    0.31 (0.11 to 0.91)
    1.19 (0.52 to 2.68)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  31 Limp: short term (N of patients)
01 RCT
  Chimento 2005 (RCT)
Subtotal (95% CI)
Total events: 6 (Mini-incision), 15 (Standard incision)
Test for heterogeneity: not applicable
Test for overall effect: z = 2.14 (p = 0.03)
02 Comparative  studies
 Asayama  2006
Total events: 19 (Mini-incision), 16 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
100.00
100.00
100.00
0.1 0.5 0.2 1 10 25
Mini-incision Standard incisionHealth Technology Assessment 2008; Vol. 12: No. 26
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       0/27                      0/29
          27                         29
        Not estimable
        Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  32 Limp: long-term (N of patients)
01 RCT
  Chimento 2005 (RCT)
Subtotal (95% CI)
Total events: 0 (Mini-incision), 0 (Standard incision)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative  studies
Total events: 0 (Mini-incision), 0 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
0.1 0.5 0.2 1 10 25
Mini-incision Standard incision
107  –84.15 (10.56)  108  –83.36 ( 8.33)
  60  –91.40 (0.00)  60  –78.50 (0.00)
167   168
  60  –91.02 (0.00)  60  –94.93 (0.00)
  30  –71.10 (9.80)  30  –66.60 (12.20)
  33  –86.29 (0.00)  33  –80.44 (0.00)
  –0.79 (–3.33 to 1.75)
         Not estimable
  –0.79 (–3.33 to 1.75)
         Not estimable
  –4.50 (–10.10 to 1.10)
         Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  33 Harris hip score (3 months)
01 RCT
  Ogonda 2005 (RCT)
  Zhang 2006 (RCT)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.61 (p = 0.54)
02 Comparative studies
 Ciminiello  2006
  de Beer 2004
 DiGioia  2003
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
100.00
100.00
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)Appendix 10
184
  27  –94.50 (0.00)  29  –94.50 (0.00)
  60  –95.50 (0.00)  60  –93.50 (0.00)
  70  –93.00 (0.00)  70  –91.00 (0.00)
  60  –95.10 (0.00)  60  –95.60 (0.00)
217   219
  52  –96.20 (0.00)  50  –96.20 (0.00)
  51  –89.71 (3.62)  95  –83.78 (8.03)
  33  –96.00 (0.00)  33  –94.00 (0.00)
  18  –92.00 (0.00)  18  –90.00 (0.00)
  20  –99.00 (0.00)  14  –97.00 (0.00)
  37  –86.90 (4.10)  39  –84.20 (6.40)
         Not estimable
         Not estimable
         Not estimable
         Not estimable
         Not estimable
         Not estimable
  –5.93 (–7.83 to –4.03)
         Not estimable
         Not estimable
         Not estimable
  –2.70 (–5.10 to –0.30)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  34 Harris hip score (>3 months)
01 RCT
  Chimento 2005 (RCT)
  Chung 2004 (Q-RCT)
  Kim 2006 (Q-RCT)
  Zhang 2006 (RCT)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative studies
 Asayama  2006
 Chen  2006
 DiGioia  2003
 Li  2005
 Woolson  2004
 Wright  2004
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 61.66
 38.34
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
  16  91.99 (0.00)  19  89.60 (0.00)
107  74.40 (13.88)  108  73.95 (12.90)
123   127
         Not estimable
    0.45 (–3.13 to 4.03)
    0.45 (–3.13 to 4.03)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  35 WOMAC osteoarthritis index (3 months)
01 RCT
  Charles 2006 (RCT)
  Ogonda 2005 (RCT)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.25 (p = 0.81)
02 Comparative studies
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
100.00
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)Health Technology Assessment 2008; Vol. 12: No. 26
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107  24.97 (7.33)  108  25.88 (6.29)
107   108
  30  26.50 (8.40)  30  28.40 (7.50)
  –0.91 (–2.74 to 0.92)
  –0.91 (–2.74 to 0.92)
  –1.90 (–5.93 to 2.13)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  36 Oxford hip score (3 months)
01 RCT
  Ogonda 2005 (RCT)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.98 (p = 0.33)
02 Comparative studies
  de Beer 2004
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
100.00
100.00
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
  60  –16.60 (0.00)  60  –14.10 (0.00)
  60    60
         Not estimable
         Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  37 Merle d’Aubigne-Charnley Score (3 months) 
01 RCT
  Hart 2005 (Q-RCT)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative studies
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
  60  –17.40 (0.00)  60  –17.30 (0.00)
  60    60
         Not estimable
         Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  38 Merle d’Aubigne-Charnley Score (>3 months)
01 RCT
  Hart 2005 (Q-RCT)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative studies
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)Appendix 10
186
107  –38.48 (10.20)  108  –37.73 (9.48)
107   108
  –0.75 (–3.38 to 1.88)
  –0.75 (–3.38 to 1.88)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  39 SF-12 physical component (3 months)
01 RCT
  Ogonda 2005 (RCT)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.56 (p = 0.58)
02 Comparative studies
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
100.00
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
107  –50.61 (11.05)  108  –51.11 (10.54)
107   108
     0.50 (–2.39 to 3.39)
     0.50 (–2.39 to 3.39)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  40 SF-12 mental component (>3 months)
01 RCT
  Ogonda 2005 (RCT)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.34 (p = 0.73)
02 Comparative studies
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
100.00
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
  16  –40.80 (0.00)  19  –40.40 (0.00)
  16    19
          Not estimable
          Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  41 SF-36 physical function (3 months)
01 RCT
  Charles 2006 (RCT)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative studies
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)Health Technology Assessment 2008; Vol. 12: No. 26
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    0    0
109  –54.50 (4.29)  56  –56.24 (3.87)
          Not estimable
     1.74 (0.45 to 3.03)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  42 SF-36 physical function (>3 months)
01 RCT
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative studies
 Dorr  2007
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
    0    0
109  –60.38 (3.84)  56  –60.74 (3.42)
          Not estimable
     0.36 (–0.79 to 1.51)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  43 SF-36 mental component (>3 months)
01 RCT
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative studies
 Dorr  2007
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)Appendix 10
188
       0                           0
       0/109                  21/56
       0/20                      0/14
       0/37                      5/37
        Not estimable
     0.03 (0.01 to 0.09)
        Not estimable
     0.12 (0.02 to 0.73)
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  44 Satisfaction (number of patients dissatisfied)
01 RCT
Subtotal (95% CI)
Total events: 0 (Mini-incision), 0 (Standard incision)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative  studies
 Corr  2007
 Woolson  2004
 Wright  2004
Total events: 0 (Mini-incision), 26 (Standard incision)
Study
or subcategory
Mini-incision
n/N
Standard incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
 
77.77
 
22.23
0.01 0.1 1 100 10
Mini-incision Standard incision
  18  –15.22 (0.00)  19  –14.59 (0.00)
  18    19
          Not estimable
          Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome: 45  Satisfaction  (score)
01 RCT
  Charles 2006 (RCT)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative studies
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)Health Technology Assessment 2008; Vol. 12: No. 26
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107  11.00 (0.00)  108  12.00 (0.00)
107   108
          Not estimable
          Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  01 Mini-incision versus standard incision
Outcome:  46 Scar contraction (% of total wound length from end of surgery)
01 RCT
  Ogonda 2005 (RCT)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative studies
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
Comparison 02: Single mini-incision versus single standard incision
(reported means and SDs supplemented with calculated SDs from 
p-values)
  20  460.00 (184.25)  20  462.50 (184.25)
  28  127.00 (48.00)  32  170.00 (65.00)
  60  136.00 (41.10)  60  200.50 (65.20)
  60  318.80 (0.00)  60  544.40 (0.00)
  70  445.80 (521.95)  70  567.50 (521.95)
109  314.20 (174.78)  110  365.80 (174.78)
347   352
  52  217.50 (0.00)  50  247.00 (0.00)
  99  154.00 (443.49)  100  278.00 (443.49)
  51  175.49 (51.90)  95  293.68 (84.50)
  60  201.67 (228.39)  60  191.73 (228.39)
  30  180.00 (69.00)  30  246.70 (99.00)
  50  387.00 (155.00)  57  469.00 (147.00)
  10  699.00 (319.20)  10  540.00 (319.20)
  38  244.00 (100.00)  43  265.00 (114.00)
  38  244.00 (100.00)  43  304.00 (136.00)
  50  603.00 (344.21)  85  507.00 (344.21)
  42  151.80 (53.90)  42  173.20 (57.50)
    –2.50 (–116.70 to 111.70)
  –43.00 (–71.69 to –14.31)
  –64.50 (–84.00 to –45.00)
        Not estimable
–121.70 (–294.62 to 51.22)
  –51.60 (–97.90 to –5.30)
  –56.59 (–71.63 to –41.55)
        Not estimable
–124.00 (–247.24 to –0.76)
–118.19 (–140.36 to –96.02)
      9.94 (–71.79 to 91.67)
  –66.70 (–109.88 to –23.52)
  –82.00 (–139.46 to –24.54)
  159.00 (–120.79 to 438.79)
  –21.00 (–67.60 to 25.60)
  –60.00 (–111.61 to –8.39)
    96.00 (–24.24 to 216.24)
  –21.40 (–45.24 to 2.44)
Review:  Minimal incision approaches to total hip replacement
Comparison:  02 Mini-incision versus standard incision (p-value)
Outcome:  09 Blood loss (intraoperative, ml)
01 RCT
  Charles 2006 (RCT)
  Chimento 2005 (RCT)
  Chung 2004 (Q-RCT)
  Hart 2005 (Q-RCT)
  Kim 2006 (Q-RCT)
  Ogonda 2005 (RCT)
Subtotal (95% CI)
Test for heterogeneity: 2 = 2.94, df = 4 (p = 0.57), I2 = 0%
Test for overall effect: z = 7.37 (p < 0.00001)
02 Comparative studies
 Asayama  2006
 Berger  2004
 Chen  2006
 Ciminiello  2006
  de Beer 2004
 Howell  2004
 Pilot  2006
 Szendrói  2006  MI/MD 
 Szendrói  2006  MI/SI 
 Woolson  2004
 Wright  2004
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
  1.73
 27.48
 59.48
  0.76
 10.55
100.00
  1.14
 35.27
  2.60
  9.30
  5.25
  0.22
  7.98
  6.51
  1.20
 30.52
–100 –50 0 50 100
Mini-incision Standard incision
N Mean (SD) N Mean (SD)Appendix 10
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  28  378.00 (151.00)  32  504.00 (205.00)
  60  613.30 (0.00)  60  853.70 (0.00)
  88    92
  51  369.51 (65.05)  95  509.63 (117.39)
  18  318.00 (223.00)  18  523.00 (210.70)
  38  744.00 (260.00)  43  708.00 (221.00)
  38  744.00 (260.00)  21  771.00 (235.00)
  10  796.00 (0.00)  10  772.00 (0.00)
–126.00 (–216.41 to –35.59)
          Not estimable
–126.00 (–216.41 to –35.59)
–140.12 (–169.72 to –110.52)
–205.00 (–346.73 to –63.27)
    36.00 (–69.82 to 141.82)
  –27.00 (–157.14 to 103.14)
          Not estimable
–125.80 (–153.13 to –98.48)
Review:  Minimal incision approaches to total hip replacement
Comparison:  02 Mini-incision versus standard incision (p-value)
Outcome:  10 Blood loss (total, ml)
01 RCT
  Chimento 2005 (RCT)
  Hart 2005 (Q-RCT)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: z = 2.73 (p = 0.006)
02 Comparative studies
 Chen  2006
 Li  2005
 Szendrói  2006  MI/MD 
 Szendrói  2006  MI/SI 
 Takahira  2006
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
100.00
 85.21
  3.72
  6.67
  4.41
100.00
–1000 –500 0 500 1000
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
  20    95.20 (23.29)  20    87.70 (23.29)
  28    70.30 (10.70)  32    70.00 (8.50)
  60    49.00 (9.40)  60    55.10 (17.90)
  60    71.00 (0.00)  60    70.00 (0.00)
  70    52.00 (15.84)  70    61.00 (15.84)
109    60.30 (9.20)  110    65.90 (13.20)
  20      0.00 (0.00)  20      0.00 (0.00)
  60    75.00 (16.60)  60    69.00 (16.60)
427   432
  50    58.60 (0.00)  50    57.90 (0.00)
  99    72.00(0.00)  100    66.00 (0.00)
  51    88.41 (17.60)  95    90.85 (17.81)
  60    55.45 (4.91)  60    56.95 (4.91)
  30    46.60 (14.31)  30    44.50 (14.31)
  33  120.00 (0.00)  33  100.00 (0.00)
  50    97.00 (19.00)  57    84.00 (15.00)
  18    91.00 (16.40)  18    97.00 (15.60)
  32    74.00 (15.00)  51    80.00 (10.00)
  10    99.50 (20.25)  10    81.00 (20.25)
  38    84.00 (16.00)  43    93.00 (18.00)
  38    84.00 (16.00)  21  102.00 (12.00)
  10  126.50 (0.00)  10  119.90 (0.00)
  50    97.00 (29.46)  85  105.00 (29.46)
  42    71.40 (11.20)  42    77.70 (13.20)
     7.50 (–6.94 to 21.94)
     0.30 (–4.64 to 5.24)
   –6.10 (–11.22 to –0.98)
        Not estimable
   –9.00 (–14.25 to –3.75)
   –5.60 (–8.61 to –2.59)
        Not estimable
     6.00 (–0.06 to 11.94)
   –3.70 (–5.67 to –1.74)
        Not estimable
        Not estimable
   –2.44 (–8.45 to 3.57)
   –1.50 (–3.26 to 0.26)
     2.10 (–5.14 to 9.34)
        Not estimable
   13.00 (6.45 to 19.55)
   –6.00 (–16.46 to 4.46)
   –6.00 (–11.88 to –0.12)
   18.50 (0.75 to 36.25)
   –9.00 (–16.40 to –1.60)
 –18.00 (–25.23 to –10.77)
        Not estimable
   –8.00 (–18.29 to 2.29)
   –6.30 (–11.54 to –1.06)
Review:  Minimal incision approaches to total hip replacement
Comparison:  02 Mini-incision versus standard incision (p-value)
Outcome:  18 Duration of operation (minutes)
01 RCT
  Charles 2006 (RCT)
  Chimento 2005 (RCT)
  Chung 2004 (Q-RCT)
  Hart 2005 (Q-RCT)
  Kim 2006 (Q-RCT)
  Ogonda 2005 (RCT)
  Sharma 2006 (Q-RCT)
  Zhang 2006 (RCT) 
Subtotal (95% CI)
Test for heterogeneity: 2 = 21.37, df = 5 (p = 0.0007), I2 = 76.6%
Test for overall effect: z = 3.69 (p < 0.0002)
02 Comparative studies
 Asayama  2006
 Berger  2004
 Chen  2006
 Ciminiello  2006
  de Beer 2004
 DiGioia  2003
 Howell  2004
 Li  2005
 O’Brien  2005
 Pilot  2006
 Szendrói  2006  MI/MD 
 Szendrói  2006  MI/SI
 Takahira  2006
 Woolson  2004
 Wright  2004
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
  1.85
 15.84
 14.76
 14.02
 42.59
 10.94
100.00
  5.33
 62.47
  3.68
  4.50
  1.76
  5.58
  0.61
  3.52
  3.69
  1.82
  7.04
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)Health Technology Assessment 2008; Vol. 12: No. 26
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  18    22.80 (6.03)  19    19.50 (6.03)
  28  285.00 (185.00)  32  319.00 (177.00)
109    42.90 (97.40)  110    45.00 (96.80)
155   161
    3.30 (–0.59 to 7.19)
–34.00 (–125.96 to 57.96)
  –2.10 (–27.82 to 23.62)
    3.11 (–0.73 to 6.95)
Review:  Minimal incision approaches to total hip replacement
Comparison:  02 Mini-incision versus standard incision (p-value)
Outcome:  22 Short-term patient-controlled anaesthesia (mg)
01 RCT
  Charles 2006 (RCT)
  Chimento 2005 (RCT)
  Ogonda 2005 (RCT)
Subtotal (95% CI)
Test for heterogeneity: 2 = 0.79, df = 2 (p = 0.67), I2 = 0%
Test for overall effect: z = 1.59 (p = 0.11)
02 Comparative studies
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 97.60
  0.17
  2.23
100.00
–100 –50 0 50 100
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
  20    5.35 (1.63)  20    5.70 (1.63)
  28    5.80 (2.20)  32    5.50 (2.20)
  60    4.41 (1.10)  60    5.34 (1.40)
109    3.65 (2.04)  110    3.68 (2.45)
  20    0.00 (0.00)  20    0.00 (0.00)
  60    7.00 (0.00)  60  13.50 (0.00)
297   302
  52    2.96 (0.56)  50    2.94 (0.56)
100    1.90 (5.74)  100    3.50 (5.74)
  51  11.16 (0.83)  95  12.83 (1.96)
  60    3.70 (5.08)  60    3.63 (5.08)
  30    5.13 (0.87)  30    5.10 (0.87)
  33    3.80 (0.77)  33    3.90 (0.77)
  50    4.40 (2.90)  57    5.70 (3.10)
  35    5.40 (2.10)  53    6.20 (2.80)
  40    5.60 (0.00)  40    6.70 (0.00)
  10  22.00 (0.00)  10  23.40 (0.00)
  50    4.30 (2.17)  85    4.00 (2.17)
  42    6.12 (2.27)  42    6.07 (2.27)
  –0.35 (–1.36 to 0.66)
    0.30 (–0.82 to 1.42)
  –0.93 (–1.38 to –0.48)
  –0.03 (–0.63 to 0.57)
        Not estimable
        Not estimable
  –0.50 (–0.83 to –0.18)
    0.02 (–0.20 to 0.24)
  –1.60 (–3.19 to –0.01)
  –1.67 (–2.13 to –1.21)
    0.07 (–1.75 to 1.89)
    0.03 (–0.41 to 0.47)
  –0.10 (–0.47 to 0.27)
  –1.30 (–2.44 to –0.16)
  –0.80 (–1.83 to 0.23)
        Not estimable
        Not estimable
    0.30 (–0.46 to 1.06)
    0.05 (–0.92 to 1.02)
Review:  Minimal incision approaches to total hip replacement
Comparison:  02 Mini-incision versus standard incision (p-value)
Outcome:  19 Length of hospital stay (days)
01 RCT
  Charles 2006 (RCT)
  Chimento 2005 (RCT)
  Chung 2004 (Q-RCT)
  Ogonda 2005 (RCT)
  Sharma 2006 (Q-RCT)
  Zhang 2006 (RCT) 
Subtotal (95% CI)
Test for heterogeneity: 2 = 7.94, df = 3 (p = 0.05), I2 = 62.2%
Test for overall effect: z = 3.03 (p < 0.002)
02 Comparative studies
 Asayama  2006
 Berger  2004
 Chen  2006
 Ciminiello  2006
  de Beer 2004
 DiGioia  2003
 Howell  2004
 O’Brien  2005
 Panisello  2006
 Takahira  2006
 Woolson  2004
 Wright  2004
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 10.30
  8.44
 51.77
 29.49
100.00
 48.52
  0.91
 11.07
  0.69
 11.83
 16.61
  1.77
  2.18
  3.99
  2.43
–4 –2 0 2 4
Mini-incision Standard incision
N Mean (SD) N Mean (SD)Appendix 10
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    0    0
  52    92.70 (0.00)  50    94.90 (0.00)
  60  118.00 (41.12)  60  121.00 (41.12)
  30  147.70 (86.75)  30  169.30 (86.75)
        Not estimable
        Not estimable
   –3.00 (–17.71 to 11.71)
 –21.60 (–65.50 to 22.30)
Review:  Minimal incision approaches to total hip replacement
Comparison:  02 Mini-incision versus standard incision (p-value)
Outcome:  23 Short-term total narcotic received (mg)
01 RCT
Subtotal (95% CI)
Test for heterogeneity: 2 = 0.79, df = 2 (p = 0.67), I2 = 0%
Test for overall effect: z = 1.59 (p < 0.11)
02 Comparative studies
 Asayama  2006
 Ciminiello  2006
  de Beer 2004
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 
89.90
 10.10
–100 –50 0 50 100
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
  18  3.94 (0.51)  19  3.68 (0.51)
  70  0.00 (0.00)  70  0.00 (0.00)
109  3.30 (1.80)  110  3.36 (1.96)
  20  4.05 (2.52)  20  6.25 (2.52)
217   219
  38  1.50 (1.15)  43  2.15 (1.20)
  38  1.50 (1.15)  21  2.10 (1.30)
    0.26 (–0.07 to 0.59)
        Not estimable
  –0.06 (–0.56 to 0.44)
  –2.20 (–3.76 to –0.64)
    0.09 (–0.18 to 0.36)
  –0.65 (–1.16 to –0.14)
  –0.60 (–1.27 to 0.07)
Review:  Minimal incision approaches to total hip replacement
Comparison:  02 Mini-incision versus standard incision (p-value)
Outcome:  26 Short-term pain (score)
01 RCT
  Charles 2006 (RCT)
  Kim 2006 (Q-RCT)
  Ogonda 2005 (RCT)
  Sharma 2006 (Q-RCT)
Subtotal (95% CI)
Test for heterogeneity: 2 = 9.63, df = 2 (p = 0.008), I2 = 79.2%
Test for overall effect: z = 0.67 (p = 0.50)
02 Comparative studies
 Szendrói  2006  MI/MD 
 Szendrói  2006  MI/SI 
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 67.59
 29.42
  2.99
100.00
 62.80
 37.20
–4 –2 0 2 4
Mini-incision Standard incision
N Mean (SD) N Mean (SD)Health Technology Assessment 2008; Vol. 12: No. 26
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107  –84.15 (10.56)  108  –83.36 (8.33)
  60  –91.40 (35.68)  60  –78.50 (35.68)
167   168
  60  –91.02 (12.17)  60  –94.93 (12.17)
  30  –71.10 (9.80)  30  –66.60 (12.20)
  33  –86.29 (11.62)  33  –80.44 (11.62)
   –0.79 (–3.33 to 1.75)
 –12.90 (–25.67 to –0.13)
   –1.25 (–3.75 to 1.24)
     3.91 (–0.44 to 8.26)
   –4.50 (–10.10 to 1.10)
   –5.85 (–11.46 to –0.24)
Review:  Minimal incision approaches to total hip replacement
Comparison:  02 Mini-incision versus standard incision (p-value)
Outcome:  33 Harris hip score (3 months)
01 RCT
  Ogonda 2005 (RCT)
  Zhang 2006 (RCT) 
Subtotal (95% CI)
Test for heterogeneity: 2 = 3.32, df = 1 (p = 0.07), I2 = 69.9%
Test for overall effect: z = 0.67 (p = 0.50)
02 Comparative studies
 Ciminiello  2006
  de Beer 2004
 DiGioia  2003
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 96.18
  3.82
100.00
 45.29
 27.39
 27.32
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
  27  –94.50 (0.00)  29  –94.50 (0.00)
  60  –95.50 (5.53)  60  –93.50 (5.53)
  70  –93.00 (35.58)  70  –91.00 (35.58)
  60  –95.10 (1.38)  60  –95.60 (1.38)
217   219
  52  –96.20 (0.00)  50  –96.20 (0.00)
  51  –89.71 (3.62)  95  –83.78 (8.03) 
  33  –96.00 (4.57)  33  –94.00 (4.57)
  18  –92.00 (2.95)  18  –90.00 (2.95)
  20  –99.00 (7.18)  14  –97.00 (7.18)
  37  –86.90 (4.10)  39  –84.20 (6.40)
        Not estimable
  –2.00 (–3.98 to –0.02)
  –2.00 (–13.79 to 9.79)
    0.50 (0.01 to 0.99)
    0.35 (–0.13 to 0.83)
        Not estimable
  –5.93 (–7.83 to –4.03)
  –2.00 (–4.21 to 0.21)
  –2.00 (–3.93 to –0.07)
  –2.00 (–6.90 to 2.90)
  –2.70 (–5.10 to –0.30)
Review:  Minimal incision approaches to total hip replacement
Comparison:  02 Mini-incision versus standard incision (p-value)
Outcome:  34 Harris hip score (>3 months)
01 RCT
  Chimento 2005 (RCT)
  Chung 2004 (Q-RCT)
  Kim 2006 (Q-RCT)
  Zhang 2006 (RCT) 
Subtotal (95% CI)
Test for heterogeneity: 2 = 5.92, df = 2 (p = 0.05), I2 = 66.2%
Test for overall effect: z = 1.43 (p = 0.15)
02 Comparative studies
 Asayama  2006
 Chen  2006
 DiGioia  2003
 Li  2005
 Woolson  2004
 Wright  2004
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
  5.85
  0.16
 93.98
100.00
 28.75
 21.25
 27.82
  4.30
 17.88
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)Appendix 10
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  16  91.99 (17.51)  19  89.60 (17.51)
107  74.40 (13.88)  108  73.95 (12.90)
123   127
    2.39 (–9.25 to 14.03)
   0.45 (–3.13 to 4.03)
   0.62 (–2.81 to 4.04)
Review:  Minimal incision approaches to total hip replacement
Comparison:  02 Mini-incision versus standard incision (p-value)
Outcome:  35 WOMAC osteoarthritis index (3 months)
01 RCT
  Charles 2006 (RCT)
  Ogonda 2005 (RCT)
Subtotal (95% CI)
Test for heterogeneity: 2 = 0.10, df = 1 (p = 0.75), I2 = 0%
Test for overall effect: z = 0.35 (p = 0.72)
02 Comparative studies
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
  8.65
 91.35
100.00
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
  16  –40.80 (2.13)  19  –40.40 (2.13)
  16    19
–0.40 (–1.82 to 1.02)
–0.40 (–1.82 to 1.02)
Review:  Minimal incision approaches to total hip replacement
Comparison:  02 Mini-incision versus standard incision (p-value)
Outcome:  41 SF-36 physical function (3 months)
01 RCT
  Charles 2006 (RCT)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.55 (p = 0.58)
02 Comparative studies
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
100.00
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
  60  –16.60 (5.80)  60  –14.10 (5.80)
  60    60
–2.50 (–4.58 to –0.42)
–2.50 (–4.58 to –0.42)
Review:  Minimal incision approaches to total hip replacement
Comparison:  02 Mini-incision versus standard incision (p-value)
Outcome:  37 Merle d’Aubigne-Charnley Score (3 months)
01 RCT
  Hart 2005 (Q-RCT)
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: z = 2.36 (p = 0.02)
02 Comparative studies
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
100.00
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)Health Technology Assessment 2008; Vol. 12: No. 26
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Comparison 03: Single mini-incision versus single standard incision
(reported means and SDs supplemented with calculated SDs from 
p-values and imputed SDs)
  20  460.00 (184.25)    20  462.50 (184.25)
  28  127.00 (48.00)  32  170.00 (65.00)
  60  136.00 (41.10)  60  200.50 (65.20)
  60  318.80 (72.74)  60  544.40 (72.74)
  70  445.80 (521.95)  70  567.50 (521.95)
109  314.20 (174.78)  110  365.80 (174.78)
347   352
  52  217.50 (88.91)  50  247.00 (88.91)
  99  154.00 (443.49)  100  278.00 (443.49)
  51    75.49 (51.90)  95  293.68 (84.50)
  60  201.67 (228.39)  60  191.73 (228.39)
  30  180.00 (69.00)  30  246.70 (99.00)
  50  387.00 (155.00)  57  469.00 (147.00)
  10  699.00 (319.20)  10  540.00 (319.20)
  38  244.00 (100.00)  43  265.00 (114.00)
  38  244.00 (100.00)  43  304.00 (136.00)
  50  603.00 (344.21)  85  507.00 (344.21)
  42  151.80 (53.90)  42  173.20 (57.50)
    –2.50 (–116.70 to 111.70)
  –43.00 (–71.69 to –14.31)
  –64.50 (–84.00 to –45.00)
–225.60 (–251.63 to –199.57)
–121.70 (–294.62 to 51.22)
  –51.60 (–97.90 to –5.30)
  –98.89 (–111.92 to –85.87)
  –29.50 (–64.02 to 5.02)
–124.00 (–247.24 to –0.76)
–118.19 (–140.36 to –96.02)
      9.94 (–71.79 to 91.67)
  –66.70 (–109.88 to –23.52)
  –82.00 (–139.46 to –24.54)
  159.00 (–120.79 to 438.79)
  –21.00 (–67.60 to 25.60)
  –60.00 (–111.61 to –8.39)
    96.00 (–24.24 to 216.24)
  –21.40 (–45.24 to 2.44)
Review:  Minimal incision approaches to total hip replacement
Comparison:  03 Mini-incision versus standard incision (dummy)
Outcome:  09 Blood loss (intraoperative, ml)
01 RCT
  Charles 2006 (CT)
  Chimento 2005 (RCT)
  Chung 2004 (Q-RCT)
  Hart 2005 (Q-RCT)
  Kim 2006 (Q-RCT)
  Ogonda 2005 (RCT)
Subtotal (95% CI)
Test for heterogeneity: 2 = 124.36, df = 5 (p < 0.00001), I2 = 96.0%
Test for overall effect: z = 14.88 (p < 0.00001)
02 Comparative studies
 Asayama  2006
 Berger  2004
 Chen  2006
 Ciminiello  2006
  de Beer 2004
 Howell  2004
 Pilot  2006
 Szendrói  2006  MI/MD
 Szendrói  2006  MI/SI
 Woolson  2004
 Wright  2004
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
1.30
20.60
44.59
25.03
0.57
7.91
100.00
12.71
1.00
30.79
2.27
8.12
4.58
0.19
6.97
5.68
1.05
26.64
–100 –50 0 50 100
Mini-incision Standard incision
N Mean (SD) N Mean (SD)Appendix 10
196
  20    95.20 (23.29)  20    87.70 (23.29)
  28    70.30 (10.70)  32    70.00 (8.50)
  60    49.00 (9.40)  60    55.10 (17.90)
  60    71.00 (12.77)   60    70.00 (12.77)
  70    52.00 (15.84)  70    61.00 (15.84)
109    60.30 (9.20)  110    65.90 (13.20)
  20    67.54 (12.77)  20    68.38 (12.77)
  60    75.00 (16.60)  60    69.00 (16.60)
427   432
  50    58.60 (8.91)  50    57.90 (8.91)
  99    72.00 (8.91)  100    66.00 (8.91)
  51    88.41 (17.60)  95    90.85 (17.81)
  60    55.45 (4.91)  60    56.95(4.91)
  30    46.60 (14.31)  30    44.50 (14.31)
  33  120.00 (8.91)  33  100.00 (8.91)
  50    97.00 (19.00)  57    84.00 (15.00)
  18    91.00 (16.40)  18    97.00 (15.60)
  32    74.00 (15.00)  51    80.00 (10.00)
  10    99.50 (20.25)  10    81.00 (20.25)
  38    84.00 16.00)  43    93.00 (18.00)
  38    84.00 (16.00)  21  102.00 (12.00)
  10  126.50 (8.91)  10  119.90 (8.91)
  50    97.00 (29.46)   85  105.00 (29.46)
  42    71.40 (11.20)  42    77.70 (13.20)
    7.50 (–6.94 to 21.94)
    0.30 (–4.64 to 5.24)
  –6.10 (–11.22 to –0.98)
    1.00 (–3.57 to 5.57)
  –9.00 (–14.25 to –3.75)
  –5.60 (–8.61 to –2.59)
  –0.84 (–8.75 to 7.07)
    6.00 (0.06 to 11.94)
  –2.86 (–4.62 to –1.10)
   0.70 (–2.79 to 4.19)
    6.00 (3.52 to 8.48)
  –2.44 (–8.45 to 3.57)
  –1.50 (–3.26 to 0.26)
    2.10 (–5.14 to 9.34)
  20.00 (15.70 to 24.30)
  13.00 (6.45 to 19.55)
  –6.00 (–16.46 to 4.46)
  –6.00 (–11.88 to –0.12)
  18.50 (0.75 to 36.25)
  –9.00 (–16.40 to –1.60)
–18.00 (–25.23 to –10.77)
    6.60 (–1.21 to 14.41)
  –8.00 (–18.29 to 2.29)
  –6.30 (–11.54 to –1.06)
Review:  Minimal incision approaches to total hip replacement
Comparison:  03 Mini-incision versus standard incision (dummy)
Outcome:  18 Duration of operation (minutes)
01 RCT
  Charles 2006 (CT)
  Chimento 2005 (RCT)
  Chung 2004 (Q-RCT)
  Hart 2005 (Q-RCT)
  Kim 2006 (Q-RCT)
  Ogonda 2005 (RCT)
  Sharma 2006 (Q-RCT)
  Zhang 2006 (RCT)
Subtotal (95% CI)
Test for heterogeneity: 2 = 25.07, df = 5 (p = 0.0007), I2 = 72.1%
Test for overall effect: z = 3.19 (p = 0.001)
02 Comparative studies
 Asayama  2006
 Berger  2004
 Chen  2006
 Ciminiello  2006
  de Beer 2004
 DiGioia  2003
 Howell  2004
 Li  2005
 O’Brien  2005
 Pilot  2006
 Szendrói  2006  MI/MD
 Szendrói  2006  MI/SI
 Takahira  2006
 Woolson  2004
 Wright  2004
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
1.49
12.71
11.84
14.84
11.25
34.16
4.95
8.78
100.00
9.83
19.56
3.32
38.83
2.29
6.49
2.79
1.10
3.47
0.38
2.19
2.30
1.97
1.13
4.37
–10 –5 0 5 10
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
28  378.00 (151.00)  32  504.00 (205.00)
60  613.30 (178.00)  60  853.70  (178.00)
88   92
51  369.51 (65.05)  95  509.63 (117.39)
18  318.00 (223.00)  18  523.00 (210.70)
38  744.00 (260.00)  43  708.00 (221.00)
38  744.00 (260.00)  21  771.00 (235.00)
10  796.00 (112.72)  10  772.00 (112.72)
–126.00 (–216.41 to –35.59)
–240.40 (–304.10 to –176.70)
–202.45 (–254.52 to –150.38)
–140.12 (–169.72 to –110.52)
–205.00 (–346.73 to –63.27)
    36.00 (–69.82 to 141.82)
  –27.00 (–157.14 to 103.14)
    24.00 (–74.80 to 122.80]
Review:  Minimal incision approaches to total hip replacement
Comparison:  03 Mini-incision versus standard incision (dummy)
Outcome:  10 Blood loss (total, ml)
01 RCT
  Chimento 2005 (RCT)
  Hart 2005 (Q-RCT)
Subtotal (95% CI)
Test for heterogeneity: 2 = 4.11, df = 1 (p = 0.04), I2 = 75.7%
Test for overall effect: z = 7.62 (p < 0.00001)
02 Comparative studies
 Chen  2006
 Li  2005
 Szendrói  2006  MI/MD
 Szendrói  2006  MI/SI
 Takahira  2006
Test for heterogeneity: 2 = 21.50, df = 4 (p = 0.0003), I2 = 81.4%
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
33.17
66.83
100.00
79.16
3.45
6.19
4.07
7.10
–1000 –500 0 500 1000
Mini-incision Standard incision
N Mean (SD) N Mean (SD)Health Technology Assessment 2008; Vol. 12: No. 26
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  20    5.35 (1.63)  20    5.70 (1.63)
  28    5.80 (2.20)  32    5.50 (2.20)
  60    4.41 (1.10)  60    5.34 (1.40)
109    3.65 (2.04)  110    3.68 (2.45)
  20    5.24 (1.66)  20    6.74 (1.66)
  60    7.00 (1.66)  60  13.50 (1.66)
297   302
  52    2.96 (0.56)  50    2.94 (0.56)
100    1.90 (5.74)  100    3.50 (5.74)
  51  11.16 (0.83)  95  12.83 (1.96)
  60    3.70 (5.08)  60    3.63 (5.08)
  30    5.13 (0.87)  30    5.10 (0.87)
  33    3.80 (0.77)  33    3.90 (0.77)
  50    4.40 (2.90)  57    5.70 (3.10)
  35    5.40 (2.10)  53    6.20 (2.80)
  40    5.60 (0.99)  40    6.70 (0.99)
  10  22.00 (0.99)  10  23.40 (0.99)
  50    4.30 (2.17)  85    4.00 (2.17)
  42    6.12 (2.27)  42    6.07 (2.27)
–0.35 (–1.36 to 0.66)
  0.30 (–0.82 to 1.42)
–0.93 (–1.38 to –0.48)
–0.03 (–0.63 to 0.57)
–1.50 (–2.53 to –0.47)
–6.50 (–7.09 to –5.91)
–1.85 (–2.13 to –1.58)
  0.02 (–0.20 to 0.24)
–1.60 (–3.19 to –0.01)
–1.67 (–2.13 to –1.21)
  0.07 (–1.75 to 1.89)
  0.03 (–0.41 to 0.47)
–0.10 (–0.47 to 0.27)
–1.30 (–2.44 to –0.16)
–0.80 (–1.83 to 0.23)
–1.10 (–1.53 to –0.67)
–1.40 (–2.27 to –0.53)
  0.30 (–0.46 to 1.06)
  0.05 (–0.92 to 1.02)
Review:  Minimal incision approaches to total hip replacement
Comparison:  03 Mini-incision versus standard incision (dummy)
Outcome:  19 Length of hospital stay (days)
01 RCT
  Charles 2006 (RCT)
  Chimento 2005 (RCT)
  Chung 2004 (Q-RCT)
  Ogonda 2005 (RCT)
  Sharma 2006 (Q-RCT)
  Zhang 2006 (RCT) 
Subtotal (95% CI)
Test for heterogeneity: 2 = 310.31, df = 5 (p < 0.00001), I2 = 98.4%
Test for overall effect: z = 13.23 (p < 0.00001)
02 Comparative studies
 Asayama  2006
 Berger  2004
 Chen  2006
 Ciminiello  2006
  de Beer 2004
 DiGioia  2003
 Howell  2004
 O’Brien  2005
 Panisello  2006
 Takahira  2006
 Woolson  2004
 Wright  2004
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
  7.37
  6.04
 37.06
 21.11
  7.11
 21.32
100.00
 42.11
  0.79
  9.60
  0.60
 10.27
 14.42
  1.54
  1.89
 10.57
  2.64
  3.46
  2.11
–4 –2 0 2 4
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
   0      0
  52    92.70 (45.73)  50    94.90 (45.73)
  60  118.00 (41.12)  60  121.00 (41.12)
  30  147.70 (86.75)  30  169.30 (86.75)
            Not estimable
    –2.20 (–19.95 to 15.55)
    –3.00 (–17.71 to 11.71)
  –21.60 (–65.50 to 22.30)
Review:  Minimal incision approaches to total hip replacement
Comparison:  03 Mini-incision versus standard incision (dummy)
Outcome:  23 Short-term total narcotic received (mg)
01 RCT
Subtotal (95% CI)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Comparative studies
 Asayama  2006
 Ciminiello  2006
  de Beer 2004
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 38.18
 55.58
  6.24
–100 –50 0 50 100
Mini-incision Standard incision
N Mean (SD) N Mean (SD)Appendix 10
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  18  3.94 (0.51)  19  3.68 (0.51)
  70  3.76 (0.97)  70  4.43 (0.97)
109  3.30 (1.80)  110  3.36 (1.96)
  20  4.05 (2.52)  20  6.25 (2.52)
217   219
  38  1.50 (1.15)  43  2.15 (1.20)
  38  1.50 (1.15)  21  2.10 (1.30)
      0.26 (–0.07 to 0.59)
    –0.67 (–0.99 to –0.35)
    –0.06 (–0.56 to 0.44)
    –2.20 (–3.76 to –0.64)
    –0.22 (–0.43 to –0.02)
    –0.65 (–1.16 to –0.14)
    –0.60 (–1.27 to 0.07)
Review:  Minimal incision approaches to total hip replacement
Comparison:  03 Mini-incision versus standard incision (dummy)
Outcome:  26 Short-term pain (score)
01 RCT
  Charles 2006 (RCT)
  Kim 2006 (Q-RCT)
  Ogonda 2005 (RCT)
  Sharma 2006 (Q-RCT)
Subtotal (95% CI)
Test for heterogeneity: 2 = 22.29, df = 3 (p < 0.0001), I2 = 86.5%
Test for overall effect: z = 2.12 (p = 0.03)
02 Comparative studies
 Szendrói  2006  MI/MD 
 Szendrói  2006  MI/SI
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 39.58
 41.43
 17.23
  1.75
100.00
 62.80
 37.20
–4 –2 0 2 4
Mini-incision Standard incision
N Mean (SD) N Mean (SD)
  27  –94.50 (1.68)  29  –94.50 (1.68)
  60  –95.50 (5.53)  60  –93.50 (5.53)
  70  –93.00 (35.58)  70  –91.00 (35.58)
  60  –95.10 (1.38)  60  –95.60 (1.38)
217   219
  52  –96.20 (4.72)  50  –96.20 (4.72)
  51  –89.71 (3.62)  95  –83.78 (8.03)
  33  –96.00 (4.57)  33  –94.00 (4.57)
  18  –92.00 (2.95)  18  –90.00 (2.95)
  20  –99.00 (7.18)  14  –97.00 (7.18)
  37  –86.90 (4.10)  39  –84.20 (6.40)
      0.00 (–0.88 to 0.88)
    –2.00 (–3.98 to –0.02)
    –2.00 (–13.79 to 9.79)
      0.50 (0.01 to 0.99)
      0.27 (–0.15 to 0.69)
      0.00 (–1.83 to 1.83)
    –5.93 (–7.83 to –4.03)
    –2.00 (–4.21 to 0.21)
    –2.00 (–3.93 to –0.07)
    –2.00 (–6.90 to 2.90)
    –2.70 (–5.10 to –0.30)
Review:  Minimal incision approaches to total hip replacement
Comparison:  03 Mini-incision versus standard incision (dummy)
Outcome:  34 Harris hip score (>3 months)
01 RCT
  Chimento 2005 (RCT)
  Chung 2004 (Q-RCT)
  Kim 2006 (Q-RCT)
  Zhang 2006 (RCT) 
Subtotal (95% CI)
Test for heterogeneity: 2 = 6.39, df = 3 (p < 0.09), I2 = 53.1%
Test for overall effect: z = 1.26 (p = 0.21)
02 Comparative studies
 Asayama  2006
 Chen  2006
 DiGioia  2003
 Li  2005
 Woolson  2004
 Wright  2004
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 22.81
  4.52
  0.13
 72.54
100.00
 23.54
 21.98
 16.25
 21.27
  3.29
 13.67
–10 –5 0 5 10
Mini-incision Standard incision
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Comparison 04: Two incisions versus single standard or mini-incision
(reported means and SDs)
       0/43                      0/43          Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  01 Revision rate (number having revision surgery)
01 RCT
02 Comparative  studies
 Duwelius  2007
Study
or subcategory
Two incisions
n/N
Single incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
 
0.01 0.1 1 100 10
Two incisions Single incision
       0/15                      0/15         Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  02 Postoperative dislocation rates
01 RCT
 Yan  2005  (Q-RCT)
02 Comparative  studies
Study
or subcategory
Two incisions
n/N
Single incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
 
0.01 0.1 1 100 10
Two incisions Single incision
       4/43                      2/43
       4/35                      6/35
   2.03 (0.39 to 10.57)
   0.63 (0.17 to 2.39)
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  03 Implant position (cup, number poorly placed)
01 RCT
02 Comparative  studies
 Duwelius  2007
  Tanavalee 2006      
Study
or subcategory
Two incisions
n/N
Single incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
 39.37
 60.63
0.1 0.2 0.5 1 10 5 2
Two incisions Single incisionAppendix 10
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       0/15                      0/15
       1/43                      1/43
       7/35                      6/35
        Not estimable
  1.00 (0.06 to 16.25)
  1.20 (0.36 to 3.98)
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  04 Implant position (stem, number poorly placed)
01 RCT
  Yan 2005 (Q-RCT)    
02 Comparative  studies
 Duwelius  2007
  Tanavalee 2006      
Study
or subcategory
Two incisions
n/N
Single incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
 
15.54
 84.46
0.1 0.2 0.5 1 10 5 2
Two incisions Single incision
       0/43                      0/43
       0/35                      0/35
        Not estimable
        Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome: 05  Implant  migration 
01 RCT
02 Comparative  studies
 Duwelius  2007
  Tanavalee 2006      
Study
or subcategory
Two incisions
n/N
Single incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
 
0.1 0.2 0.5 1 10 5 2
Two incisions Single incision
       6/39                      6/38     0.97 (0.29 to 3.30)
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  06 Limb length inequality (number with unequal lengths)
01 RCT
02 Comparative  studies
 Duwelius  2007
Study
or subcategory
Two incisions
n/N
Single incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
100.00
0.2 0.5 1 5 2
Two incisions Single incisionHealth Technology Assessment 2008; Vol. 12: No. 26
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  15  760.00 (0.00)  15  650.00 (0.00)
  43  366.00 (215.00)  43  247.00 (90.00)
           Not estimable
   119.00 (49.34 to 188.66)
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  07 Blood loss (intra-operative, ml)
01 RCT
  Yan 2005 (Q-RCT) 
02 Comparative studies
 Duwelius  2007
Study
or subcategory
Two incisions Single incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
–1000 –500 0 500 1000
N Mean (SD) N Mean (SD)
Two incisions Single incision
  35    699.00 (0.00)          35    603.00 (0.00)            Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  08 Blood loss (total, ml)
01 RCT
02 Comparative studies
 Tanavalee  2006
Study
or subcategory
Two incisions Single incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
–1000 –500 0 500 1000
N Mean (SD) N Mean (SD)
Two incisions Single incision
        3/43                          1/43
        2/35                          0/35
  2.82 (0.38 to 20.74)
  7.61 (0.47 to 124.15)
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  09 Fractures: intra-operative
01 RCT
02 Comparative  studies
 Duwelius  2007
  Tanavalee 2006      
Study
or subcategory
Two incisions
n/N
Single incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
 66.19
 33.81
0.01 0.1 1 100 10
Two incisions Single incisionAppendix 10
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       1/15                      1/15
       2/35                      0/35
  1.00 (0.06 to 16.79)
  7.61 (0.47 to 124.15)
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  10 Fractures:  post-operative
01 RCT
 Yan  2005  (Q-RCT)
02 Comparative  studies
  Tanavalee 2006      
Study
or subcategory
Two incisions
n/N
Single incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
100.00
100.00
0.01 0.1 1 100 10
Two incisions Single incision
       0/15                      0/15         Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome: 11  Infection
01 RCT
 Yan  2005  (Q-RCT)
02 Comparative  studies
Study
or subcategory
Two incisions
n/N
Single incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
 
0.1 0.5 0.2 1 10 25
Two incisions Single incision
       1/15                      0/15
       6/43                      0/43
       4/35                      0/35
 7.39 (0.15 to 372.38)
 8.37 (1.61 to 43.58)
 8.09 (1.09 to 60.03)
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  12 Nerve injury
01 RCT
 Yan  2005  (Q-RCT)
02 Comparative  studies
 Duwelius  2007
  Tanavalee 2006      
Study
or subcategory
Two incisions
n/N
Single incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
100.00
 59.61
 40.39
0.001 0.01 0.1 1 1000 100 10
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  15  100.00 (0.00)  15    80.00 (0.00)
  43    93.70 (90.00)  43    61.70 (60.00)
  35  168.00 (0.00)  35  113.00 (0.00)
100  72.00 (0.00)  118    52.00 (0.00)
           Not estimable
    32.00 (–0.33 to 64.33)
           Not estimable
           Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  13 Duration of operation (minutes)
01 RCT
  Yan 2005 (Q-RCT)
02 Comparative studies
 Duwelius  2007
 Tanavalee  2006
 Yoon  2005
Study
or subcategory
Two incisions Single incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
–100 –50 0 50 100
N Mean (SD) N Mean (SD)
Two incisions Single incision
  15  6.00 (0.00)  15  13.00 (0.00)
  43  1.25 (0.00)  43    1.90 (0.00)
            Not estimable
            Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  14 Length of hospital stay (days)
01 RCT
  Yan 2005 (Q-RCT)
02 Comparative studies
 Duwelius  2007
Study
or subcategory
Two incisions Single incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 
–4 –2 0 2 4
N Mean (SD) N Mean (SD)
Two incisions Single incision
     20/43                    10/43   2.75 (1.14 to 6.64)
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  15 Short-term pain (N of patients)
01 RCT
02 Comparative  studies
 Duwelius  2007 
Study
or subcategory
Two incisions
n/N
Single incision
n/N
Peto OR
95% CI
Peto OR
95% CI
Weight
%
100.00
0.1 0.2 0.5 1 10 5 2
Two incisions Single incisionAppendix 10
204
  43  2.00 (0.00)  43  2.50 (0.00)             Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  16 Short-term pain (score)
01 RCT
02 Comparative studies
 Duwelius  2007
Study
or subcategory
Two incisions Single incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 
–10 –5 0 5 10
N Mean (SD) N Mean (SD)
Two incisions Single incision
  37  1.60 (0.00)  30  1.60 (0.00)             Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  17 Long-term pain (score)
01 RCT
02 Comparative studies
 Duwelius  2007
Study
or subcategory
Two incisions Single incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 
–10 –5 0 5 10
N Mean (SD) N Mean (SD)
Two incisions Single incision
  43  14.00 (0.00)   43  26.00 (0.00)             Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  18 Time to return to shopping (days)
01 RCT
02 Comparative studies
 Duwelius  2007
Study
or subcategory
Two incisions Single incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 
–100 –50 0 50 100
N Mean (SD) N Mean (SD)
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  43  13.00 (0.00)  43  24.00 (0.00)
  26  32.00 (0.00)  26  34.00 (0.00)
            Not estimable
            Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  19 Time to return to driving (days)
01 RCT
02 Comparative studies
 Duwelius  2007
  Pagnano 2006        
Study
or subcategory
Two incisions Single incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 
–10 –5 0 5 10
N Mean (SD) N Mean (SD)
Two incisions Single incision
  26  28.00 (0.00)  26  27.00 (0.00)             Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  20 Use of walking aids (days)
01 RCT
02 Comparative studies
  Pagnano 2006        
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 
–10 –5 0 5 10
N Mean (SD) N Mean (SD)
Two incisions Single incision
  15  –89.00 (0.00)  15  –86.00 (0.00)
  43  –89.00 (0.00)  43  –88.00 (0.00)
            Not estimable
            Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  21 Harris hip score (3 months)
01 RCT
  Yan 2005 (Q-RCT)
02 Comparative studies
 Duwelius  2007
Study
or subcategory
Two incisions Single incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 
–10 –5 0 5 10
N Mean (SD) N Mean (SD)
Two incisions Single incisionAppendix 10
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  15  –93.00 (0.00)  15  –93.00 (0.00)
  43  –94.00 (0.00)  43  –88.00 (0.00)
  35  –94.50 (4.70)  35  –94.60 (4.50)
            Not estimable
            Not estimable
       0.10 (–2.06 to 2.26)
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  22 Harris hip score (>3 months)
01 RCT
  Yan 2005 (Q-RCT)
02 Comparative studies
 Duwelius  2007
 Tanavalee  2006
Study
or subcategory
Two incisions Single incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
–10 –5 0 5 10
N Mean (SD) N Mean (SD)
Two incisions Single incision
  43  –80.00 (0.00)  43  –70.00 (0.00)             Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  23 SF-36 physical function (3 months)
01 RCT
02 Comparative studies
 Duwelius  2007
Study
or subcategory
Two incisions Single incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 
–10 –5 0 5 10
N Mean (SD) N Mean (SD)
Two incisions Single incision
  37  –80.00 (0.00)  30  –85.00 (0.00)             Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  04 Two incisions versus single standard or mini-incision
Outcome:  24 SF-36 physical function (>3 months)
01 RCT
02 Comparative studies
 Duwelius  2007
Study
or subcategory
Two incisions Single incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 
–10 –5 0 5 10
N Mean (SD) N Mean (SD)
Two incisions Single incisionHealth Technology Assessment 2008; Vol. 12: No. 26
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Comparison 05: Two incisions versus single standard or mini-incision
(reported means and SDs supplemented with calculated SDs from 
p-values)
  15  760.00 (147.06)  15  650.00 (147.06)
  43  366.00 (215.00)  43  247.00 (90.00)
  110.00 (4.75 to 215.25)
  119.00 (49.34 to 188.66)
Review:  Minimal incision approaches to total hip replacement
Comparison:  05 Two incisions versus single standard or mini-incision (p-value)
Outcome:  07 Blood loss (intra-operative, ml)
01 RCT
  Yan 2005 (Q-RCT)
02 Comparative studies
 Duwelius  2007
Study
or subcategory
Two incisions Single incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
100.00
–1000 –500 0 500 1000
N Mean (SD) N Mean (SD)
Two incisions Single incision
  35  699.00 (168.56)  35  603.00 (168.56)    96.00 (17.03 to 174.97)
Review:  Minimal incision approaches to total hip replacement
Comparison:  05 Two incisions versus single standard or mini-incision (p-value)
Outcome:  08 Blood loss (total, ml)
01 RCT
02 Comparative studies
 Tanavalee  2006
Study
or subcategory
Two incisions Single incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
–1000 –500 0 500 1000
N Mean (SD) N Mean (SD)
Two incisions Single incision
  15  100.00 (26.74)  15    80.00 (26.74)
  43    93.70 (90.00)  43    61.70 (60.00)
  35  168.00 (86.82)  35  113.00 (86.82)
100    72.00 (0.00)  118    52.00 (0.00)
     20.00 (0.86 to 39.14)
     32.00 (–0.33 to 64.33)
     55.00 (14.32 to 95.68)
           Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  05 Two incisions versus single standard or mini-incision (p-value)
Outcome:  13 Duration of operation (minutes)
01 RCT
  Yan 2005 (Q-RCT)
02 Comparative studies
 Duwelius  2007
 Tanavalee  2006
 Yoon  2005
Study
or subcategory
Two incisions Single incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
 61.29
 38.71
–100 –50 0 50 100
N Mean (SD) N Mean (SD)
Two incisions Single incisionAppendix 10
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  15  6.00 (5.22)  15  13.00 (5.22)
  43  1.25 (0.88)  43    1.90 (0.88)
    –7.00 (–10.74 to –3.26)
    –0.65 (–1.02 to –0.28)
Review:  Minimal incision approaches to total hip replacement
Comparison:  05 Two incisions versus single standard or mini-incision (p-value)
Outcome:  14 Length of hospital stay (days)
01 RCT
  Yan 2005 (Q-RCT)
02 Comparative studies
 Duwelius  2007
Study
or subcategory
Two incisions Single incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
100.00
–10 –5 0 5 10
N Mean (SD) N Mean (SD)
Two incisions Single incision
  43  14.00 (21.11)  43  26.00 (21.11)   –12.00 (–20.92 to –3.08)
Review:  Minimal incision approaches to total hip replacement
Comparison:  05 Two incisions versus single standard or mini-incision (p-value)
Outcome:  18 Time to return to shopping (days)
01 RCT
02 Comparative studies
 Duwelius  2007
Study
or subcategory
Two incisions Single incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
–100 –50 0 50 100
N Mean (SD) N Mean (SD)
Two incisions Single incision
  43  13.00 (24.45)  43  24.00 (24.45)
  26  32.00 (8.14)  26  34.00 (8.14)
  –11.00 (–21.33 to –0.67)
    –2.00 (–6.42 to 2.42)
Review:  Minimal incision approaches to total hip replacement
Comparison:  05 Two incisions versus single standard or mini-incision (p-value)
Outcome:  19 Time to return to driving (days)
01 RCT
02 Comparative studies
 Duwelius  2007
 Pagnano  2006
Study
or subcategory
Two incisions Single incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
 15.49
 84.51
–10 –5 0 5 10
N Mean (SD) N Mean (SD)
Two incisions Single incisionHealth Technology Assessment 2008; Vol. 12: No. 26
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  26  28.00 (11.25)  26  27.00 (11.25)        1.00 (–5.12 to 7.12)
Review:  Minimal incision approaches to total hip replacement
Comparison:  05 Two incisions versus single standard or mini-incision (p-value)
Outcome:  20 Use of walking aids (days)
01 RCT
02 Comparative studies
 Pagnano  2006
Study
or subcategory
Mini-incision Standard incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
–10 –5 0 5 10
N Mean (SD) N Mean (SD)
Two incisions Single incision
  15  –89.00 (4.01)  15  –86.00 (4.01)
  43  –89.00 (0.00)  43  –88.00 (0.00)
  –3.00 (–5.87 to –0.13)
        Not estimable
Review:  Minimal incision approaches to total hip replacement
Comparison:  05 Two incisions versus single standard or mini-incision (p-value)
Outcome:  21 Harris hip score (3 months)
01 RCT
  Yan 2005 (Q-RCT)
02 Comparative studies
 Duwelius  2007
Study
or subcategory
Two incisions Single incision WMD (fixed)
95% CI
WMD (fixed)
95% CI
Weight
%
100.00
–10 –5 0 5 10
N Mean (SD) N Mean (SD)
Two incisions Single incision(Coyle D and Coyle K, University of Ottawa:
personal communication, 18 May 2007)
Based on the completed SF-36 questionnaire data,
SF-6D scores were calculated using the algorithm
of Brazier and colleagues.80 Overall data were
collected for the 40 participants within the study.
There were, however, a number of individuals with
missing data. To look at the impact of this, three
analyses were conducted, each using a different
approach to missing values. 
In the first analysis, a last value carried forward
approach was used. There were, however, four
participants who did not have any data for the
baseline assessment and these individuals were
therefore removed from the analysis, leaving 36
participants in the analysis. In the second analysis,
data from all participants were included without
regard to whether or not they had complete data.
Consequently, the number of participants with
data to analyse changes from one analysis 
period to the next. In the final analysis, all 
cases that did not have a complete data set were
deleted, which left only 24 individuals within the
analysis. 
In each of these three analyses, mean scores of
each time point were compared in an analysis of
covariance adjusting for baseline SF-6D scores.
Overall, the differences between the minimally
invasive arm and the control arm were small and
the different approaches to handling missing
values did not significantly affect the results
(Tables 55–57). 
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Appendix 11
Detailed analyses of SF-6D scores based on the trial 
by Charles and colleagues69
TABLE 55 Analysis using last value carried forward approach to missing values
Period Group N Mean SD SE of mean Adjusted  p-Value
difference (SE)
Preoperation Control 18 0.6527 0.15075 0.03553
MIS 18 0.5722 0.16453 0.03878
3 months postoperation Control 18 0.7632 0.10304 0.02429
MIS 18 0.7924 0.08298 0.01956
Difference 0.045 (0.31) 0.158
6 months postoperation Control 18 0.8014 0.09470 0.02232
MIS 18 0.8001 0.07565 0.01783
Difference 0.001 (0.030) 0.963
1 year postoperation Control 18 0.8139 0.11936 0.02813
MIS 18 0.7895 0.06912 0.01629
Difference –0.011 (0.033)  0.731
2 years postoperation Control 18 0.8186 0.09312 0.02195
MIS 18 0.8026 0.07627 0.01798
Difference –0.006 (0.029) 0.842
SD, standard deviation; SE, standard error.Appendix 11
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TABLE 56 Analysis of complete dataset without regard to missing values
Period Group N Mean SD SE of mean Adjusted  p-Value
difference (SE)
Preoperation Control 18 0.6527 0.15075 0.03553
MIS 18 0.5722 0.16453 0.03878
3 months postoperation Control 18 0.7687 0.10421 0.02456
MIS 19 0.7884 0.08419 0.01932
Difference 0.047 (0.031) 0.142
6 months postoperation Control 18 0.8151 0.08430 0.01987
MIS 17 0.7954 0.07376 0.01789
Difference –0.002 (0.028) 0.936
1 year postoperation Control 20 0.8149 0.11301 0.02527
MIS 19 0.7906 0.06473 0.01485
Difference –0.005 (0.032) 0.880
2 years postoperation Control 16 0.8371 0.07071 0.01768
MIS 14 0.8101 0.06748 0.01803
Difference –0.011 (0.029) 0.719
SD, standard deviation; SE, standard error.
TABLE 57 Analysis of cases with complete datasets
Period Group N Mean SD SE of mean Adjusted  p-Value
difference (SE)
Preoperation Control 14 0.6722 0.13263 0.03545
MIS 10 0.5762 0.17112 0.05411
3 months postoperation Control 14 0.7844 0.08720 0.02330
MIS 10 0.7915 0.09543 0.03018
Difference 0.030 (0.037) 0.437
6 months postoperation Control 14 0.7902 0.07735 0.02067
MIS 10 0.8170 0.05719 0.01808
Difference 0.028 (0.031) 0.371
1 year postoperation Control 14 0.8415 0.10403 0.02780
MIS 10 0.7899 0.04939 0.01562
Difference –0.031 (0.035) 0.398
2 years postoperation Control 14 0.8350 0.07544 0.02016
MIS 10 0.8066 0.07307 0.02311
Difference –0.015 (0.032) 0.644
SD, standard deviation; SE, standard error.Health Technology Assessment 2008; Vol. 12: No. 26
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Appendix 12
Summary of included economic evaluations
Study identification Author and year Duwelius, 2006 (unpublished)
Interventions studied/ Mini-incision and MIS 2-incision total hip replacement (THR)/
comparators standard THR
Hypothesis/question To evaluate the cost-effectiveness at 6 weeks of minimally invasive
THR (mini-incision and two mini-incision) relative to the standard
technique in patients with advanced degenerative joint disease
Key elements of the study Type of study Cost-effectiveness analysis based on data from 10 hospitals in
various geographic locations in the USA. Non-randomised,
unmatched cohorts
Target population/ Patients with advanced degenerative joint disease in 10 USA 
study sample hospitals
Setting Secondary care with inclusion of some community costs. 
10 unspecified US hospitals and 14 orthopaedic surgeons
Dates to which data relate 2002–5
Source of effectiveness data Effectiveness data derived from a prospective unmatched
comparative cohort study 
Modelling NA
Link between effectiveness  The costing was undertaken retrospectively on the same sample 
and cost data as that used for the effectiveness study. Charge data provided by 9
of 10 hospitals regarding initial hospitalisation and for
complications requiring re-hospitalisation and cost-to-charge ratios
were used to convert billed charges into estimated costs 
Indirect costs in terms of productivity losses from time away from
work linked to time to WWOS, which is assumed as an indicator
of ability to return to work 
Details about clinical  Eligibility/patient group/ No specified eligibility criteria or patient group stated/14 surgeons 
evidence: study design  study sample at 10 hospitals provided data on 591 patients (235 MIS two-
and main outcomes incision, 325 mini-incision, 31 standard THR) 
Study design Prospective unmatched cohort study
Analysis of effectiveness The main clinical outcomes were time to WWOS, psychometric
health status as measured through SF-36, postoperative recovery
approximated by WWOS from the Harris hip score and HRQoL.
SF-6D estimated from the SF-36 scores using UK algorithm 
Effectiveness results/ Significantly different (p  0.05) demographics between groups at 
outcome measures time of surgery. MIS 2-incision hip procedure had greatest
operating time averaging 20 minutes more than standard
technique. Duration of acute hospital stay for MIS 2-incision
patients was 2.4 days shorter than standard cases (p  0.05).
Compared with standard surgery, MIS 2-incision and mini-incision
patients had a 60 and 44% decline in hospital length of stay,
respectively; discharges to facility-based rehabilitation declined by
97 and 80%, respectively; and WWOS at 6 weeks increased by
209 and 123%, respectively. Intraoperative and postoperative
complications were low for all groups. Dislocation related
complications, resulting in re-hospitalisation within 6 months 
post-surgery, reported for 2 (n = 325) mini-incision cases 
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Clinical conclusions The MIS 2-incision and mini-incision cases had a similar or better
postoperative quality of life than standard technique cases and
experienced a significantly earlier recovery from THR 
Economic analysis Measure of health benefits  QALYs estimated as the product of the surgical technique-specific 
used in the economic  HRQoL estimates by the proportion of subjects able to WWOS at 
analysis 6 weeks (used as predictive of ability to return to work). In the
calculation of QALYs, patient selection was compensated by three
methods: WWOS multiplied by average HRQoL, HRQoL within
each stratum and stratified HRQoL including covariance analysis. 
It is unclear if this is an appropriate approach to calculate QALYs 
Direct costs Surgeon costs estimated from the Medicare unadjusted national
average rate for primary THR, weighted for annual volume.
Charge data provided by 9 of 10 hospitals regarding initial
hospitalisation and for complications requiring re-hospitalisation
for 518 of 591 cases (201 MIS 2-incision, 296 mini-incision and 21
standard technique); one hospital did not release any charge data.
Two hospitals provided only technique-specific annual average
charges. Hospital cost-to-charge ratios were used to convert billed
charges into estimated costs. Post-acute rehabilitation provider
costs were modelled from inpatient hospital discharge and
Medicare reimbursement schedules. Hospital discharge data were
obtained from the study for the minimally invasive techniques (189
MIS 2-incision, 291 mini-incision) and from publicly available survey
data for the standard technique 
Indirect costs Wages foregone by employed THR patients during recovery from
surgery were estimated as indirect costs and modelled from the
patient being able to WWOS, THR incidence and employment
data
Currency US$. Unclear what the price year is and if prices have been
adjusted for differential timing, although sensitivity analysis around
inflation rates has been performed 
Statistical analysis of  HRQoL was calculated using two propensity scoring methods to 
quantities/costs minimise selection bias. 1st method: average HRQoL within five
strata formed from percentiles of pooled preoperative SF-6D
scores estimated followed by weighted averaging over strata. 2nd
method: propensity scores estimated from two logistic models
followed by covariance analysis of HRQoL, adjusted for propensity
scores to reflect differences in case mix. QALYs estimated using a
non-standard method; the validity of this approach is unclear 
Sensitivity analysis Two-way sensitivity analysis of all costs and utility values. Inpatient
rehabilitation facility, skilled nursing facility, home healthcare, home
only (no rehabilitation) and physician costs all varied by either
+30% or –30% of BC values. Wages and hospital cost-to-charge
ratio varied by either +10% or –10% of BC values. Inflation
varied by +5% or –5% of BC values. Combined incremental
effectiveness presented, although it is unclear what has been
combined in order to calculate this measure. Minimum
incremental effectiveness and maximum incremental effectiveness
of minimally invasive procedures relative to standard procedure
also presented. Four methods of imputing data for missing HRQoL
entries performed; imputation using last observation carried
forward, imputation of the interval-by-approach average, use of all
available data and restriction to complete cases with no missing
data. BC, minimum incremental effectiveness and maximum
incremental effectiveness are presented 
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Results Estimated benefits used in  6-week QALYs for all techniques: 0.053 QALYs for 2-incision, 
the economic evaluation 0.039 QALYs for mini-incision and 0.016 QALYs for standard
technique. Incremental effectiveness of minimally invasive
techniques compared with standard techniques: BC 0.037 QALYs
for 2-incision and 0.023 QALYs for mini-incision. Minimum
incremental effectiveness: 0.037 QALYs for MIS 2-incision and
0.021 QALYs for mini-incision. Maximum incremental
effectiveness: 0.040 QALYs for 2-incision and 0.023 QALYs for
mini-incision. Note: differences in QALYs are not statistically
significant and it is likely that CIs would be wide. Some attempt to
adjust for case mix was performed. It is also worth noting that the
effectiveness measure used to calculate utilities (SF-6D), based on
postoperative recovery, may not capture all the potential gains that
patients who receive MIS might benefit from 
Costs results Total costs were lower for the MIS 2-incision hip procedure and
highest for the standard technique (MIS 2-incision, $16,085; mini-
incision, $16,615 and standard technique, $21,705). Rate adjusting
surgical technique costs suggest nearly identical hospital cost for
the MIS 2-incision and the mini-incision technique (MIS 2-incision,
$12,725; mini-incision, $12,720; and standard technique, $14,903).
Lowest indirect costs reported for MIS 2-incision patients as they
were able, at higher proportions, to walk without support earlier
than mini-incision and standard technique patients (MIS 2-incision,
$1433; mini-incision, $1790 and standard technique, $2254).
Rehabilitation resource utilisation reflected the need for and
intensity of post-acute care treatment (MIS 2-incision, $540; mini-
incision, $719; and standard technique, $3161). Surgeon costs for
all three procedures were identical; $1386. It is not stated if
differences in costs are statistically significant and no confidence
intervals are reported. No adjustments have been made for case
mix 
Synthesis of costs and  Incremental costs and incremental QALYs are reported for the 
benefits two minimally invasive procedures relative to the standard
procedure, but no attempt is made to combine these into cost-
effectiveness ratios as MIS is assumed to be cost saving and more
effective although the difference in QALYs is not statistically
significant and differences in cost are not tested. Furthermore, it is
unclear if the method of converting for case mix adequately
corrects for selection biases. Principle cost drivers are hospital,
rehabilitation and indirect costs 
Authors’ conclusions Even under conservative assumptions, MIS 2-incision and mini-
incision THR techniques have better 6-week outcomes at less cost
than the standard technique 
Study identification Author and year Straumann, 200682
Interventions studied/ Minimal invasive surgery total hip replacement (MIS THR) vs 
comparators standard THR 
Hypothesis/question To evaluate and illustrate the cost-effectiveness, economic
consequences and QALYs of MIS THR in Switzerland using a
model-based and quantitative analysis 
Key elements of the study Type of study Modelling with retrospective costing exercise of standard THR.
Effectiveness data and cost difference based on a US study
Target population/ Cost data estimated for standard THR patients originating from 
study sample the Balgrist Orthopaedic University Hospital of Zurich. This figure
was then applied to the total number of THRs performed in
Switzerland to obtain the aggregate cost 
Setting Secondary care with inclusion of some community costs
continuedAppendix 11
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Dates to which data relate Cost data from Switzerland taken for the year 2003.
Source of effectiveness data No effectiveness data are presented in the paper, assumed MIS
better based on US study. Differences in indirect costs
(productivity losses) utilised by applying the human capital
accounting method to estimate benefit in terms of productivity
savings 
Modelling Applied mean difference in cost between minimally invasive and
standard THR from previous US-based cost-effectiveness analysis
and applied this mean difference in cost to total cost data for all
standard THR 
Link between effectiveness  Effectiveness taken from a US-based unpublished cost-
and cost data effectiveness analysis (Duwelius and colleagues, 2006). Little
information on this paper is reported 
Details about clinical  Eligibility/patient group/ 13,101 primary THRs performed in Switzerland in 2003. 
evidence: study design  study sample Aggregate estimation of savings following MIS techniques, 
and main outcomes estimated from decreases in productivity losses and rehabilitation
costs at indication rates of 30% (conservative) and 50%
(optimistic) 
Study design Data based on an unpublished US study with potential serious
biases in assessment of effectiveness
Analysis of effectiveness Productivity losses are only measure of benefit
Effectiveness results/ NA
outcome measures
Clinical conclusions No primary clinical outcomes sought as part of this study, although
stated that early postoperative recovery is apparent after MIS
techniques (assumed from results of unpublished data which are
utilised heavily) and suffers from serious selection bias
Economic analysis Measure of health benefits  Human capital accounting method applied to determine gains in 
used in the economic  productivity following MIS techniques 
analysis
Direct costs 2003 average cost total cost data for THR originating from the
Balgrist Orthopaedic University Hospital of Zurich. Definitive cost
difference between standard and MIS techniques taken from an
unpublished cost-effectiveness analysis and applied to Swiss cost
data to obtain cost of operation for a standard and minimally
invasive patient relevant to Switzerland. For rehabilitation costs, it
is assumed 50% patients (n = 6550) need outpatient rehabilitation
at €1335 per patient. 40% (n = 5240) take advantage of a
rehabilitation programme outside a hospital (€3335 per patient)
and 10% (n = 1311) need in-hospital rehabilitation (€13,335 per
patient). It should be noted that it is unclear what biases these
assumptions have 
Indirect costs Productivity losses incurred from inability to return to work
measured and applied to standard and minimally invasive groups to
estimate potential productivity losses that might be avoided by
adopting MIS techniques. 80.1% reduction in productivity loss
from MIS estimated from average work disability (assumed
45 days) with unemployment rate of 4.4% for the employed age
category (n = 6547) and an employment rate of 7.4% for patients
older than 70 years (n = 464). Total number of days saved is
252,324, which is multiplied by average GDP per work day/person
(€315) to obtain the potential reduction of productivity losses.
Assumed average disability of 45 days, but unclear why this
assumption is made. Figure of 80.1% reduction is productivity
losses given, but it is unclear where this number has come from 
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Currency Euros. 2003 prices 
Statistical analysis of  None performed
quantities/costs
Sensitivity analysis Two indication rates for MIS used, 30% (conservative) and 50%
(optimistic). Both presented as part of main analysis 
Results Estimated benefits used  No measure of benefit other than cost savings from reduction in 
in the economic evaluation productivity losses 
Costs results Indirect costs, assumed to be productivity losses, totalling €79.4
million (if 100% of THRs are performed using minimally invasive
methods). For the assumed MIS indication rates the effective
reduction of productivity losses ranges between €23.8 million
(conservative) and €39.7 million (optimistic) 
There were 36 fewer work days lost per employed patient with
MIS THR than with the standard THR technique 
Average hospital costs per patient were €13,511 for standard
THR and €11,534.40 for MIS THR. Given the total THRs in
Switzerland (€13,101) and indications rates of THR of 30 and
50%, calculated effective hospital cost savings are €7.8 million and
€12.9 million 
Overall rehabilitation costs are €43.7 million. Rehabilitation costs
are 82.9% lower with MIS 2-incision and 77.3% lower with mini-
incision technique. Using assumed MIS indication rates, the
effective cost savings range between €10.9 million and
€18.1 million for MIS 2-incision procedure and between
€10.1 million and €16.9 million for mini-incision technique 
Synthesis of costs and  No attempt is made to synthesise cost and benefits as the main 
benefits benefit measure “productivity loss” is measured as a cost.
Assumption made of equal or better outcomes and application of
cost saving rate from USA assumes that data are correct even for
the USA and the data might be applicable to Switzerland 
Authors’ conclusions Recommendation of adoption of MIS techniques in THR as they
may allow the reduction of healthcare costs 
BC, base-case; HRQoL, health-related quality of life; NA, not applicable; WWOS, walking without support.T
he diagram below displays the unpopulated model for the standard THR arm. The tree structures for
both the standard and minimal incision arms are identical. 
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Appendix 13
Markov model for the management of arthritic 
disease of the hip
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Non-operative management 
Dead
non-operative 
management
dieM
ortality is weighted by sex as the National Joint Registry reports that 60% of all primary total hip
replacements are performed on women; therefore, the all-cause mortality for the model cohort was
weighted to reflect this. 
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Appendix 14
Balanced life table for general mortality 
(40% male, 60% female)
Age (years) Mortality Age (years) Mortality
68 0.016562 89 0.153176
69 0.018324 90 0.164534
70 0.019946 91 0.179646
71 0.022501 92 0.196954
72 0.02522 93 0.217126
73 0.027967 94 0.232363
74 0.031561 95 0.255651
75 0.035162 96 0.27421
76 0.039297 97 0.29536
77 0.043814 98 0.314326
78 0.048593 99 0.329341
79 0.054145 100 0.356988
80 0.059932 101 0.356988
81 0.066966 102 0.356988
82 0.073952 103 0.356988
83 0.081779 104 0.356988
84 0.088514 105 0.356988
85 0.098279 106 0.356988
86 0.109397 107 0.356988
87 0.126424 108 0.356988
88 0.138485B
oth standard and mini-incision THR patients would move through the model as shown. It is the cost
and outcomes associated with the two forms of surgery that drive the cost–utility results.
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Appendix 15
Cohort analysis showing 1000 patients as they 
progress through the 40-year model for both
standard and mini-incision THR
Stage Primary THR Successful THR Revision Successful THR  Non-operative  Dead
(revision) management
0 1000 0 0 0 0 0
1 09 6 8 70 02 6
2 0 938 12 7 0 43
3 0 903 16 18 0 63
4 0 865 18 33 0 84
5 0 820 24 49 0 107
6 0 769 29 70 0 132
7 0 713 33 94 0 160
8 0 654 37 120 0 190
9 0 591 41 147 0 222
10 0 523 45 175 0 256
11 0 456 47 204 0 293
12 0 389 48 231 0 332
13 0 325 48 255 0 372
14 0 265 46 274 0 415
15 0 212 43 287 0 458
16 0 166 39 292 0 503
17 0 127 36 290 0 547
18 0 94 31 282 0 592
19 0 68 27 267 0 637
20 0 48 23 246 0 683
21 0 33 20 220 0 727
22 0 22 16 193 0 769
23 0 14 13 165 0 807
24 0 9 11 138 0 842
25 0 6 9 112 0 873
2 6 0 378 9 09 0 1
2 7 0 256 9 09 2 4
2 8 0 145 1 09 4 3
2 9 0 133 8 09 5 9
3 0 0 022 7 09 7 1
3 1 0 011 8 09 8 0
3 2 0 011 2 09 8 7
33 0 0 1 8 0 991
34 0 0 0 5 0 995
35 0 0 0 3 0 996
36 0 0 0 2 0 998
37 0 0 0 1 0 999
38 0 0 0 1 0 999
39 0 0 0 1 0 999
40 0 0 0 0 0 1000Volume 1, 1997
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